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ABSTRACT
The synthesis of a series of polyfunctional Ca,Ca-disubstituted glycines is
described. The lysine-like amino acid analog, Api, was prepared by regioselective
hydrolysis of a triBoced hydantoin intermediate, followed by N“-protection to yield the
first orthogonally protected ionizable Ca,Ca-disubstituted amino acid which is alicyclic
in nature.
The synthesis of three orthogonally protected tetrafimctional amino acids, Bap,
Bglu, and Basp was envisioned by the mild alkylation of the common organic synthon
ethyl nitroacetate.

Subsequent regioselective modification should allow for the

isolation of the first synthesized tetrafimctional amino acid derivatives suitable for
solid-phase synthesis. These amino acids are designed to induce peptide secondary
structure by salt-bridge stabilization.
A series of peptides, incorporating 80% Ca,Ca-disubstituted glycines were
synthesized to establish the helix stabilizing effect of amphipathicity in short helices.
The peptides were prepared as the following permutation isomer pairs, Pi-10 & Ipi-10;
Ach-lOa & Ach-10; and Cyh-10 & Ich-10. The peptides within each pair contains the
same amino acid content, but with different sequences, each designed to preferentially
adopt a 3 to- or a-helix. Circular dichroism studies confirm that amphipathicity is a
significant factor in shifting the 3io-/a-helix equilibrium, notably so in micellar
environments which mimic biological membranes.
The bioactivity o f the aforementioned peptides was established by minimum
inhibitory concentrations (MICs) against representative Gram-positive and Gram-

xix
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negative bacteria. The more hydrophobic peptides showed higher levels of cytotoxicity
than the less hydrophobic peptides.

In addition, in vitro studies using a strain of

Brucella abortus expressing Green Fluorescent Protein (GFP) show that all of the
peptides exhibit moderate to high selectivity towards the destruction of murine
macrophages infected with the intracellular pathogen.
The spectroscopic properties o f the o-nitrobenzenesulfonyl (oNBS) group have
been established to confirm the practical use of this protecting group in solid-phase
synthesis. Synthesis of the deprotection product, resulting from treatment of the oNBSprotected amino acid with mercaptoacetic acid / DBU, shows a linear correlation
between concentration and absorption at 390nm. The molar absorptivity,

£390

was

determined to be 2950 cm*lM'[. This number was verified by solution-phase cleavage
of several oNBS-protected Ca,Ca-disubstituted amino acids, which were synthesized by
a modified Bolin procedure to allow for synthesis under non-aqueous conditions.

xx
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CHAPTER 1
AN INTRODUCTION TO PEPTIDE CHEMISTRY
1.1.

INTRODUCTION
Proteins, along with carbohydrates, lipids and nucleic acids, make up the

cornerstones upon which life is based.

Yet the structural, functional and catalytic

mechanisms, by which proteins function, are just beginning to be understood. This is
presumably due to the incredible ubiquity and complexity o f proteins in nature. As
structural molecules they provide much of the cytoskeletal framework of cells, as
enzymes they act as biocatalysts for innumerable physiological functions, and as motile
structures, they provide movement to cells and cell structures.

They stabilize and

control the activity o f nucleic acids, forming active parts of ribosomal processes, and
play a key role in membrane transport and recognition. The ability of these molecules
to adopt such a broad spectrum of functional and structural properties is due to the
ingenious design scheme by which these molecules are structured.

Proteins are

composed of as many as 50,000 individual amino acid residues (Figure 1.1). The

o

R

Figure 1.1. Basic structure o f the amino acid. Stereochemistry about the C“-carbon is
not specified, but exists overwhelmingly as the L-isomer in nature. All common amino
acids vary only by the R-group side chain, which distinguishes the amino acids from
one another.
l
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presence o f the 20 commonly occurring ammo acids, and the more than 300 less
common variants which have been found to exist in nature, make an almost endless
variety o f proteins possible. A relatively small protein of only 50 amino acid residues
in length, in which any of the naturally occurring amino acids may occupy any position
along the sequence, allows for 2050 permutation isomers, without modifying any
individual amino acid. This number is roughly equivalent to the number of grams of
matter in the known universe.1'1 Considering the huge spectrum of protein size, the
large number of modified amino acids, the recent rise in the number o f synthetic amino
acids, and the conformational and quaternary structural interactions which are possible,
the numbers of possible proteins and protein conformations are essentially infinite.
However, every change in sequence and/or composition can result in distinctly different
functions and properties. It is the ability to understand the structure and function of
protein fragments, or peptides, as a result of primary amino acid sequence which is the
very dogma o f peptide chemistry. This introduction will present an overview o f the
basic principles of peptide chemistry and introduce some of the vital contributions made
to this field in recent years.
1.2.

THE AMINO ACID
Amino acids are the building blocks of all proteins. There are 20 commonly

occurring amino acids in nature that are encoded by the genome, and hundreds of posttranslationally modified amino acid derivatives which are used to synthesize the
countless proteins which provide structure and function to the biological world. The
first natural amino acid to be discovered in proteins was asparagine, in 1806, the last of
the common 20 was threonine, which was not identified until 1938.1-2 Since then, a

2
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multitude o f synthetic amino acids have emerged to complement the naturally occurring
20. A list o f the commonly occurring amino acids is presented in Table 1.1. Once
released from the ribosome, proteinogenic amino acids can be post-translationa lly
modified by processes such as acetylation, amidation, glycosylation, methylation,
hydroxylation, halogenation and phosphorylation.1’3 These alterations provide endless
possibilities in terms of final form and function of the resulting peptide.
In addition to the 20 naturally occurring amino acids and their posttranslationally modified analogs, several synthetic amino acids and amino acid analogs
have been reported within the past twenty years. A particularly interesting group of
these synthetic amino acids are the Ca,Ca-disubstituted amino acids (oocAAs), whose
most common member, 2-aminoisobutyric acid (Aib) or Ca-methylalanine, is illustrated
in Figure 1.2. Ca,Ca-disubstituted amino acids are characterized by substituting the
hydrogen at the Ca-carbon with an alkyl group. Most aaAAs are achiral, although
synthesis and application o f chiral aaAAs, where the amino acid side-chains are
different, has become more common in recent years.
2-Aminoisobutyric acid was first discovered as a strongly helix promoting
residue in the channel-forming peptide alamethicin. Alamethicin was found to be more
helical than would have been predicted by the helix forming propensities of the
proteinogenic amino acids which encompass the peptide.1'4 Since, it has been shown
that Aib, and several other disubstituted amino acids, are strongly helix promoting.1,5*6
The additional R group at the C“-carbon sterically restricts the possible conformations
o f the peptide, and in the case o f Aib and alicyclic Ca,Ca-disubstituted amino acids,
favors the formation of a helix. It has also been shown that amino acids with extended
3
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Table 1.1. The twenty commonly occurring amino acids.
Amino Acid

Code

Alanine

Ala (A)

Arginine

Arg(R)

Amino Acid

R
H3< H
H N ^.N H 2

Code

R

Leucine

Leu (L)

Lysine

Lys (K)

Methionine

Met(M)

Phenylalanine

Phe (F)

Proline

Pro (P)

Serine

Ser(S)

HOv/|

Threonine

Thr(T)

H ey}

HNnX V ^I
Asparagine

Asn (N)

Aspartic Acid

Asp (D)
H O ^ ^

Cysteine

C ys(Q

Glutamic Acid

Glu(E)

0

Q u
<3T

HO,^ SsX V ' |

Glutamine

O

Gln(Q)

CHj

Gly (G)

Histidine

His(H)

•A*
1
X

Glycine

Ou

Tryptophan

Trp (W)

Tyrosine

Tyr(Y)

Valine

Val (V)

H

Isoleucine

ne(I)

h3c ^ Y ^

ch3
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“X u

h 2n ^

C 0 2h

h 3c

ch3

Figare 1.2. 2-aminoisobutyric acid
w-alkyl side chains larger than a methyl group, i.e. diethylglycine and dipropylglycine,
favor extended conformations.1'7 ocaAA influences on peptide structure is discussed in
more detail in chapter 3 of this document.
Since most Ca,Ca-disubstituted amino acids are hydrophobic in nature, peptides
rich in these derivatives are generally restricted to study in organic solvents due to their
low solubility in aqueous media. There have been very few examples of side-chain
functionalized Ca,Ca-disubstituted amino acids which would allow for the synthesis of
highly water-soluble peptide rich in C°,Ca-disubstituted amino acid content.1'8 This is
primarily due to difficulty of synthesis. Since poly-functionalized C°,Ca-disubstituted
amino acids have the ability to induce branching and side-reaction at their side-chain
functionality, they must be orthogonally protected to allow for incorporation into solidphase peptide synthesis. Thus, we present the syntheses of new orthogonally protected
polyfunctional amino acids in Chapter 2 of this text. These synthetic schemes include
two Ca,C“-disubstituted amino acid analogs of lysine, the alicyclic 4-aminopiperidine4-carboxylic acid (Api) and 2,2-bis(3-aminopropyl)gIycine (Bap), and two Ca,C“disubstituted

amino

acid

analog

of

glutamic/aspartic

acid,

2,2-bis(3-

carboxyethyl)glycine (Bglu) and 2,2-bis(3-carboxymethyl)glycine (Basp).

The

structures of these amino acid targets are shown in Figure 1.3. The incorporation of
these new residues should allow for the development of short peptides, with highly
stabilized secondary structures.
5
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OtBu

BuOt

O ^O tB u

Fmoc

Fmocv
O

O

O
Fmoc-Api(Boc)-OH

Fmoc-Bap(Boc)rOH

Fmoc-Bglu(/Bu)j-OH

O
Fmoc-Basp(/Bu)rOH

Figure 1.3. Target Ca,Ca-disubstituted amino acids Api, Bap, and Bglu and Basp in
their fully protected forms.

1.3.

PRIMARY STRUCTURE AND SOLID-PHASE PEPTIDE SYNTHESIS.
Amino acids are joined to produce peptide segments by linking them together

via a condensation reaction to make a chain of intramolecular amides known as "peptide
bonds", as is illustrated in Figure 1.4. All peptides have this fundamental substructure
and vary only in the composition of amino acids and the sequence in the polypeptide
backbone, which is referred to as the primary structure of the peptide. The process by
which peptide bonds are formed synthetically are very different from those performed
by biological processes. There have been numerous methods developed to synthesize
peptides chemically. However, none o f them have been as revolutionary for the field of
peptide chemistry as solid-phase peptide synthesis (SPPS), introduced by Merrifield in
the 1960s.1'9 Merrifield's method is founded on anchoring an amino acid to an insoluble
polymeric support and "growing" the peptide off o f the polymer until it has reached it's
final sequence. The peptide is then cleaved from the resin and purified. The advantage
o f using solid-phase methods is the ability to utilize large accesses o f reagent without
encountering

difficulties in purification.

These accesses drive the equilibrium

6
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towards completion and thus provide greater yield and purity o f the targeted product
SPPS has grown into a prominent application in chemistry since the first seminal
publications, and is now a major driving force behind discovery sciences such as
combinatorial chemistry,1'10 the incorporation of synthetic amino acid derivatives and
the synthesis of other biomolecules.111' 19 SPPS has, in turn, enabled peptide structurefunction studies, such as those presented in chapters 3 and 4 o f this dissertation.1'20*28
The theory and practice of solid-phase peptide synthesis, coupling methods for peptide
linkage formation and protection schemes are reviewed in further detail in chapter 5.

peptide bond
O

NHa^COzH

R*

NH2^ C 0 2H

Figure 1.4. Condensation of two amino acids to generate a peptide bond.

As with N-alkylated amino acids, C^C^-disubstituted amino adds offer a
significant challenge in their ability to couple under solid phase peptide synthesis
conditions.*'30'31 The difficulty in coupling C^.C^disubstituted amino adds stems
primarily from the steric repulsion that arises between residues being coupled;01
Although some Ca,Ca-disubstituted amino adds, such as 2-aminoisobutyric add, are
found extensively in nature and are easily coupled under solid-phase peptide conditions,
couplings of larger and more sterically hindered residues are tedious and require long
coupling times under harsh reaction conditions.1'47 The need for a newer, more efficient
coupling method for the incorporation of Ca,Ca-disubstituted amino adds and other
7
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sterically hindered residues into synthetic peptides led to the development of the onitrobenzenesulfonyl (oNBS)/acid chloride coupling scheme which is presented in
chapter 5. This method is designed to utilize the higher reactivity of protected amino
acid chloride derivatives1'29'31 as activated coupling agents, which has so far been
impossible with the use of Fmoc chemistry due to high levels of competing oxazolone
formation by intramolecular cyclization.

Use of the less nucleophilic o-

nitrobenzenesulfonyl protecting group should allow for the synthesis of this highly
active species without competing side-reactions.

Successful application of these

derivatives should dramatically increase coupling yields and lower reaction times
required for the coupling of Ca,Ca-disubstituted amino acids. We have shown that the
protecting group is easily incorporated into proteinogenic amino acids and aaAAs
under non-aqueous conditions (Figure 1.5) and is quantitatively cleaved under
nucleophilic conditions to yield a chromophore that can be detected by UVspectroscopy, allowing for on-resin monitoring of coupling efficiency.
1.4.

PE PTID E SECONDARY STRU CTU RE

Biological function o f peptides and/or proteins is dependent on two factors: 1)
bonding interactions with the substrate (usually hydrogen bonding or coulombic
effects), and 2) overall peptide structure. Protein structure is divided into four levels of
complexity, primary, secondary, tertiary and quaternary (see chapter 3), where primary
structure is the description o f amino acid sequence and composition. The chemical
characteristics o f the primary sequence allow the peptide to establish internal hydrogen
bonding patterns along the amino acid backbone. This bonding pattern, in turn, induces
the next level of structure in the peptide, secondary structure. Factors that determine
S
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which secondary structure will be adopted and the characteristics o f secondary structure
are discussed further in the introduction of chapter 3. The secondary structure of
peptides can be divided into four general categories: 1) the extended conformation, 2)
helices, 3) (3-sheets and 4) (3-tums. O f these four, the helical configurations are of most
interest for the work presented in this dissertation. Figure 1.6 illustrates several helical
secondary structures of peptides. Using fundamental chemical principles and a few
experimental observations, Linus Pauling and Robert Corey elucidated the two most
prominent secondary structures, the a-helix and (3-sheet, as early as 1951, years before

a-helix 3io-heiix x-helix

Figure 1.6. Helical secondary structure conformations. Of these structures, the a-helix
is by far the most common. The 3to-helix makes up less than 10% of all peptide
structure. The x-helix is not found in nature.

10
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the first crystal structure of a protein was ever defined.1*32 Of the known helical
secondary structures, the a-helix is the most thermodynamically stable and is the most
common secondary structure in nature.
Recently, the 3io-helix has gained attention as a significant helical motif in
peptides, making up nearly 10% of all peptide helices.1*33 The delicate equilibrium
between the 3 to- and a-helix, which is thought to be significant in protein folding
processes, has not been fully explored.

In addition, it is not known what factors

stabilize one helix over the other. To gain understanding of this process, we prepared a
series of short peptides rich in Ca,Ca-disubstituted amino acids. The peptides were
designed to be perfectly amphipathic as a result of adopting either an a - or 3to-helical
conformation.

Since the peptides are paired as permutation sequence isomers, the

adopted conformation is based purely on the peptides’ preference to adopt an
amphipathic cross-section, not induced by their amino acid composition. The structures
of the peptides were deduced by electronic circular dichroism spectroscopy (ECD)1*32 3S.
ECD, along with crystallographic methods and NMR, are the primary methods of
obtaining information of peptide secondary structure. The results of these structural
studies are presented in chapter 3 o f this dissertation.

IS .

A M PH IPA TH IC PE PTID ES

Amphipathic peptides are predominantly hydrophilic along one side of the helix
axis and predominantly hydrophobic in character on the other side (Figure 1.7). The
tendency o f these structures to self-associate and interact with bi-lipid membranes result
in high levels of bioactivity. They play an important part in membrane-dependent
processes1*41 and are found extensively in lipoproteins1*42, hormones1*43, lung surfactant
11
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Figure 1.7. Representative amphipathic a-helix and 3io-helix wheel diagrams. N
represents non-polar, hydrophobic residues. P represents polar, cationic residues.
Empty circles represent non-occupied positions on the helical wheel cross-section.

proteins1'44, cytotoxic immunodefense proteins1'45 and antimicrobial agents.1'46

By

generating sequence permutation isomers of several peptides, we have attempted to
selectively induce a- or 3io-helices, based purely on amphipathic sequence design.
Incorporation of the ionizable C“,Ca-disubstituted amino acid, 4-aminopiperidine-4carboxylic acid (Api) (see chapter 2) along with other common Ca,Ca-disubstituted
amino acids such as 2-aminoisobutyric acid (Aib) and l-aminocyclohexane-lcarboxylic acid (Ac6c) allows for the production o f short, amphipathic peptides with up
to 80% Ca,Ca-disubstituted amino acids which are highly water soluble, but retain
helical character in organic and aqueous/organic media (Table 1.2). Each peptide is
designed to have maximum amphipathic character either as an a-helix or a 3to-helix,
and were found to preferentially adopt their respectively designed structures (see
Chapter 3).

12
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Table 1.2. List of prepared de novo peptides designed for study of structural influences
of amphipathic design and antimicrobial activity against Brucella abortus.

Peptide

Sequence

Design

Pi-10

H-Aib-Aib-Api-Iys-Aib-Aib-Api-Lys-Aib-Aib-NH2

a

Ipi-10

H-Api-Aib-Aib-Zys-Aib-Aib-Lys-Aib-Aib-Api-bftfc

3io

Ach-lOa

H-Ac6 c-Aib-Lys-Api-Aib-Ac6 c-Api'£ys-Ac6 c-Aib-NH2

a

Ach-10

H-Api-Aib-Ac6c-Lys-Ac6c-Aib-Iys-Aib-Ac6c-Api-NH2

3io

Cyh-10

H-Ac6c-Ac6c-Api-Iyj-Ac6c-Ac6c-Api-Zy.s-Ac6c-Ac6c-NH2

a

Ich-10

H-Api-Ac6c-Ac6c-Iys-Ac6c-Ac6c-Lyy-Ac6c-Ac6c-Api-NH2

3io

Amphipathic peptide structures are gaining considerable recent attention due to
growing interest in utilizing these compounds as antimicrobial agents.1*36*37 Antibiotic
resistance is a growing problem, which is developing in a number of pathogenic
bacteria. To combat this problem, new sources o f antibiotic therapy are required. Some
o f the most promising candidates for this purpose are antimicrobial peptides. Naturally
occurring antimicrobial peptides are generally linear, amphipathic a-helices, and are
relatively short in length (<40 residues). Although this number is relatively small in the
realm of protein science, it is far too large to allow these compounds to be used
effectively in a therapeutic fashion. However, sequences o f this length are generally
required to produce significant helical character in proteinogenic helices.
13
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The

incorporation o f high levels o f Ca,C°-disubstituted amino acids into the peptide
structure allows for the production o f relatively short sequences (~10 amino acids)
which display high levels o f helicity in amphipathic environments. Besides showing
moderate to high levels of antimicrobial activity against representative Gram-positive
and Gram-negative bacteria, the designed peptides show a significant selectivity
towards the destruction of macrophages infected with intracellular pathogens (see
chapter 4). An added benefit of using aaAAs in the design of therapeutic peptides is
their resistance towards enzymatic degradation and increased thermal stability.
1.6.

IN TRA CELLU LA R PA THOGENS

Infection with intracellular pathogens, such as Brucella abortus (Ba) and
Mycobacterium tuberculosis (Mtb), are very difficult to treat by classical antibiotics due
to the lack of any significant extracellular component to the infection.138 The bacteria
reside within the white blood cells o f the host, where no significant concentrations of
antibiotic accumulate. Current recommended treatments for Mtb infection include the
administration o f four first-line antibiotics over periods of six to eight months.139 In
vitro studies o f the cytolytic activity of our designed peptides show that infected
macrophages are killed selectively over non-infected macrophages with high
selectivity.1,40 In addition, in vivo studies of the peptide Pi-10 have shown that
administration of oxytetracycline together with peptide in BALB/c mice infected with
Ba results in a dramatic reduction of intracellular infection over 24 hours.1,40 This
promising result prompted us to investigate the selective cytolytic activity o f the rest of
the peptides in the Pi-10 family (Table 12). These results are presented in chapter 4 of
this manuscript
14
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The mechanism by which antibiotic peptides function is still under considerable
debate.

It is generally accepted, however, that the peptides induce cell membrane

disruption by one of several proposed mechanisms (see chapter 4).

In contrast to

classical antibiotics, the interaction is not enzyme or receptor mediated, which lowers
the possibility of resistance development towards this kind of therapy.

Peptide

selectivity towards bacterial cells in mammalian environments is due to cellular
membrane composition differences between eukaryotic and prokaryotic cells.1-37
Bacterial cell walls are unique in that they contain lipopolysaccharides (Gram-negative)
or teichoic and teichuronic acids (Gram-positive), giving their cell wall a predominantly
negative charge, which attracts the positive charge of cationic peptides. Mammalian
cells are composed predominantly of zwitterionic sphingomyelin phospholipids, which
have been shown to show low affinity for natural antimicrobial peptides.1-37 This theory
is further supported by the significantly lower activity of linear amphipathic peptides
which are anionic in character, suggesting a coulombic interaction between peptide and
target cell.

Subsequent incorporation o f the peptide into the cellular membrane of the

target causes membrane disruption and cell death.
A question that remains unanswered is why these peptides are selective towards
macrophages that are infected with intracellular pathogens.

Since it has been

established that coulombic attraction is the prime method of peptide incorporation into
pathogenic membranes, is there a change of potential in the infected macrophage which
promotes incorporation o f the peptide, or are peptides evenly distributed between
healthy macrophages and infected ones?

hi the latter case, are the infected

macrophages more susceptible towards membrane disruption than the healthy ones?

15
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These questions are addressed further in chapter 4. The first step towards answering
these questions is addressed by a study in which macrophages are activated by PMA
and show the same susceptibility towards Pi-10 as macrophages infected with
intracellular pathogens. In turn, inhibition o f PKC production in the cell results in
reduced sensitivity, rendering Pi-10 inactive. This suggests that intracellular pathways
“signal” the presence o f an infection to the exterior cellular matrix (chapter 4).
1.7.

CONCLUSIONS
Clearly there is more to be discovered within this field o f peptide chemistry.

New amino acids, new solid-phase coupling techniques, and new methods for the
determination of peptide structure will provide the tools with which we can accomplish
these goals. The ultimate goal is, of course, to deduce protein function directly from
primary sequence. A greater understanding of peptide structure-function relationships
will allow us to apply synthetic peptides more effectively as therapeutic agents. Future
studies stemming from the material presented in this dissertation are summarized in
chapter 6. These future studies include fluorescently labeling peptides so as to more
carefully monitor the mechanism by which macrophages infected with intracellular
pathogens are destroyed, and designing new, highly active peptides with shorter length.
Increased awareness of the cellular response to these types of infections is crucial for
the ongoing war against disease.
1.8.
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CHAPTER 2
SYNTHESIS OF A SERIES OF IONIZABLE
C“,Ca-DISUBSTITUTED AMINO ACIDS
2.1.

IN TRO D U CTIO N

The use o f Ca,Ca-disubstituted amino acids (aaAAs, Figure 2.1) in the design
o f novel peptides has taken a sharp rise within the past few years. There are several
reasons why these derivatives are desirable in the synthesis of de novo peptides with
bioactive applications. 1) It has been shown that peptides containing high levels of
Ca,C“-disubstituted amino acids are resistant to enzymatic degradation under
physiological conditions.2,1,61 2) The presence of the common Ca,Ca-disubstituted
amino acid Aib (2-aminoisobutyric acid) in naturally occurring, membrane active
peptides.2,2,3 3) The high secondary structure promoting ability of Ca,Ca-disubstituted
amino acids by peptide torsion angle restriction.2'4' 13

H
i

.N.
H3C C H 3
h 2n

c o 2h
A lb

h 2n ' " c o 2h
A cte

Q

h 2n '

.

" c o 2h

A pi

Figure 2.1.
Ca,Ca-Disubstituted amino acids aminoisobutyric acid (Aib), 1aminocyclohexyl-1-carboxylic acid (Ac«c), and 1-aminopiperidine-1 -carboxylic acid
(Api).

20

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

2-Axninoisobutyric acid (Aib) is the most commonly used Ca,Ca-disubstituted
amino acid and is found extensively in nature. The antibiotic alamethicin,2'14*15 and
related antimicrobial peptides suzukacillin,216 emmerimidns,2'17 and antiamoebins218
all contain high levels of this amino acid. Most of the pioneering work on the structural
influences of Aib in short, synthetic peptides is accredited to Balaram, 2‘8'10’11’19’20 and
more recently by Toniolo, Benedetti and coworkers.2'2'12,21'n

Aib, and other aaAAs

like it, promote secondary structure formation by severely restricting possible rotation
about the N-C° (<j>) and C°-C' (\y) bonds.2'8 Theoretical calculations have deduced that
allowable torsion angles of these bonds in aaAA-rich peptides fall in a very narrow
region near -57°, -47°, and +57°, +47°, respectively.2-23 In Ramachandran space, this
corresponds to the formation of a right or left handed a-helix or 3to-helix (see chapter
3). Since symmetrical aaAAs do not have a chiral center, they may give rise to either
right or left handed screw sense, if no other chiral amino acids are present in the peptide
to induce enantiomeric preference. In contrast to Aib, C°,C°-di-n-ethylglycine and
Ca,Ca-di-n-propylglycine have been shown to induce extended conformations of
resulting peptides (Figure 2.2).2*10

h 2n

Dpg

o

c o 2h

h 2n

Acsc

Deg

c o 2h

y

h 2n

c o 2h

Ac7c

Figure 2.2. Other common Ca,C°-disubstituted amino acids: Ca,Ca-Dipropylglycine
(Dpg), Ca,Ca-Diethylglycine (Deg), 1-amino-1-cyclopentanoic acid (Acsc), and 1amino-l-cycloheptanoic acid (Ac7c).
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The effect o f alicyclic Ca,Ca-disubstituted amino acids on secondary structure
has been extensively researched. 2 ' 1 0 ,1 2 ,2 4 ’2 5 While longer chain Ca,Ca-di-n-alkyl amino
acids promote extended conformations, 2 ,1 0 alicyclic C^C^-disubstituted amino acids, in
which the Ca carbon forms a cyclic bridge with itself, such as 1-aminocyclopentane-1carboxylic acid (Acsc) and 1-aminocyclohexane-l-carboxylic acid (Acgc), have helix
forming characteristics similar to those of Aib. 2 ,1 0 ,2 4 This theory was recently extended
to include the seven membered ring variant, 1 -amino-cycloheptane- 1 -carboxylic acid
(AC7 C) (Figure 2.2).124
Due to the presence of symmetry at the exposition, achiral aaAAs due not
induce selective screw sense and are equally prone towards the formation of right and
left handed helices. Synthetic peptides, incorporating high levels o f Ca,C“-disubstituted
amino acids, often include proteinogenic amino acids to induce preferred helical sense.
It has been shown that synthetic peptides increase their helical character by substituting
Aib residues with chiral aaAAs such as C“-methyl valine or Ca-ethyl alanine. 2 '2 6 ,2 7
Some chiral Ca-alkylated phenylglycines have also recently found use as selective
antagonists of metabotropic glutamate receptor. 2 -2 8 ,2 9

Chiral aaAAs are generally

synthesized by the enandoselective alkylation of chiral enolates. 2"3 0 " 3 2 However, these
reaction conditions are limited due to multiple reaction steps and difficult separations of
racemic products.
Since most Ca,Ca-disubstituted amino acids are hydrophobic in nature, peptides
rich in aaAAs are generally restricted to study in organic solvents due to their low
solubility in aqueous media.

There have been very few examples of side-chain

functionalized aaAA s that would allow for the synthesis o f highly water soluble
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peptide rich in Ca,C“-disubstituted amino acid content6'62 This is primarily due to
difficulty of synthesis.

Since side-chain functionalized aaAAs have the ability to

induce branching and side-reaction at their side-chain functionality, they must be
orthogonally protected to allow for incorporation into solid-phase peptide synthesis.
The harsh conditions, under which standard methods o f C“,Ca-disubstituted amino acid
synthesis are performed, make this a difficult task (Figure 2.3).

©
A

9
R

NH3
R’

B

R

9
R

| H

R'

HCN ^ H2N ,CN

R’

(NH4 )2 C 03^
KCN

R

hnT X 0
R
R'

R'

H3Q+ ^ H3 N CO2 H
heat

r^

r-

60M u O V H2 ^ ° ?
heat, pressure
R
R'

Figure 2J . The Strecker Method A, and the Bucherer-Berg Method B, for the synthesis
o f C“,Ca-disubstituted amino acids.

Two traditional methods exist for the synthesis of aaAAs. The Strecker method
is characterized by the addition of cyanide to an imine synthesized from the
corresponding symmetrical ketone, followed by acid catalyzed hydrolysis of the
resulting a-aminonitrile (Figure 2.3).2J3 This method is experimentally simple, but
limited to the use of simple ketones as starting materials as the hydrolysis requires
strongly acidic conditions, high temperatures and pressure.

Recently, Ma and

coworkers presented an asymmetrical Strecker synthesis to generate chiral aaA A s from
a-aryl ketones.234 The Bucherer-Berg method of hydantoin formation by the reaction
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o f ketones with sodium cyanide and ammonium carbonate is still the most prevalent
method to generate aaAAs in good yields.2'35,36 However, hydantoins also suffer from
the limitation o f requiring harsh conditions for hydrolysis, thus minimizing the ability to
generate side-chain functionalized amino acids (Figure 2.3). This problem was partially
overcome

by

Rebek

and

coworkers,

whom

discovered

that

N,N'-Bis-(/-

butyloxycarbonyl) hydantoins can be hydrolyzed under much milder conditions.2,37 The
ease of hydrolysis of the functionalized hydantoin is presumably due to a number of
reasons: 1) Induced ring strain in the hydantoin moiety, 2) greater electrophilicity o f the
hydantoin carbonyls, making it more susceptible towards nucleophilic attack by
hydroxide and, 3) The nitrogen of the hydantoin becomes a better leaving group as a
carbamate.

The progress made in Ca,Ca-disubstituted amino acid synthesis by

hydantoin hydrolysis allowed us to develop the synthesis of the orthogonally protected
C°\Ca-disubstituted amino acid Fmoc-Api(Boc)-OH 2.1 (Figure 2.4).2J8 This alicyclic
Ca,C°-disubstituted amino acid analog of lysine allows for the preparation of peptides
rich in aaAAs, while retaining water-solubility.2,6 As with other alicyclic aaAAs, Api
has been found to strongly favor helical conformations of resulting peptides.

2.1
Figure 2.4. Orthogonally protected C°,Ca-disubstituted amino acid 9-1 -tertbutyloxycarbonyl-4-((9-fluorenylmethyloxycarbonyl)amino)-piperidine-4-carboxylic
acid (Fmoc-Api(Boc)-OH).
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Nitroacetic esters are common starting materials for a number of synthetic
transformations.239 The high reactivity of the a-methylene group of these compounds
allows for unique carbon-carbon bond forming ability. Alkylations of these activated
starting materials has been useful in the synthesis of 2-nitroalkanoic acids, nitro
alcohols, nitro amines, halonitro compounds, nitroacrylates, oxazolidines, oxazoles and
carbohydrates.239 Although there have been reports o f the use o f benzyl- and r-butylnitroacetate,2*40'43 most of the work on nitroacetates have been restricted to the use of
the methyl and ethyl esters2'44"47 due to the difficulty of synthesizing other derivatives.
The ability to efficiently alkylate nitroacetic esters has lead to the successful synthesis
of amino acids and amino acid esters.2'48’53

These reactions are usually

monoalkylations with an appropriate electrophile using weakly basic conditions,
followed by reduction of the nitro group to the corresponding amine. Alkylations have
been performed by the use o f sodium or potassium hydroxide, benzyltrimethyl
ammonium hydroxide, trimethylanilinium benzenesulfonate and diethylamine as
bases.239 In addition, metal catalysis by copper (II) acetate and palladium catalysts has
been employed for a number of Michael additions.2*4534 Electrochemically generated
anions have been used on a small scale to perform mono- and di-alkylations of
nitroacetic esters.2*47

However, since monoalkylation o f nitro acetates is non-

stereospecific, these reactions result exclusively in racemic mixtures of a-nitro esters,
which have limited application for peptide synthesis.
Dialkylation o f nitroacetic esters yields symmetrical dialkylated nitroacetates
which are suitable precursors for the synthesis of Ca,Ca-disubstituted amino acids
(Figure 2.5). The high acidity o f the a-methylene protons o f ethyl nitro acetate allow
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o
o 2n ^

0.

BASE

Figure 2.5. Base catalyzed alkylation o f ethyl nitroacetate.
hydroxide, sodium hydroxide, sodium ethoxide, trialkylamine.
Michael acceptor.

BASE= potassium
Rg= alkyl halide,

for alkylations under very mild conditions. This, in turn, allows for the incorporation of
chemically labile groups, which would be too unstable to incorporate via the Strecker,
Bucherer-Bergs, malonic ester alkylation or glycine template alkylation methods. A
synthetic scheme was envisioned for the preparation of three orthogonally protected
tetrafunctional Ca,Ca-disubstituted amino acid analogs of glutamic acid, aspartic acid
and lysine / omathine using ethyl nitroacetate as a synthetic precursor: N“-(9fluorenylmethyloxycarbonyl)-2,2-bis(ter/-butylcarboxyethyl)
Bu)2 -OH,

glycine

(Fmoc-Bglu(r-

2.2), Na-(9-fluorenylmethyloxycarbonyl)-2,2-bis(terf-butylcarboxymethyl)

glycine (Fmoc-Basp(/-Bu)2-OH, 2.3)

and Na-(9-fluorenyImethyloxycarbonyl)-2,2-

bisCN^-tert-butyloxycarbonyl-S-aminopropyl)

glycine

(Fmoc-Bap(Boc)2 -OH,

2.4)

(Figure 2.6). These targets were chosen for three reasons: 1) There does not, as o f date,
exist any recorded results on the synthesis o f orthogonally protected tetrafunctional
amino acids capable of incorporation into peptides by solid-phase peptide synthesis (see
chapter 6). 2) The use of a polyfunctional amino acid may allow for the synthesis of
peptides that retain high levels o f amphipathicity with very short length (see chapter 3).
3) Polyanionic and polycationic am ino acids have interesting possibilities for
application as salt bridge inducers towards stabilization of peptide secondary structure.
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Figure 2.6.
Fmoc-Bglu(r-Bu)2 -OH 2.2, Fmoc-Basp(/Bu)2 -OH 2 3 and FmocBap(Boc)2 -OH 2.4.

23.

RESULTS AND DISCUSSION
Synthesis

of

l-ter/-butyloxycarbonyl-4-((9-fluorenylmethyloxycarbonyl)

amino)-piperidine-4-carboxylic acid (Fmoc-Api(Boc)-OH) 2.1 was realized according
to the synthetic scheme in Figure 2.7. The reaction of 4-piperidone hydrate 2.1a with
potassium cyanide and ammonium carbonate in ethanol/water gives the resulting
hydantoin 2.1b in good yields. The piperidone hydantoin is then tri-Boced using excess
l-butyldicarbonate in DME with triethylamine and a catalytic amount of DMAP as
deduced by Wysong et. al.2-55 Attempts to tri-Boc the piperidone hydantoin without the
use of DMAP or triethylamine results in incomplete reaction.

Hydrolysis of the

resulting triBoc piperidine hydantoin 2.1c under alkaline conditions results in the
formation of the amino acid 2.1d in good yield. This hydrolysis was initially achieved
by aqueous NaOH. However, isolation of the resulting zwitterion 2.1d is difficult, as
the product is highly contaminated with the hydrolysis side-product, bis(fbutyl)carbamate.

Isolation of this side product verifies that the mechanism o f

hydrolysis occurs by one of two pathways as shown in Figure 2.8. In the first
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Figure 2.7. Synthesis o f Fmoc-Api(Boc)-OH 2.1.
mechanism, A, nucleophilic attack of hydroxide on the amide carbonyl of the hydantoin
ring substitutes the carbamate-type moiety. Intramolecular f-butyloxycarbonyl transfer,
followed by base catalyzed hydrolysis and subsequent decarboxylation of the resulting
carbamic acid give the observed products. The other hydrolysis mechanism, B, is
initiated by nucleophilic hydroxide attack on the urea-carbonyl of the hydantoin.
Decarboxylation of the carbamic acid and intramolecular /-butyloxycarbonyl transfer
yields the free amine. Base hydrolysis of the resulting amide releases bis-(f-butyl)carbamate and results in the free carboxylate (Figure 2.8).
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Figure 2.8. Possible mechanisms of di-Boc hydantoin hydrolysis.
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Although both mechanisms are theoretically feasible, mechanism A is more
likely to occur for two reasons:

1) The greater electrophilicity o f the amide-type

carbonyl versus the urea-type carbonyl promotes initial nucleophilic attack according to
mechanism A. 2) Intramolecular f-butyloxycarbonyl transfer in mechanism A involves
an amide leaving group, mechanism B requires that a deprotonated amine act as
a leaving group. The greater kinetic activity of the amide-type leaving group would
promote mechanism A. It was attempted to probe the mechanism of the hydrolysis by
13C-NMR. However, the results were inconclusive.
Although the hydrolysis of the tri-Boc hydantoin give the desired amino acid in
high yield, the reaction has difficulties associated with bis-(/-butyl)-carbamate
contamination of the isolated amino acid.

Bis-(/-butyl)-carbamate has a pKa and

solubility similar to that of the Api(Boc) zwitterion making separation difficult even by
chromatographic means. Presence of this contamination causes difficulty in isolation
and residual bis-(/-butyI)-carbamate results in severe side reaction if present in the
preparation of Fmoc-Api(Boc)-OH.
Contamination with bis-(f-butyl)-carbamate is avoided by performing the
hydrolysis of 2.1c in a biphasic mixture of THF and 2.0M KOH.

Under basic

conditions, bis-(/-butyl)-carbamate has a higher solubility in THF, while the
deprotonated zwitterion stays in the aqueous solution. Under high ionic contents THF
and water are not miscible and are easily separated in a separatory funnel (Figure 2.9).
Evaporation of the separated THF yields a nearly quantitative recovery of bis-(r-butyl)carbamate. Neutralization o f the aqueous layer yields the precipitated zwitterion 2.1d in
very good yield. To introduce the Fmoc group for N*- protection, Fmoc-Cl is used, as
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Figure 2.9. Biphasic hydrolysis of triBoc Api hydantoin.
reported by Bolin.2-63 The N8-f-butyloxycarbonyl group was found to be stable under
these conditions and the reaction yields the orthogonally protected amino acid 2.1 in
good overall yield. Unfortunately, the tri-Boc-hydantoin route can not be extended to
non-cyclic multi-functional amino acid derivatives.

The required a-, P-, or y-

difunctionalized ketones do not form hydantoins to an appreciable extent (Figure 2.10).
Thus, the tri-Boc-hydantoin route was not utilized for the synthesis of Fmoc-Bglu(fBu)2 -OH and Fmoc-Bap(Boc)2 -OH.

<

•

/ i\
B ocH N ' v

COjMa

~ 0% Hydantoin :

NHBOC

.

o

Figure 2.10. Failed attempts at difunctionalized hydantoin synthesis.
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The scheme devised for the synthesis of Fmoc-Bglu(f-Bu)2 -OH and FmocBap(Boc)2 -OH is shown in Figure 2.11 and 2.12. Based on evidence that the ethyl
nitroacetate anion is a more potent nucleophile when the counter ion is a highly
dissociated quaternary ammonium salt, initial dealkylation was achieved using N,N'diisopropyl ethylamine.2*47 The reactivity of the anion is increased when a catalytic
amount o f tetraethylammonium bromide is added to the reaction to act as an activated
counter ion. Michael addition was performed with a number o f electrophilic acceptors.
Reaction of the nucleophile with acrolein is facile but gives a diastereomeric mixture of
products due to the very rapid intramolecular Aldol cyclization of the resulting enolate
(Figure 2.13). Michael addition with terf-butyl acrylate and acrylonitrile, respectively,
gave the Ca-disubstituted ethyl nitroesters in excellent yields. Interestingly, alkylation
with benzyl acrylate gave only a small portion of dialkylated product after 24 hours at
room temperature. Most of the recovered product was monoalkylated. The ethyl ester
o f the dialkylated nitroacetate cannot be hydrolyzed without risking carbon dioxide
elimination. Thus, the next logical step in the synthesis o f an amino acid derivative is to
reduce the a-nitro group to the corresponding amine. However, reduction of the nitro
group did not prove trivial. Nitro compounds are known to be reduced by a variety of
methods, the most prevalent being catalytic hydrogenation over Pd2-49'50 or Raney
Ni.2-48,52’53

There are, however, several other techniques, such as Zn/acetic acid

reduction and tin catalyzed hydrochloric acid reduction.

Ammonium formate has

recently found application as a suitable catalytic hydrogen transfer agent for the
reduction of nitro compounds.2'56’58 To our surprise, only catalytic hydrogenation at 50
psi over T -l Raney Nickel in ethanol resulted in the desired amine: ethyl-2,2-bis(/-
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Figure 2.11. Synthetic soheme of the synthesis of Fmoc-Bglu(tBu>2 -OH 2.2.
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Figure 2.13. Addition of acrolein to ethyl nitroacetate, followed by base catalyzed
intramolecular Aldol cyclization to yield diastereomeric mixture.

butylcarboxyethyl)glycine 2.2b.

Hydrogenation over Pd/C (5 or 10%) at 50 psi in

ethanol or with ammonium formate results in almost quantitative conversion to the
corresponding hydroxylamine, which was apparent by NMR and MS analysis (Figure
2.14-16).

While suitable for the reduction of ethyl-2,2-bis(/-butylcarboxyethyl)-2-

nitroacetate 2.2a, catalytic hydrogenation can not be utilized in the reduction of the
corresponding nitro group of ethyl-2,2~bis(3-cyanoethyl)-2-mtroacetate 2.4a, as nitriles
are readily reduced under these conditions.
Acid catalyzed hydrolysis of the ethyl ester of 2.2b results in immediate /-butyl
deprotection and saponification using KOH, NaOH, or LiOH in various aqueous and/or
aqueous/organic mixtures failed to selectively hydrolyze the ethyl ester. Recovered
material from several hydrolyses showed evidence that the /-butyl groups o f the 8carboxylates were also lost to an appreciative extent. Selective hydrolysis of ethyl
versus /-butyl esters has been well documented. 2J9' 60

However, hydrolysis of this

ethyl / /-butyl ester compound is very difficult. Difficulty in isolation of the complex
mixtures of partially hydrolyzed derivatives makes definitive evidence impossible, but a
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Figure 2.14. 'H-NMR analysis of Pd catalyzed reduction of nitro group to yield
hydroxylamine (top) versus Raney nickel catalysis to yield amine 2.2b (bottom).
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theoretical lack of selectivity in hydrolysis arises from the presence of a tertiary carbon
center a to the ester carboxylate. This ester, thus, becomes essentially

neopentyl in

character and is highly sterically inaccessible. The lowered kinetics o f the ethyl ester
hydrolysis may compete with the already very low rates o f t-butyl ester hydrolysis and
result in lower selectivity. In turn, side-chain a-deprotonation and/or intramolecular
cyclization by Dieckmann-type reactions may be a prominent factor. In addition to acid
and base catalyzed ester hydrolysis, nucleophilic dealkylations of the ethyl ester with
NaCN, Nal, NaSePh and KOSi(Me) 3 were attempted with no success. 2 -6 0 The best
hydrolysis results were realized by the use of 1.4 equivalents tetramethyl ammonium
hydroxide in a

1 :2

water and methanol mixture which was cooled to zero degrees and

slowly allowed to rise to room temperature over 24 hours. Evaporation o f the solvent
and acidic precipitation of the zwitterion from a saturated sodium chloride solution
gives the amino acid in 20-30% yield. Isolation of side-products from this hydrolysis
showed that ester-hydrolysis selectivity was not the primary cause o f the problems
associated with the synthesis.
weakly basic conditions.
cyclizes with the

8

Selective ethyl ester hydrolysis occurs slowly under

However, the a-amino carboxylate that results rapidly

-f-butyl ester to form a racemic mixture of 3-carboxy-3-(r-

butylcarboxyethyl)-2-pyrrolidinone (Figure 2.17). The structure of this intermediate,
which was isolated in -70% yield, was verified by X-ray crystallography and NMR
(Figure 2.18).

The N°-Alloc protected ethyl amino ester was also prepared (see

experimental 2.3.15) to attempt to avoid cyclization.

However, hydrolysis of this

compound resulted in a complex mixture o f side-products, most likely arising from
incomplete hydrolysis, over-hydrolysis of the t-butyl esters, and/or cyclization.
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To overcome the problem o f intermediate cyclization during ethyl ester
hydrolysis, ethyl-2-nitroacetate was alkylated with l-butyl-2-bromoacetate in DMF and
tetrabutyl ammonium iodide at SO °C. The shorter chain length of this alkylating agent

OH
tBu

tBu

OH
tBu

. c

2 2

. d

2 2

°"tBu

Figure 2.17. Base catalyzed intramolecular cyclization of 2,2-Bis(f-butylcarboxyethyl)
glycine to yield racemic mixture o f 3-carboxy-3-(f-butylcarboxyethyl)-2-pyrrolidinone
2 .2 d.

Figure 2.18. ORTEP o f 3-carboxy-3-(/-butylcarboxyethyl)-2-pyrrolidinone.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

assures that base catalyzed cyclization does not occur.

Subsequent catalytic

hydrogenation over Raney nickel in EtOH/AcOH at 60 psi yields the desired ethyl-2,2bis(f-butylcarboxymethyl)glycine in quantitative yield (Figure 2.19).
hydroxide induced hydrolysis yields the desired zwitterion of

Lithium

, -bis(/-butyl

2 2

carboxymethyl)glycine in high yield. The zwitterion of this derivative can now be N°protected to allow for SPPS incorporation (Figure 2.20).

04
C3

02
05

C9

C2

C4

03

C6

08

C12
C10

C7

C11

06

C16

07
C13
C14

C15

Figure 2.19. ORTEP of 2,2-Bis(/-butylcarboxymethyl)-2-nitroacetate.

A selectivity problem is encountered when attempting selective reduction of the
nitro versus nitrile groups in the synthesis of Fmoc-Bap(Boc)2 -OH.

Catalytic

hydrogenation over Raney nickel shows complete reduction o f all three functional
groups. However, isolation of the triamine derivative has been found to be difficult and
selective Fmoc/Boc protection of the resulting triamine resulted in low yields and
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Figure 2.20. Synthetic scheme of the synthesis of Fmoc-Basp(Boc)2 -OH 23.

5

3

as

(

complex mixtures. Borane is known to selectively reduce nitriles in the presence of
nitro groups. Reduction with this reagent, however, yielded primarily starting material.
Additional attempts at selective reduction of the nitro or nitriles have been unsuccessful.
Thus, further attempts at the synthesis of Fmoc-Bap(Boc)2 -OH from this starting
material were abandoned.

Alternative routes, which may lead to the successful

synthesis of this fascinating amino acid, are presented in chapter 6 of this dissertation.
23.

EXPERIMENTAL

23.1. Piperidine-4-spiro-5'-hydantoin (2.1b)
H

(NH4 )2C03
KCN
MeOH / H20

HN

O'
2.1a

2

.1 b

A 1000 mL round-bottom flask was fitted with a stirbar and charged with 4piperidone monohydrate hydrochloride 2.1a (30.0 g, 195 mmol), ammonium carbonate
(4139 g, 420 mmol), methanol (250 mL) and deionized water (150 mL). The mixture
was allowed to stir at room temperature until all solids were dissolved and potassium
cyanide (26.71 g, 410 mmol) dissolved in deionized water (100 mL) was added
dropwise to the reaction mixture over a period of 10 minutes. The reaction was sealed
with a rubber stopper and allowed to stir at room temperature for 48 hours. The
resulting suspension was concentrated to a volume of 300 mL using rotary evaporation
at 40 °C and the solution was cooled to 10 °C. The precipitated white solid was
collected in a Buchner funnel using suction filtration. Additional concentration of the
filtrate to a volume o f200 mL gave some additional product that was filtered and added
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to the first crop.

The combined light yellow solid was washed with portions of

deionized water (4 x 25 mL) until pure white. The product was allowed to air dry for 2
hours and then dried in a vacuum oven (85 °C, 0.5 torr) overnight to yield 28.10 g (85%
yield) of pure hydantoin 2.1b. 1H NMR (200 MHz, ck-DMSO) 5 10.75 (bs, 1H), 8.35
(s, 1H), 2.84 (dt, 2H), 2.66 (td, 2H), 1.67 (td, 2H), 1.38-1.24 (m 2H). ,3C NMR (50
MHz, d6 -DMSO) 177.46,156.30,61.09,41.14,37.79.
23.2. l-terf-butyloxycarbonylpiperidine-^-spiro-S’-O ’^ ’-bisff-butyloxy carbonyl))
hydantoin (2 . 1 c)

TEA/DMAP

2

.1 b

2

.1 c

Hydantoin 2.1b, (26.0 g, 154 mmol), was suspended in 1000 mL of dry 12dimethoxyethane in a 2000 mL three-necked round bottom flask, which was equipped
with an argon inlet valve, an oil bubbler, and an overhead mechanical stirrer. To this
suspension, triethylamine (15.7 g, 154 mmol) was added in one portion and the
suspension was allowed to stir for 30 minutes. While stirring, di-/ert-butyl dicarbonate
(168.0 g, 770 mmol) was transferred by pipette into the reaction mixture, followed by 4*
dimethylaminopyridine (DMAP) (0.19 g, 1.54 mmol). A catalytic amount (020 g) of
DMAP was added every 12 hours during the course o f the reaction. The reaction vessel
was flushed briefly with argon and allowed to stir vigorously for 72 hours. The solvent
was removed by rotary evaporation and the crude product was dissolved in chloroform
(500 mL). The solution was washed with 1.0 N H Q (3 x 200 mL) and the combined
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acid washes were backwashed with chloroform (100 mL). The organic layer was
washed with saturated NaHCC) 3 (100 mL) and brine (100 mL). The organic layer was
dried over MgSC> 4 and the solvent removed by rotary evaporation. The resulting crude
product was dried under vacuum at 0.01 torr for 24 hrs. The resulting light yellow solid
was triturated by suspending the finely ground product in diethyl ether (400 mL),
stirring for two hours, and vacuum filtering the solid in a Buchner funnel followed by
washings with portions o f diethyl ether (4 x 50 mL). The product was dried under
vacuum (85 °C, 0.5 torr) for 24 hours to give 57.9 g (80% yield) of 2.1c. lH NMR (200
MHz, CDClj) 5 4.29-4.01 (m, 2H), 3.42-3.57 (app dt, 2H), 2.67 (dt, 2H), 1.76 (m, 2H),
1.58 (s, 9H), 1.54 (s, 9H), 1.47 (s, 9H). 13C NMR (50 MHz, CDClj) 169.98, 154.71,
14824,147.50,145.35,87.51,8536,80.13,62.53,39.96,29.87,28.62,2821,27.91.
2 3 3 . l-/eif-butyIoxycarbonylpiperidine-4-amino-4-carboxylic ad d (2.1d)
Boc
i,

O

Boc

- 1) 2.0M KOH/THF

B o c -Nn ' Tr^ 0

O

2\ oH 7 0

2) pH 7.0

'Boc
2 .1 c

rS
I

I

h3N
2

®
C02

.1 d

l-rerf-butyloxycarbonylpiperidine-4-spiro-5’-(r,3 ’-bis(/errt>utyIoxycarbonyl))
hydantoin 2.1c (40.0 g, 0.083 mole), was suspended in THF (340 mL) in a 2000 mL
Erlenmeyer flask. While stirring vigorously with a stirbar, 2.0 M aqueous potassium
hydroxide solution (340 mL) was added in one portion. The flask was stoppered and
the mixture was allowed to stir for 4 hours. The clear solutions were poured into a
separatory funnel and the bottom layer was drained into a 1000 mL round bottom flask.
Residual dissolved THF was removed by rotary evaporation and the aqueous solution
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was chilled in an ice bath. While stirring at 4 °C, the pH of the aqueous solution was
adjusted to 7.0 by slow addition o f a 2.0 N HC1 solution.

The resulting white

precipitate is filtered and dried in vacuo (85 °C, 0.5 torr) to yield 19.7 g (95% yield) of
the amino acid. *H NMR (200 MHz, tk-DMSO)

8

3.61-3.35 (m, 4H), 1.95-1.79 (in,

4H), 1.39 (s, 9H).
2.3.4. l-terf-butyloxycarbonyl-4-(9-fluorenylinethyloxycarbonylamino)-piperidine
4-carboxylic acid (2.1) 4
Boc
Boc

e
co2

0

h 2n

2

Q

DIEA / TMS-CI

COjH

Fmoc-CI / DCM

.1 d

2 .1

Finely ground tri-Boc hydantoin 2.1d (17.0 g, 69.6 mmol) was placed, together
with a stirring bar, in a 1000 mL three-necked round bottom flask, which was stoppered
and evacuated for three hours prior to use. While flushing with argon, the flask was
equipped with an argon inlet/outlet valve, a septum, and a bubbler submerged into a 6 . 0
M KOH bath. Anhydrous DCM (500 mL) was cannulated into the reaction vessel and
DIEA (22.5 g, 174 mmol, 30.3 mL) was added via syringe. The reaction was stirred for
thirty minutes and chlorotrimethylsilane (17.6 mL, 15.1 g, 140 mmol) was added
dropwise while stirring.

The reaction was allowed to stir for an additional thirty

minutes and the septum was replaced with a reflux condenser.

The solution was

refluxed for three hours during which the reaction became homogeneous. At thirtyminute intervals, the reaction vessel was flushed for thirty seconds with argon to
remove HC1 formed in the reaction.

The solution was cooled to -10 °C and 9-
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fluorenylmethyl chloroformate (Fmoc-Cl) (18.0 g, 70.0 mmol) was added in one
portion. The solution was allowed to stir for 3 hours, under a constant slow stream of
argon. The solvent was removed by rotary evaporation and the product distributed
between diethyl ether (200 mL) and aqueous 2.5% Na2 C0 3 (1000 mL). The aqueous
layer was separated and washed with additional portions of diethyl ether (2 x 100 mL).
The aqueous layer was placed on a rotary evaporator at room temperature to remove
any dissolved ether and acidified to pH 2.0 in an ice bath using 2.0 N HC1. The
precipitated free acid was extracted with ethyl acetate (300 mL) and additional portions
o f ethyl acetate (2 x 150 mL). The ethyl acetate extracts were combined, dried over
MgS0 4 , filtered, and the solvent was removed by rotary evaporation to yield 29.56 g
(91 % yield) of pure product 2.1e. lH NMR (200 MHz, CDC13) 5 8.30 (bs, 1H), 7.70 (d,
2H), 7.53 (d, 2H), 7.30 (t, 2H), 7.25 (t, 2H), 4.37 (m, 3H), 3.76 (m, 2H), 3.04 (m, 2H),
1.96 (m, 2H), 1.51 (m, 2H), 1.44 (s, 9H).

l3C NMR (50 MHz, d^-DMSO) 175.01,

155.41, 153.89, 143.81, 140.76, 127.63, 127.06, 125.28, 120.07, 78.71, 65.39, 59.74,
56.69.46.78.31.28.28.05.
2.3.5. Ethyl-2,2-Bis(f-butylcarboxyethyl)-2-nitroacetate (2.2a)

DIEA, TEAB
CH3CN

tBu

Ethyl nitroacetate (8.0 g, 60.1 mmol) was dissolved in acetonitrile (100 mL) in a
250

mL

roundbottom

flask

together

with

a

magnetic

stirrer.

N,N'-

diisopropylethylamine (15.54 g, 120.0 mmol) was slowly added to the solution while
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stirring at 0 °C. A catalytic amount o f tetraethylammonium bromide (TGAB) (0.63g,
0.3 mmol) was added, the reaction was sealed with a rubber septum and allowed to stir
at 0 °C for 10 minutes. f-Butylacrylate (15.41g, 17.6 mL, 120.0 mmol) was added
dropwise over a period of 15 minutes. The reaction was allowed to slowly rise to room
temperature and stirred for 48 hours. The reaction was monitored by TLC (100%
dichloromethane) until all starting material was consumed.

The acetonitrile was

removed in vacuo and the resulting crude was dissolved in diethyl ether (100 mL). The
organic layer was washed with IN HCl (2 x 100 mL) and saturated sodium carbonate
solution (2 x 100 mL). The organic layer was separated and filtered over a thin pad of
silica in a Buchner funnel. The silica was washed with diethyl ether (2 x 30 mL) and all
organic fractions combined. The ether was dried over anhydrous sodium sulfate and
removed by rotary evaporation. The desired dialkylated a-nitro ester 2.2a was obtained
in good purity with no further need for purification (21.95 g, 94.1%). ‘H NMR (250
MHz, ck-DMSO)

8

4.24 (q, 2H), 2.38 (m, 4H), 2.24 (m, 4H), 1.40 (s, 18H), 1.21 (t,

3H). 13C NMR (60 MHz, de-DMSO) 170.39, 165.81, 94.58, 80.33, 62.94, 29.04,
28.33, 27.63, 13.53.

HRFAB-MS m/z 3902119 (M +H)\

EA: Ci8 H3 iN 08. calc:

55.51% C, 8.02% H, 3.60% N, found: 55.31%C, 7.83% H, 3.87% N.
23.6. Ethyl-2,2-bis(f-butylcarboxyethyl) glycine (2.2b)
h2n

H2 (50psi)
Raney Ni

O

Nitroester 2.2a (8.0 g, 24.63 mmol) was dissolved in absolute ethanol (30 mL)
and 3.0 g o f a 50% (w/w) slurry of Raney Nickel in water was added. The reaction was
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hydrogenated over hydrogen gas (60 psi) for 72 hours. The reaction was monitored by
TLC (100% DCM). The reaction was filtered carefully over Celite and the Celite cake
washed with DCM (100 mL). Organic solvents were removed in vacuo to yield 2.2b in
excellent purity (7.4 g, 93%). ‘H NMR (250 MHz, dg-DMSO)

8

4.09 (q, 2H), 2.34-

1.64 (m, 8 H), 1.81 (s, 2H), 1.39 (s, 18H), 1.84 (t, 3H). I3C NMR (60 MHz, d<s-DMSO)
17524,172.03,79.51,60.40,59.22,34.20,29.83,27.69,14.05.
23.1. Ethyl-2,2-bis(f-butylcarboxyethyl)-2-hydroxylaminoacetate
OH O

n
H2 (50psi)

2 2

a

Nitro ester 2.2a (1.0 g, 2.57 mmol) was dissolved in absolute ethanol (20 mL)
and 10% (w/w) palladium on carbon (O.lg) was added carefully to the solution. The
dark black suspension was placed in a hydrogenation flask and hydrogenated at 50 psi
for 24 hours. The reaction was monitored by TLC (100% DCM) and continued until all
starting material was consumed. The Pd / C was removed by vacuum filtration through
a Celite cake which was washed with several portions of ethyl acetate. Additional
filtrations through Celite may be required to remove all traces of catalyst The organic
filtrate was dried over anhydrous sodium sulfate and the crude isolated by rotary
evaporation.

Drying under high vacuum overnight yields the hydroxylamine in

quantitative yield (0.97 g, 100%). lH NMR (250 MHz, ds-DMSO) 5 723 (s, 1H), 5.69
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(s, 1H), 4.06 (q, 2H), 2.15 (m, 4H), 1.72 (m, 4H), 137 (s, 18H), 1.17 (t, 3H ).). I3C
NMR (60 MHz, dfi-DMSO) 173.65, 172.03, 79.54, 66.60, 29.12, 27.71, 26.31, 14.07.
FAB-MS m/z 376.77 (M+H)+.
23.8. 2,2-bis(f-butyIcarboxyethyl) glycine (Bglu(/Bu)2 -OH, 2.2c)
O

O
1.4 eg. Me4NOH^

> r°
1

o

o

r

H20 / MeOH

> r°
1

. b

o.
o

o

r

2.2c

2 2

Amino ethyl ester 2.2b (3.0 g, 8.34 mmol) was dissolved in methanol (20 mL) in
a 100 mL round-bottom flask and 10 mL water was added to the solution. The solution
was cooled to 0 °C and MejNOH solution (4.26 g, 25% w/w in methanol) was added
dropwise through a pressure equalizing addition funnel. The flask was sealed with a
rubber septum and was slowly allowed to rise to room temperature and stirred for 24
hours. The reaction is monitored by TLC (100% EtOAc) until complete. After the
reaction was determined to be complete, it was diluted with saturated NaCl (50 mL)
solution and the pH adjusted to 5.0 with 1.0 N HC1. The methanol was removed in
vacuo by rotary evaporation and the resulting suspension cooled in the refrigerator at 6
°C for 24 hours until of the zwitterion precipitated from solution. The precipitated
zwitterion was removed by suction filtration and dried overnight under high vaccum to
yield the pure product 2.2c (0.72 g, 26%). lH NMR (250 MHz, d«-DMSO)

8

4.92 (s,

3H), 2.42-1.91 (m, 8 H), 1.43 (s, 18H) I3C NMR (60 MHz, cfc-DMSO) 18022, 173.78,
81.87,66.60,34.44,31.41,2831.
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23.9. 3-Carboxy-3-(f-butylcarboxyethyl)-2-pyrrolidinone (2.2d)

O

O
n II
Nv / ^

o.»
^

0

H

Me4N0H
tB u''

a

.0

H20/M e0H
tBu
0

0

tBu

. d

. b

2 2

2 2

Amino ethyl ester 2.2b (3.0 g, 8.34 mmol) was dissolved in methanol (20 mL) in
a 100 mL round-bottom flask and water (10 mL) added to the solution. The solution
was cooled to 0 °C and Me^NOH solution (4.26 g, 25% w/w in methanol) was added
dropwise through a pressure equalizing addition funnel. The flask was sealed with a
rubber septum and slowly allowed to rise to room temperature while stirring for 24
hours. The reaction was monitored by TLC (100% EtOAc) until complete. After the
reaction was determined to be complete, it was diluted with saturated NaCl (50 mL)
solution and the pH adjusted to 5.0 with 1.0 N HC1. The methanol was removed in
vacuo by rotary evaporation and the resulting suspension cooled in the refrigerator at 6
°C for 24 hours until the zwitterion precipitated from solution.

The precipitated

zwitterion was removed by suction filtration and the aqueous filtrate further acidified to
pH 2.0 with 1.0N HQ. The precipitated product was extracted with diethyl ether (2 x
50 mL) and recrystallized from hot carbon tetrachloride to yield pyrrolidinone 2.2d in
good yield (2.07 g, 78%) ‘H NMR (250 MHz, d^-DMSO)
8

8

8.10 (s, 1H), 2.46-1.63 (m,

H), 139 (s, 9H).
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23.10. Ethyl-2,2-bis(f-butyIcarboxymethyI)-2-nitroacetate (23a)

DIEA, TBAI, DMF

O'

bromo f-butyl acetate

23a
Ethyl nitroacetate (S.O g, 37.5 mmol) was dissolved in 20 mL DMF in a 250 mL
round-bottom flask and 2-bromo-/-butylacetate (15.4 g, 78.9 mmol) was added. While
stirring, tetrabutylammonium bromide (1.39 g, 3.75 mmol) was added in one portion
and the solution allowed to stir for 15 minutes. In a pressure equalizing addition funnel,
DIEA (10.7 g, 82,6 mmol) was added dropwise. The rate of addition was controlled to
keep the temperature of the reaction at under 50 °C. After addition, the reaction was
sealed tightly and kept at 50 °C for an additional 24 hours while stirring.
consumption of

2

The

-bromo-f-butylacetate can be monitored by gas chromatography.

After 24 hours, the reaction was allowed to cool to room temperature, diluted with
diethyl ether (500 mL) and washed successively with IN HC1 (2 x 100 mL), saturated
aqueous sodium carbonate solution (2 x 100 mL), water (4 x 100 mL) and brine (100
mL). The organic phase was dried over anhydrous sodium sulfate and the solvent
removed in vacuo by rotary evaporation. Residual DMF was removed under high
vacuum over 24 hours. The resulting dark red crude was recrystallized from boiling
hexane to yield 9.8 g (79%) of analytically pure ethyl-2 ,2 -bis(f-butylcarboxymethyl)-2 nitroacetate (23a) as pale yellow crystals. lH NMR (250 MHz, CDC13)

8

435 (q, 2H),

335 (dd, 4H), 1.42 (s, 18H), 137 (t, 3H). l3C NMR (60 MHz, CDC13) 167.43,165.07,
90.09,82.64,63.58,39.90,28.15, 13.91. FAB-MS m/z 362.40 (M+H)+
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2J.11. Ethyl-2J-bis(r-butylcarboxymethyI) glycine (23b)

H2 /6 0 P S I

_

Raney Ni. EtOH, AcOH ^

23a

23b

Ethyl-2 J-bis(r-butylcarboxymethyl)-2-nitroacetate 23a (1.3 g, 3.92 mmol) was
dissolved in absolute ethanol (10 mL) together with glacial acetic acid (1 mL). A 50%
(w/w) slurry of Raney nickel in water (1.0 g) was added.

The reaction was

hydrogenated over hydrogen gas (60 psi) for 24 hours. The reaction was monitored by
TLC (silica gel, 100% DCM). The resulting solution was filtered carefully over Celite
and the Celite cake washed with EtOH (30 mL). Volatile solvents were removed in
vacuo and the resulting crude dissolved in diethyl ether (30 mL). The ether was washed
with saturated sodium carbonate (30 mL) and brine (SO mL). The organic fraction was
separated, dried over anhydrous sodium sulfate and rotary evaporated to yield 2 J b in
excellent yield (1.1 g, 92%) and purity ‘H NMR (250 MHz, CDCI3 )

8

4.12 (q, 2H),

2.58 (dd, 4H), 2.26 (s, 2H), 1.37 (s, 18H), 120 (t, 3H). l3C NMR (60 MHz, CDCI3 )
174.98,169.74,81.50,61.53,57.79,45.05,28.19,1428. FAB-MS m/z 331.8 (M+H)+
2 3 .1 2 .2J-bls(/-butylcarboxymethyl) glycine (Basp(fBu)rOH, 23c)

h2n .

LiOH
EtOH, H20

OtBu

23b

23c
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Ethyl-22-bis(/-butylcarboxymethyl) glycine (2.0g, 6.03 mmol) was dissolved in
absolute ethanol (20 mL). LiOH (0.4g, 18.1 mmol) in water (10 mL) was added and
the reaction stirred at SO °C until all starting material was consumed by thin layer
chromatography (silica gel, 100% ethyl acetate, ca. 3 hours). The resulting solution was
cooled to room temperature, diluted with brine (40 mL) and the ethanol removed in
vacuo. The aqueous solution was neutralized with IN HC1 to pH 6.0 and the resulting
precipitate was filtered. The white powder was allowed to dry under vacuum for 24
hours to yield the analytically pure zwitterion 23c in quatitative yield (1.81.g, 100%).
lH NMR (250 MHz, cfe-DMSO)

8

2.69 (dd, 4H), 1.40 (s, 18H). l3C NMR (60 MHz,

dfi-DMSO) 171.80, 171.23,82.40,71.23,59.59,29.51.
23.13. N'-(9-fluorenylmethyloxycarbonyl)-2,2-bis(r-butylcarboxymethyI) glycine
(Fmoc-Basp(fBu)2 -OH, 23)

DMF. HaO
DIEA Fmoc-CI

Fmoc—N

OH

tBuO'

23c

23

23c (0.25 g, 0.81 mmol) was dissolved in wet DMF (10 mL) along with DIEA
(0.22 g, 1.61 mmol). Enough water was added to allow for the amino acid to go into
solution, and Fmoc-CI (0.20 g, 0.78g) was added in one portion. The reaction was kept
at 50 °C for 24 hours. IN HQ (30 mL) was added and the reaction extracted with
diethyl ether (30 mL). The ether was washed with IN H Q (3 x 20 mL) and the organic
layer dried over Na2 S04. Rotary evaporation gives the crude Fmoc-Basp(/Bu)2 -OH in
fair yield (0.30g, 71%). lH NMR (400 MHz, CDQ3) 8 7.68-7.19 (m, 8 H), 622 (t, 1H),
426 (d, 2H), 336-2.61 (dd, 4H), 131 (s, 18H).
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23.14. Ethyl-2,2-Bis(2-cyanoethyl)-2-nitroacetate (2.4a)
O

o

DIEA/TEAB
acryionitrile
AcCN

NC'

CN

2.4a

Ethyl nitroacetate (8.0 g, 60.1 mmol) was dissolved in acetonitrile (100 mL) in a
250

mL

roundbottom

flask

together

with

a

magnetic

stirrer.

N,N’-

diisopropylethylamine (15.54 g, 120.0 mmol) was slowly added to the solution while
stirring at 0 °C. A catalytic amount tetraethylammonium bromide (TEAB) (0.63g, 0.3
mmol) was added, the reaction was sealed with a rubber septum and allowed to stir at 0
°C for 10 min. Acryionitrile (6.37 g, 120.0 mmol) was added dropwise over a period of
15 min. The reaction was allowed to slowly rise to room temperature and stirred for 48
h.

The reaction was monitored by TLC (100% dichloromethane) until all starting

material was consumed. The acetonitrile was then removed in vacuo and dissolved in
diethyl ether (100 mL). The organic layer was washed with IN HC1 (2 x 100 mL) and
saturated sodium carbonate solution (2 x 100 mL). The organic layer was separated and
filtered over a thin pad of silica in a Buchner funnel. The silica was washed with
diethyl ether (2 x 30 mL) and all organic fractions combined. The ether was dried over
anhydrous sodium sulfate and removed by rotary evaporation. The desired dialkylated
a-nitro ester was obtained in good purity with no further need for purification (16.47 g,
84.1%). ‘H NMR (250 MHz, de-DMSO) 5 437 (q, 2H), 2.63 (m, 8 H), 134 (t, 3H) l3C
NMR (60 MHz, (fe-DMSO) 164.71,118.99,9337,63.58,28.55,13.44,11.79 HRFAB-
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MS m/z 262.0809 (M+H)+, EA: CioHl3 N 3 0 4 , calc: 5020% C, 5.48% H, 17.56% N,
found: 50.07% C, 5.36% H, 17.61% N.
22.15. 0-Ethyl-N“-Allyloxycarbonyl-2,2-Bis(f-butylcarbo:xyethyl) glycine

Alloc—N

AllooCI
DIEA/DCM

tBu

tBu

tBu'

tBu

. b

2 2

The a-amino ethyl ester 2.2b (4.0g, 11.1mmol) was dissolved in anhydrous
DCM (40 mL) in a round-bottom flask. DIEA (1.72g, 13.4 mmol, 2.33 mL) was added
in one portion and the reaction cooled to 0 °C in an ice-bath. Allyl chloroformate
(1.48g, 1224 mmol, 1.30 mL) was added dropwise through an addition tunnel and the
reaction was allowed to rise to room temperature over 20 h. The reaction was then
diluted with DCM (50 mL) and washed with 1.0 N HC1 (2 x 100 mL). The organic
layer was dried over anhydrous sodium sulfate and all volatiles removed in vacuo to
yield the crude Alloc-Bglu(/Bu)2 -OEt as a pale yellow oil (4.82 g, 97%), which was
used without further purification. lH NMR (250 MHz, (k-DMSO)

6

7.53 (s, 1H), 5.73

(m, 1H), 527 (dd, 1H), 5.15 (dd, 1H), 4.42 (d, 2H), 4.03 (q, 2H), 2.13-1.81 (m, 8 H),
1.37 (s, 18H), 1.13 (t, 3H). I3C NMR (60 MHz, d«-DMSO) 172.18, 171.57, 154.40,
133.71,116.74,79.69,6423,60.45,32.30,29.16,28.32,27.66,13.93.
2.4.

CONCLUSIONS
Ca,C°-disubstituted amino acids (cmxAAs) are highly useful tools for inducing

desired secondary structure in short peptide segments. The synthesis of highly watersoluble amphipathic peptides with high levels of ococAAs is hindered by the intrinsically
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low solubilities o f these residues. The synthesis of a series of polyfuctional aaAAs
have been presented to overcome these difficulties. The incorporation of the Ca,Cadisubstituted lysine analog, Api, into short peptides has been shown to successfully
induce helical secondary structures while retaining high water solubility. Api has been
synthesized through the application of the Bucherer-Berg hydantoin hydrolysis to yield
an orthogonally protected derivative suitable for solid-phase peptide synthesis.
Problems associated with contamination by bis(/-butyl)carbamate can be overcome by
utilizing a selective aqueous / organic hydrolysis mixture composed o f 2.0 M KOH and
THF.
The successful application o f Bglu/Basp and Bap, will allow for new peptides
with interesting salt-bridging possibilities and increased amphipathic character in short
sequences.

These derivatives are synthesized by the rapid dialkylation o f ethyl

nitroacetate under weakly basic conditions.

Tetraethyiammonium bromide (TEAB)

facilitates Michael-type alkylations by acting as a highly dissociated counterion. Sn2
alkylation with r-butylbromoacetate was achieved with DMF/TBAI.

The use o f a

tetraalkylammonium iodide in the reaction of alkyl bromides was found necessary to
result in satisfactory yields.

Catalytic hydrogenation of the bis(/-butylcarboxylate)

derivatives yields the corresponding ethyl amino esters in excellent yield.
Saponification of the ethyl ester of the Bglu derivative results in rapid intramoecular
cyclization to yield a racemic mixture of lactams.

This was not observed in the

corresponding 2 ,2 -bis(f-butylcarboxymethyl) derivative, as the cyclization would result
in a four-membered ring. Na-Fmoc protection yields the orthogonally protected amino
acid.
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The use of these synthetic pathways allows for the preparation of synthetically
sensitive side-chain protecting groups to be incorporated into polyfunctional amino acid
derivatives. Application o f these derivatives in peptide synthesis will give new insight
into sequence induced secondary structure formation and structure-function studies.
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CHAPTER 3
AMPHIPATHIC CONTROL OF PEPTIDE STRUCTURE
3.1.

INTRODUCTION
The ability to design desired secondary peptide structure is a major goal in

peptide studies. How proteins function, as a result of peptide structure, is the central
dogma of many areas of pharmacology, immunology, cell biology and medicinal
chemistry. Like learning a new written language, the process of understanding how a
protein works, is dependant upon one's ability to first have a thorough concept o f the
letters (or amino acids) which make up the alphabet of protein science. Once this is
achieved, and the basis of the language is established, one moves on to piece the letters
together to form words, which would represent structural domains within the protein.
Next, the words are connected to make sentences, paragraphs, chapters and so on, until
the entire quaternary structure of the protein is realized. However, to understand the
meaning o f what is in the text, one must be able to decipher the code of the words.
What effect does rearranging the words in a sentence have on the overall expression of
the sentence?

In turn, what effect does rearranging the amino acid sequence of a

peptide ultimately have on peptide structure and function? To answer this question, one
must strive towards the ability to determine peptide structure and function a priori from
specific amino acid sequence.
Protein structure is composed of four levels o f complexity: 1) Primary structure:
the description of which amino acids are present in the peptide and in what sequence
they are found. 2) Secondary structure: the local folding pattern that arises, as a direct
result of hydrogen bonding in the primary sequence. These patterns include primarily
sheet-type folding or helix-type folding.

3) Tertiary structure: long-distance

62

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

interactions between residues (hydrogen bonding or covalent (disulfide bridging)),
4) Quaternary

which induce a globular three-dimensional shape to the protein.

structure: two or more proteins may converge to form a macromolecular cluster, which
in turn encompass the functional protein.
The determination o f peptide secondary structure depends on the intrinsic ability
of covalent bonds within the peptide backbone to adopt preferred torsion angles. The
torsion angle about the N-Ca bond of a peptide is denoted by <|>; the torsion angle about
the Ca-C bond is denoted by y ; and the torsion angle about the amide C’-N bond by to,
as is shown in Figure 3.1. In the cis configuration, these angles are all given the value
of 0. Rotation from this point about the bonds, so that the atoms viewed behind the
bond move clockwise are given positive values up to 180*.

Rotation in the

counterclockwise direction gives a negative torsion angle, to the extent of -180*.3,1
The torsion angles o f conformations such as (3-sheets, a-helices and 3to-helices are well
established (Table 3.1).
Table 3.1. Parameters for peptide secondary structure. 3 ' 1
Conformation

Bond Angle (degrees)

Residues
/turn

Translation
/residue (A)

<|>

\|f

CD

Antiparallel [3-sheet

-139

+135

-178

2 .0

3.4

Parallel [3-sheet

-119

+113

180

2 .0

3.2

a-helix

-57

-47

180

3.6

1.5

3 io-helix

-49

-26

180

3.0

2 .0

x-helix

-57

-70

180

4.4

1.15
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Figure 3.1. Perspective drawing o f polypeptide backbone showing two peptide units.
The peptide is shown in the fully extended trans conformation where <jFtp=ca=180*.

More than any other secondary structure, the helix motif is found throughout
nature in proteins. Helices are often found in, or near, active sites and constitute a large
portion of the functional aspect of proteins. O f these helical motifs, the a-helix is by far
the most prevalent, constituting nearly 80% of all protein structure. The a-helix has 3.6
residues per turn and a translation per residue o f 1.5A, or 5.41A per turn. The torsional
angles for the a-helix are very favorable for most amino acids.

The structure is

characterized by the rth carbonyl oxygen o f each residue hydrogen bonding to the
backbone amide N-H bond of the r+4th residue along the chain. These hydrogen bonds
are nearly parallel to the helix axis (Figure 3.2). This allows most proteinogenic amino
acids to adopt the conformation without side chain interaction. Only proline is not
found in the a-helical motif. 3 ' 1
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Figure 3.2. Hydrogen bonding pattern of the right handed a-helix.
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Figure 3J . Hydrogen bonding pattern o f the right handed 3io-helix.
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Although similar in structure, the a-helix is much more stable and occurs more
frequently than it's relatively unexplored cousin, the 3io-helix; which comprises < 1 0 %
of all helix structure and is often found at the ends of a-helices (Figure 3.3). While the
factors favoring a-helical (i«—i+4) structures have been well documented, the secrets of
the 3 1 0 -helical conformation (/<— i + 3 hydrogen bonding) have only recently begun to
be understood. This helix is, however, gaining interest, as it is believed to be a folding
intermediate to the a-helical configuration. 3 -2 ' 7 In addition, short stretches of 3io-helix
frequently occur in globular proteins and protein recognition steps may involve facile
transitions between the a-helix and 3io-helix. 3 -2 ' 10 Thus, the ability to understand and
control the delicate equilibrium between these two closely related structures is desirable
in the development o f peptide design research.
Most studies exploring the equilibrium between the a - and 3io-helix have been
concentrated on short, hydrophobic peptides containing several Ca,Ca-disubstituted
amino acids (aaA A ’s) . 3 -1 1 ' 14 Natural a-helical sequences commonly require more than
20-30 amino acid residues to obtain a significant helical character at room
temperature. 3 -1 5 ' 1 7

However, the incorporation of high levels of C“,Ca-disubstituted

amino acids (e.g. aminoisobutyric acid) into the sequence allows for the preparation of
much shorter peptides with significant helical character (Figure 3.4) . 3 -1 2 ’ 1 4 ,1 8 ' 2 2 These
peptides, however, exhibit higher hydrophobic character than their proteinogenic
counterparts.
limited

As a result, spectroscopic studies of these peptides have often been

to organic

solvents such as dimethylsulfoxide (DMSO), methanol,

trifluoroethanol (TFE) and acetonitrile. Structures o f these peptides have also been
obtained by X-ray analysis of crystals grown from organic solvents. 3 - 1 9 ,2 3 ,2 4 Recently,
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Toniolo and co-workers have reported spectroscopic studies o f a peptide exhibiting 310helical structure in water by the incorporation o f the novel, aza-crown amino acid
ATANP.3-25,26 Due to the interest of these helical configurations as they relate to
physiological conditions and membrane interactions, it is important to study the helix
equilibrium in aqueous/organic environments.
The first characterization of the amphipathic helix was performed by Kendrew
and Perutz on the heme proteins.3-27 These structures are defined by the presence o f a
hydrophilic face and a hydrophobic face along the axis of the peptide. The tendency of
these types of structures to self-associate and interact with bi-lipid membranes results in
high levels of bioactivity and they play an important part in membrane-dependent
processes3-28 as well as lipoproteins3-29, hormones3-30, lung surfactant proteins331,
cytotoxic immunodefense proteins3-32 and antimicrobial agents.3-33
The use o f Ca,Ca-disubstituted amino acids in synthetic helix design has been
shown to induce high levels of helicity into short peptide sequences by introducing
steric constraints on the peptide backbone. This has been exhaustively investigated
with the use of a-aminoisobutyric acid, Aib (1, Figure 3.4)3-11'14, but also with the use
o f alicyclic amino acids, such 1-cyclohexane-1-carboxylic acid, Ac$c (2, Figure
3.4).3-12-34 Recently, the availability of the ionizable Ca,C°-disubstituted amino acid 4aminopiperidine-4-carboxylic acid, Api (3, Figure 3.4) allows us to investigate the
helix-forming ability of highly polar cyclic residues towards peptide secondary
structure.3-35 In addition to introducing high levels of helicity to the peptide, aaAAs
stabilize the peptide towards enzymatic degradation in vivo, which is important in the
development of bioactive agents.

68

Reproduced with permission o f the copyright owner. Further reproduction prohibited without permission.

H

Halk CH32

h 2n

co h

0

h 2n

1

c o 2h

Q

h 2n

2

c o 2h

3

Figure 3.4. Ca,Ca-Disubstituted amino acids aminoisobutyric acid (Aib) 1, 1aminocyclohexyl-1-carboxylic acid (Ac6c) 2 and 1-aminopiperidine-1-carboxylic acid
(Api) 3.
Amphipathicity is a characteristic found in most naturally occurring
antimicrobial peptides such as magainins, cercropins and dermaseptin.3'36 Due to the
high levels of bioactivity of amphipathic peptides, it is not surprising that 50% of all othelices in soluble globular proteins are amphipathic.3*37 The amphipathic character of
these peptides is thought to play a dominant role in the peptide-membrane interactions,
which are responsible for antimicrobial activity.

These amphipathic membrane

interactions prompted us to investigate peptide helicity in micellar and aqueous/organic
environments. Researchers have demonstrated that amphipathicity and hydrophobic
interactions have a large influence on helix stability in aqueous solution.3*37 By
generating sequence permutation isomers of several peptides, we have attempted to
selectively induce a - or 3t0-helices, based purely on primary sequence design.
Incorporation of ionizable and alicyclic Ca,Ca-disubstituted amino acids allow for the
production of short, amphipathic peptides with up to 80% Ca,Ca-disubstituted amino
acids which are highly water soluble, but retain helical character in organic and
aqueous/organic media (Table 3.2).

Each peptide is designed to have maximum

amphipathic character either as an a-helix or a 3io-helix.

69

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Table 3.2. List of prepared de novo peptides. The incorporation of 20% L-lysine (Lys)
allows for CD spectroscopic determination of peptide secondary structure by inducing
right-handed helix formation. Pi-10, ACh-lOa and Cyh-10 were designed to be
perfectly amphipathic as an a-helix while Ipi-10, ACh-10 and Ich-10 were designed to
be perfectly amphipathic as a 3io-helix.
Peptide

Sequence

Design

Pi-10

H-Aib-Aib-Api-Lys-Aib-Aib-Api-Lys-Aib-Aib-NH2

a

Ipi-10

H-Api-Aib-Aib-Lys-Aib-Aib-Lys-Aib-Aib-Api-NH2

3io

Ach-lOa

H-Ac6c-Aib-Lys-Api-Aib-Ac6c-Api-Iys-Ac6c-Aib-NH2

a

Ach-10

H-Api-Aib-Ac6c-Lys-Ac6c-Aib-Iys-Aib-Ac6c-Api-NH2

3io

Cyh-10

H-Ac6c-Ac6c-Api-Lys-Ac6c-Ac6c-Api-Lys-Ac6c-Ac6c-NH2

a

Ich-10

H-Api-Ac6c-Ac6c-Lys-Ac6c-Ac6c-Lys-Ac6c-Ac6c-Api-NH2

3io

The ability of the peptides to selectively adopt their preferred helical motifs can
be illustrated by studying the helical wheel conformations o f the peptides in their a - and
their 3io-helical configurations. Amphipathicity is maximized when the peptides have a
continuous hydrophobic and a continuous hydrophilic face.

Otherwise hydrophilic

residues are distributed throughout the cross-section of the helix. The work presented in
this chapter tests this premise as a design principle. The general sequence o f our a helical peptides is: H-N-N-P-P-N-N-P-P-N-N-NH2; (N=non-polar residues; P=polar
residues) and our 3to-helical peptides have the sequence: H-P-N-N-P-N-N-P-N-N-PNH2.

Peptides designed to adopt the a-helical amphipathic conformation are less

amphipathic in the 3io-helical form and vice versa, (Figure 3.5-11).
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©

a-helical wheel

Preferred Conform ation

Non-preferred Conformation

Figure 3S . Helical wheel cross-sections o f empirical peptide sequences in their
preferred conformation and non-preferred conformations. P designates ionizable polar
amino acid residues (Lys or Api); N designates non-polar residues (Aib or Acec).
Empty circles represent non-occupied locations in the alpha helical wheel.
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a-helix
(preferred)

® Lv*
3io-helix
(non-preferred)

Figure 3.6. Helical wheel motifs showing a-helical and 3io-helical conformations of
Pi-10 (designed to be a-helical).
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©
Api

oc-helix
(non-preferred)

Mb
Mb

Mb

X
©
Figure 3.7. Helical wheel motifs showing a-helical and 3io-helical conformations of
Ipi-10 (designed to be 3io-helical).
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l»»X

^

Api

a-helix

cyti

(preferred)

Aib
Api
Cyh
L**

3io-heUx
(non-preferred)

Y Aib

Apt
Api
Cyh
Alb
Cyh

Cyh

Ab
Uy*

Figure 3.8. Helical wheel motifs showing a-helical and 3io-helical conformations o f
ACh-lOa (designed to be a-helical; Cyh=Ac6c).
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3io-helix
(preferred)

/ubX **•
Cyh

a-helix
(non-preferred)

V

Cyh

Ly*

Figure 3.9. Helical wheel motifs showing a-helical and 3io-helical conformations of
ACh-10 (designed to be 3io-helical; CyhFAcec).
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Cyh

a-helix

Cyh

(preferred)

Cyh
Api
Cyh

Y Cyh

Cyh
Api

3io-helix
(non-preferred)

®( Ly«
Cyh

Api
Cyh

Cyh
Cyh

Cyh

Figure 3.10. Helical wheel motifs showing a-helical and 3 io-helical conformations of
Cyh-10 (designed to be a-helical; Cyh=Ac6c).
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@( Ly«

3to-belix
(preferred)

(= $ #

©
Cyh

a-helix
(non-preferred'

Lyt

Cyh

Cyh
^

YApt

Figure 3.11. Helical wheel motifs showing a-helical and 3io-helical conformations of
Ich-10 (designed to be 3io-heIical; Cyh=Ac6c).
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In order to study the relative formation of 3io- and a-helices in the
aforementioned peptides, one needs to distinguish between the two. For this purpose,
electronic circular dichroism (ECD) spectroscopy has been established as a powerful
tool, hi ECD spectroscopy, helical peptides are characterized by two minima. The
n—mc* transition is centered around 222 nm and one of the two the 7t—>7t* transitions is
centered near 207 nm. Since both the 3io- and a-helices exhibit these minima, the
relative intensities of the minima are used to distinguish between a-helical and 310helical structures. The ratio, R, where R = [0]n-nc*/[6]n-««, has been proposed as the
factor to distinguish a 3io-helix from an a-helix. In 3io-helices R < 0.4, while for ahelices R = l.3'38 An additional distinguishing feature is the positive CD band near 195
nm. This band is much weaker in the 3io-helix than in the a-helix. Other techniques
such as electron spin resonance and NMR are complicated by peptide dynamics and
have met with mixed results, especially with peptides containing aaAA’s.3'39'41
As stated previously, a sufficient database of 3to-helix structures does not yet
exist. As a result, exact estimation of % 3to-helicity in a specific peptide is very
difficult.

It has been suggested that the CD bands of a 3io-helix will be highly

dependent on the <|>- and nt-torsion angles in the peptide backbone. 3io-HelicaI peptides
comprised of aaA A ’s have different <(>- and y-angles than 3io-helical peptides
comprised only of natural amino acids.

Toniolo and co-workers synthesized Ac-

(cxMeVal)g-OtBu which exhibited significant 3io-helical structure, and recently reported
a short peptide exhibiting significant 3io-helical structure in water.3*38,42 The peptide
contains the novel azacrown functionalized amino acid, 2-amino-3-[ 1-(1,4,7triazacyclononane)] propanoic acid.3,26
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3.2.

RESU LTS AND DISCU SSIO N

It was hypothesized that the peptides would adopt the helical structure that
allowed them to be most amphipathic. As expected, Pi-10 (Figure 3.12), ACh-lOa
(Figure 3.14) and Cyh-10 (Figure 3.16) shows CD spectra characteristic of an a-helix in
all solvent systems. Ipi-10 (Figure 3.13) and ACh-10 (Figure 3.15) display a transition
from an a-helix to a 3io-helix as the solvent system increases in organic content. The
most prominent 3io-helical character for both Ipi-10 and ACh-10 was observed in SDS
micelles, which indicates that an amphipathic environment strongly favors the
amphipathic structure in the peptide. It was expected that Ich-10 would display this
same transition; however, this does not occur. Ich-10 displays an nearly perfect ahelical CD-spectrum in all of the solvent systems tested (Figure 3.17). This effect may
be due to steric interactions between adjacent cyctohexano moieties in the tightly
wound 3io-helix (see modeling in figure 3.11). A transition to an a-helix would relieve
this stress by increasing the diameter of the helix, as well as staggering adjacent
alicyclic groups to avoid interference. It is interesting to note the prominent minimum
present at 185 nm for both of these 3io-helices in SDS micelles. These minima are not
found in any of the a-helical peptides, nor are they apparent in the constitutional
isomers o f Ipi-10 and Ach-10. Thus, one must assume that this transition is structure
based and not an effect of solvent or residue absorption. This minimum has seldom
been studied due to solvent interferences in the <190 nm region. It may, however, be an
important factor in the interpretation o f 3io- vs. a-helical segments.

Further

investigation into the significance of these minima in 3io-helical peptides is currently
underway.

79

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

PMO

20x10'

10] (deg x cm2 x dmof1)

15-

1:1 CH3CN -H 20
25m M SD S
9:1 CH 3CN -H20
9:1 CH3CN-TFE

10-

5-

-5 -

-

10-

180

190

200

210

220

230

240

250

Wavelength (nm)

Figure 3.12. CD spectrum o f Pi-10 in various solvent systems.
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Figure 3.13. CD Spectrum o f Ipi-10 in various solvent systems.
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15x10
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Figure 3.14. CD Spectrum of Ach-lOa in various solvent systems.
Ach-10

[6] (deg x cm2 x dmof1)

1:1 CH3CN-H20
9:1 CH3CN-H20
9:1 CH3CN-TFE
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Figure 3.1S. CD Spectrum of Ach-10 in various solvent systems.
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Figure 3.16. CD Spectrum of Cyh-10 in various solvent systems.
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Figure 3.17. CD Spectrum of Ich-10 in various solvent systems.
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250

The percent a-helix was estimated according to the following: percent a-helix
= -lOOCfBjn-Hf + 3000)/33000, where the minimum for the [0]n-wi* transition is
observed in the range 222-225 nm. Little work has been done to quantify the percent
3[o-character in a helix; therefore, we have used the CD spectrum of H-(Leu-Arg-Leu)gOH in diphosphatidyl-choline liposomes as the model 3io-helix.3'42 In this peptide,
= -21,500 deg cm2 dmol'1 is defined as 100% 3io-helix. Using this model, the
above equation is modified to estimate percent 3io-helicity: percent 3to-helix = 1OO([0]ff_«./-21500). It should, however, be noted that the issue of determining relative
amounts of 3io-helical character is still under review and a widely accepted
determination of % 3io-helicity is still not available. The results of CD-spectra 3.12-17
are summarized in Tables 3.3,4 and 5. The peptides showed minimal structure in water
or pH 7.1-7.4, 2.5 mM phosphate buffer. This is not surprising since solvation of the
ionizable residues, which account for 40% of the peptide composition would inhibit
intramolecular hydrogen bonding patterns necessary for secondary structure formation.
Interestingly, Pi-10, ACh-lOa and Cyh-10 all exhibit an isodichroic point near 201,203
and 205 nm, respectively.

This suggests a cooperative helix/coil transition.

An

additional observation is the reduction o f helicity as organic solvent composition
declines.

The increase in helicity as the solvent system becomes rich in organic

composition has been observed in other monomeric a-helices.337 Others have predicted
that peptides with high percentages of aaA A ’s

50%), such as Pi-10 and Cyh-10,

would be 3 io-helical.319,43 In addition, theoretical calculations suggest these peptides
would exhibit a shift to a 3io-helix as organic content increases.33 This is not observed
in our studies, suggesting that amphipathy is a significant factor in determining helix
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Table 3 3 . CD data and calculated structural information for Pi-10 and Ipi-10.a Peptide
concentration was 200 pM. b Units for [0] are deg cm2 dmol'1. c The minimum for the
[0]jc-*x* band is taken in the range from 205-209 nm. d The minimum for the [9]n-»x*
band is taken in the range from 222-225 nm. e In this solvent, Ipi-10 is probably
mixtures of coil structures. The % a-helix is estimated to be -20% and the % 3io-helix
is estimated to be -30%.

ieix^

Peptide*

Solvent

Pi-10

25 mM SDS

-8748

9:1 CHjCN-TFE

Ipi-10

R

% Helicity

Helix

-7933

0.90

33

a

-10709

-7930

0.74

33

a

9:1 CH3CN-H20

-6184

-4287

0.71

22

a

1:1 CHjCN-HjO

-3181

-2128

0.66

15

a

25 mM SDS

-5516

-1750

0.32

25

3io

9:1 CHjCN-TFE

-9916

-3145

0.33

33

3 to

9:1 CHjCN-HiO

-6740

-3605

0.54

e

e

1:1 CHjCN-H20

-4204

-3118

0.74

19

a
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Table 3.4. CD data and calculated structural information for ACh-lOa and ACh-10.a
Peptide concentration was 200 pM. b Units for [0] are deg cm2 dmol'1. 6 The minimum
for the [0]*-*. band is taken in the range from 205-209 nm. d The minimum for the
[0]n-Mc* band is taken in the range from 222-225 nm. e In this solvent, ACh-10 is
probably mixtures o f coil structures. The % a-helix is estimated to be ~20% and the %
3io-helix is estimated to be ~30%.
Peptide*

Solvent

I9 U V

[01b-«*M

R

% Helicity

Helix

ACh-lOa

25 mM SDS

-9542

-7218

0.76

31

a

9:1 CHjCN-TFE

-10580

-6714

0.63

29

a

9:1 CH3CN-H20

-4334

-3358

0.77

19

a

1:1 CH3CN-H20

-2943

-1886

0.64

15

a

25 mM SDS

-3288

-893

027

15

3 io

9:1 CHjCN-TFE

-7480

-4622

0.62

e

e

9:1 CH3CN-H20

-6898

-5785

0.84

27

a

1:1 CH3CN-H20

-6869

-6494

0.95

29

a

ACh-10
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Table 3.5. CD data and calculated structural information for Cyh-10 and Ich-10. *
Peptide concentration was 200 pM. b Units for [0] are deg cm2 dmol'1. c The minimum
for the [0]x-»k« band is taken in the range from 205-209 nm. d The minimum for the
[0]n-«* band is taken in the range from 222-225 nm.
Peptide*

Solvent

[el*-**6*

[e in ^

R

% Helicity

Helix

Cyh-10

25 mM SDS

-10874

-9978

0.92

39

a

9:1 CHjCN-TFE

-10285

-9014

0.88

37

a

9:1 CH3CN-H20

-9339

-8185

0.88

34

a

1:1 CHjCN-HjO

-7846

-7027

0.88

30

a

25 mM SDS

-4792

-5461

1.14

26

a

9:1 CHjCN-TFE

-10959

-8063

0.73

33

a

9:1 CHjCN-HjO

-6974

-6094

0.87

28

a

1:1 CH3CN-H20

-6766

-6579

0.97

29

a

Ich-10
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structure. The transition o f Ipi-10 from an a-helix to a 3io-helix and the lower R-value
fen* Ich-10 in 100% organic solvent agrees with predictions of solvent effects on the 3io/a-helix equilibrium. It has been shown that peptides rich in Aib favor a 3io-helix in
less polar media and an a-helix in water.3*3 The increased stability of the 3io-helix in
non-polar solvents is attributed to the extra hydrogen bond formed relative to the a helix. a-Helices are favored in water because the “extra” carbonyl and amide are able
to interact with the solvent For Pi-10, Ich-10, Cyh-10 and Ach-lOa, a maximum
number of 7 hydrogen bonds are possible in the a-helix conformation. For Ipi-10 and
ACh-10, in 3io-helical structure, 8 hydrogen bonds are possible. Helix end effects and
incomplete micelle binding tend to reduce the absolute helicity of peptides. In the case
of Pi-10, ACh-lOa, Cyh-10 and Ich-10, three N-terminal amides and the two Cterminal carbonyls do not have any internal hydrogen bonding partners. For Ipi-10
and ACh-10, the two N-terminal amides and the two C-terminal carbonyls are without
internal hydrogen bonding partners. As a result, the peptides may adopt non-ideal
structures at the ends to interact with solvent.
Temperature studies of a number of the peptides show a surprisingly high
stability towards helix melting in the range 5-50 °C. This further confirms the theory
that a,a-disubstituted amino acids stabilize helix stability towards temperature
denaturation, as well as enzymatic hydrolysis.313 Representative CD spectra o f ACh-10
in SDS micelles and Cyh-10 in 9:1 acetonitrile/TFE are shown in Figure 3.18 and 3.19.
This relatively small deviation in peptide helicity as a result of increasing temperature
in the range between 5-50 °C was, however, observed in all of the peptides. Helicity
was not determined at 0°C due to the insolubility o f SDS micelles at that temperature.
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Figure 3.18. Helix stability temperature studies of ACh-10 in 25mM SDS micelles.
Note the strong minimum at 186 nm.
Cyh-10 Temperature Study (9:1 CH3CN-TFE)
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Figure 3.19. Helix stability temperature studies of Cyh-10 in 9:1 CH3 CN-TFE.
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33.

EXPERIMENTAL

33.1. Peptide synthesis
Peptides were synthesized using standard Fmoc-amino acid fluoride coupling
conditions. The first 3 or 4 residues were manually coupled onto PAL-PEG-PS solid
support by gently stirring

8

equivalents of the Fmoc-acid fluoride, 3 equivalents of

DIEA and the resin in methylene chloride, until an acceptable yield was determined by
quantitative Fmoc test.

Sometimes gentle reflux was required to obtain successful

coupling. After the first residues were coupled to the resin, the remainder of the peptide
was synthesized using a Milligen 9050 peptide synthesizer on the PAL-PEG-PS solid
support using

8

equivalents o f preformed Fmoc-amino acid fluorides, 3 equivalents of

DIEA and a 1.5 h recycling time. Residues were double coupled when they are third in
a series of Ca,Ca-disubstituted amino acids and the coupling times were extended to 2.5
hrs. A solution o f 20% piperidine / 2% l,8-diazabicyclo[4.5.0]undec-7-ene (DBU) in
DMF was used for Fmoc removal. The peptides were simultaneously cleaved from the
resin and side-chain deprotected using reagent B (8 . 8 : 0.2 : 0.5 : 0.5, trifluoroacetic
acid (TFA) : triisopropylsilane : water : phenol). The resulting acidic solution was
diluted with cold 30% acetic acid, washed with diethyl ether (4 x 50 mL), and
lyophilized.
33.2. Peptide Purification
The crude peptides were purified by preparative reverse-phase HPLC on a
Waters 15 pM Deltapak C4 column using a water (0.05% TFA) and acetonitrile (0.05%
TFA) gradient system.

The gradient was run from 10% to 50% organic and the

absorption monitored at 222 nm. Purity o f the peptides was then checked on a Vydac 5
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jiM Cis column using the same conditions. Matrix assisted laser desorption ionization
(MALDI) mass spectrometry was used to verify the peptide masses. All peptides were
analyzed in positive ion mode using a glycerol matrix. P i-10,1037.1 (M+H)+; Ipi-10,
1037.1 (M+H)+; ACh-lOo, 1157.6 (M+H)+; ACh-10, 1157.6 (M+H)+; Cyh-10, 1277.8
(M+H)+; Ich-10,1277.8 (M+H)+.
3 3 3 . Circular Dichroism
Circular dichroism measurements were taken on a (+)-camphor sulfonic acid
calibrated Aviv 60DS spectrophotometer at 5°C. The measurements were recorded
over 250-180 nm using a 0.1 cm path length quartz cell, 1 nm bandwidth, 10 nm/min
scan speed and a 5 second time constant. Background spectra were acquired prior to
each sample spectrum and the two subtracted. Three repetitive scans were recorded and
averaged to improve signal to noise. The reported mean residue ellipticity [6] (deg cm2
dmol'1) was derived from the observed ellipticity, [6]obs (millidegrees), using the
formula [0] = [0]obs (MRW/10/c), where MRW is the mean residue molecular weight of
the peptide (molecular weight of the peptide divided by the number of peptide bonds), /
is the pathlength (cm) and c is the peptide concentration (mg/mL). CD spectra of all
peptides in this study were taken in solvent systems ranging from 100% organic to 1:1
organic/water.

Final peptide concentrations of 0.2 mM were used for all CD

experiments. The peptides were dissolved in trifluoroethanol for spectra taken in 9:1
CH3 CN:TFE, pH 7.1-7.4, 2.5 mM phosphate buffer for spectra taken in SDS, and
doubly distilled water for the aqueous/organic spectra.

For representative

aqueous/organic experiments, pH 7.1, 2.5 mM buffer was also used as the aqueous
component and resulting spectra were nearly identical to the pure H2O/CH3CN spectra!'
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3.4.

CONCLUSIONS
Ca,Ca-Disubstituted amino acids have long been recognized as powerful tools

for inducing helicity into relatively short peptide sequences. With this work, we have
shown that amphipathicity, too, is a significant driving force in the secondary structure
adopted by short peptides rich in Ca,Ca-disubstituted amino acids. Increasing helicity,
and a transition from a-helix to 3to-helices as a result of increasing organic
environments may suggest that there is a cooperative aggregation by the hydrophilic
side of the amphipathic helices in organic solvents.

In addition, it is shown that

micellar environments, similar to those found under physiological conditions, have a
significant effect upon the ability of peptides to adopt an amphipathic configuration. It
is interesting to hypothesize as to the nature of Ich-10 and why it does not, in fact, adopt
the 3 1 0 -helical formation. Previous studies have supported the fact that cyclic aaAAs
form stable 3i0-helices. This does not, however, occur in the case of Ich-10. It is
possible that steric repulsion, due to the eclipsed i and t+3rd residues in 3io-helical
segments, is a determining factor.
The study of the bioactivity of these types o f peptides may lead to the
development of new therapeutic agents that act by selective interactions with cellular
membranes of macrophages that are infected with pathogenic bacteria such as Brucella
abortus and Afycobacterium tuberculosis. The bioactivity assays and selectivity of the
peptides included in this study are described in chapter 4 of this manuscript.
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CHAPTER 4
SELECTIVE BIOACTIVITY OF SYNTHETIC AMPHIPATHIC
PEPTIDES AGAINST AN INTRACELLULAR PATHOGEN
4.1.

INTRODUCTION
Brucella abortus (Ba) and Mycobacterium tuberculosis (Mtb) are intracellular

pathogens that live and replicate within the macrophages of their hosts.4'1 Ba are rod
shaped gram-negative bacteria which are the primary cause of brucellosis, or undulant
fever in humans.4'2 The fever is characterized by fever, anorexia, muscular weakness,
arthritis and dementia, as well as cardiac and neurological disorders, and may be fatal if
untreated.4,3 In animals, Ba localizes in the reproductive organs, resulting in abortion
and infertility.4'4,5 Human infection often results from exposure to infected animals or
infected animal products, thus brucellosis is a prominent occupational hazard for
humans whom are involved with animal handling.46

Since the bacteria live and

replicate within the white blood cells o f the host, treatment is difficult. The multiple
membrane barrier which seperates the pathogen from the extracellular environment
reduces the antibiotic concentration within the macrophage and reduces the
effectiveness of the antibiotic.4'7,8 In addition, the mechanism by which these organisms
survive and replicate within host macrophages is poorly understood.4'15,16
Mycobacterium species are intracellular pathogens that cause diseases with
etiologies similar to Brucella. Afycobacterntm tuberculosis {Mtb), the causative agent
of tuberculosis, and is one of the more worrisome elements of the developing antibioticresistance problem since Mtb patients that fail treatment have a high risk of death. The
pathogen infects about a third of the world’s population and kills more people, about
two million each year, than any other infectious agent besides HIV/AIDS.4'9*12 Unlike
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many lethal pathogens, Mtb has been found on all continents and is especially prevalent
in countries of the former Soviet Union.4'13
Mtb is a rod-shaped, acid-fast Gram-positive bacterium that localizes mainly in the
respiratory system.

The symptoms of tuberculosis include low-grade fever, night

sweats, fatigue, weight loss and persistent cough. Like Ba, Mtb can live and replicate
within a host’s macrophages, making it difficult to treat Current treatment consists of
short-course chemotherapy based on a regiment of four first-line drugs taken for 6-8
months.4,9,10,12 In addition, there are currently no vaccines to prevent Ba or Mtb in
humans.4,14

Many strains of Mycobacterium now resist antibiotics, making the

development of alternative treatments critical.
Due to exponential growth in the use of classical antibiotic therapy, bacterial
resistance towards antibiotics is becoming an ever growing problem. This problem is
exacerbated in the case of intracellular pathogens since they reside within the cellular
environment of the very immune system which is used to target it and infection is not
associated with a significant extracellular component of the pathogen. Because of this
resistance problem, several new approaches towards antimicrobial defense have been
explored within the past twenty years.

One o f the most promising routes toward

developing a new weapon to battle bacterial agents have been the growing interest in
linear amphipathic peptides as antimicrobial agents. Amphipathic peptides are highly
ubiquitous in nature and make up an important part of the natural defenses of several
species of invertebrates,4,17*22,36,37 fish,4-23"26 amphibians,4'27'30'39,40 and mammals.4"31,32,42
The peptides are characterized by the presence of a definable cationic amphipathic
helical structure and are usually relatively short (<40 residues), thus suggesting that

96

Reproduced with permission o f the copyright owner. Further reproduction prohibited without permission.

considerable biological activity can be exhibited by relatively short sequences.433
These peptides have been found to be active against a wide array of pathogens,
including gram-positive and gram-negative bacteria, protozoa, and fungi.434 Although
currently not prevalent as therapeutic agents, some peptides are currently under review
for use as drugs.

Recently, Hancock reviewed two antimicrobial peptides that are

currently being clinically studied as topical treatments for oral mucositis and the
sterilisation of central venous catheters.435 Some examples of naturally occuring, linear
antimicrobial peptides are listed in Table 4.1.

Table 4.1. Naturally occurring antimicrobial peptides.
Peptide

Source

Ref.

Andropin

Fruit Fly (Drosophila melangaster)

4.36

Bombolitin

Bumblebee (Megabombus pennsylvcmicus)

4 J7

Cercropin A

Silk Moth (,Hyalophora cercropia)

4.18

Clavanin A

Tunicate (Styela clava)

4 J*

Dermaseptin 1

Arboreal frog (Phyllomedusa sauvageii)

4 J9

Magainin 1

South African clawed frog (Xenopus laevis)

4.40

Melittin

Honeybee {Apis mellifera)

4.41

Pleuroddin

Winter flounder {Pleuronectes americanus)

423

Seminalplasmin

Ox {Bos taurus)

4.42
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There has been overwhelming evidence to suggest that these peptides function
by a non-receptor mediated response, thus making them less susceptible towards the
development of resistance.4’43"47

This has been established by the fact that most

antimicrobial peptides are equally active in their D- and L-isoforms. Peptides are,
apparently, initially attracted to cellular membranes by coulombic interactions. The
charge on the polar face o f the peptide cross-section is almost exclusively positive,
which accounts for the peptides’ selectivity and bioactivity towards bacterial cells.
Bacterial cell membranes are unique in that they contain lipopolysaccharides (gramnegative) or teichoic and teichuronic acids (gram-positive), giving their cell membrane
a predominantly negative charge, which attracts the positive charge o f the peptides.434
Mammalian cells are composed predominantly of zwitterionic sphingomyelin
phospholipids, which have been shown to show low affinity for natural antimicrobial
peptides.433,34 Although there have been several theories on the mode o f action of
antimicrobial peptides, it is generally accepted that they function by cellular membrane
permeation after a threshold concentration has been established on the cell surface.
Most antimicrobial peptides are non-helical in solution, which makes pre-surface
aggregation to form rod-like pores, that insert into the membrane, an unlikely scenario.
Hydrophobic partitioning of the surface peptides into the amphipathic environment of
the cellular membrane induces helix formation and disrupts the membrane integrity by
one of two proposed mechanisms:

the “carpet model”4'48 or the “barrel-stave

model”.4*49 Each of these models involves the aggregation of peptides on the cell
surface and disruption of the cellular membrane. However, the process by which the
membrane is permeabilized varies between the two mechanisms.

98

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

The carpet

mechanism is characterized by massive peptide aggregation on the cell surface with the
non-polar face o f the peptides incorporated into the hydrophobic interior of the lipid bi
layer and the polar face facing the exterior of the cell (A). This aggregation is most
likely electrostatically driven between the negative phospholipid headgroups and the
positive charge of the amphipathic peptide. When a threshold concentration of peptide
has been reached, the membrane can fold in on itself (B), exocytizing a portion of the
membrane as a solubilized micelle (Q , resulting in membrane disruption. (Figure 4.1).

carpet" mechanism

barrel-atave" mechanism

mum
nmaffimmr

Figure 4.1. "Carpet" vs. "Barrel-Stave" mechanism of amphipathic peptide-cell
membrane insertion (reproduced from: Oren, Z., Shai, Y. Biopolymers, Pept. Set 1999,
451-463).
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The “barrel-stave” model follows a different pathway. It assumes that peptides
aggregate into a pore-like superstructure on the surface prior to membrane interaction
(A). The pre-formation o f a peptide-aggregate pore allows a relatively small number of
peptides to acquire great potency as membrane disruptors.

After the intial pore

formation, the pore inserts itself into the membrane causing cell lysis (B). This model
holds less credence for explaining the activity o f shorter peptides (<20 residues), which
in theory do not have the physical size to transverse the cell membrane bilayer (—35
A).434 Because the peptide-host interaction is not receptor mediated, the issue of
selectivity has always been a key factor to consider in anti-microbial peptide design.
This question of selectivity may be overcome by the presence of hyper-susceptibility of
target cells towards the attacking peptide.
Due to the promising outlook of amphipathic peptides as potential antimicrobial
agents, six helical amphipathic peptides were designed to act as natural antimicrobial
peptide analogs.

Incorporation of high levels of Ca,Ca-disubstituted amino acids

allowed for the preparation of amphipathic helices which were helical in amphipathic
environments despite very short sequences (10 residues, see chapter 3). In addition, the
presence of Ca,Ca-disubstituted amino acids prevents enzymatic degradation of the
peptides in vitro and in vivo. The designed peptides are shown in Table 4.2.
These peptides were designed to be either 3io- or a-helical based on amphipathic
distribution of the residues (see chapter 3). Although preliminary testing of the direct
bacteriacidal activity of these peptides showed low to moderate direct effect towards
bacteria, the selectivity o f Pi-10 towards killing macrophages infected with intracellular
pathogens such as Ba and Mtb430 prompted us to further investigate the selectivity of
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the rest o f this family o f peptides.

Studies on the effect o f these peptides on

intracellular pathogens, such as Ba, may provide insight in to the development of
therapeutics to battle infections o f higher current interest, such as Mtb.

Table 4.2. List o f prepared de novo peptides. The incorporation of 20% L-lysine (JLys)
allows for CD spectroscopic determination o f peptide secondary structure by inducing
right-handed helix formation. Pi-10, Ach-lOa and Cyh-10 were designed to be
perfectly amphipathic as an a-helix while Ipi-10, Ach-10 and Ich-10 were designed to
be perfectly amphipathic as a 3io-heIix.
Peptide

Sequence

Helix Design

Pi-10

H-Aib-Aib-Api-Iys-Aib-Aib-Api-Z.ys-Aib-Aib-NH2

a

Ipi-10

H-Api-Aib-Aib-£y^-Aib-Aib-Z!yj-Aib-Aib-Api-NH2

3jo

Ach-lOa

H-Ac6C-Aib-£ys-Api-Aib-Ac6C-Api-Z,ys-Ac6C-Aib-NH2

a

Ach-10

H-Api-Aib-Ac6 c-Lys-Ac6c-Aib-Ly.y-Aib-Ac6 c-Api-NH2

3io

Cyh-10

H-Ac6c-Ac6c-Api-Lyj-Ac6c-Ac6c-Api-Iy5-Ac6c-Ac6c-NH2

a

Ich-10

H-Api-Ac6C-Ac6C-Z,_V5-AcsC-Ac«c-£._ys-Ac6C-Ac6C-Api-NH2

3io

To test the hypothesis, that the selective cytocidal character of the peptides are
dependent on the activation o f the macrophage membrane, in vitro activation o f protein
kinase C (PKQ was performed with the application of PMA.4-53,54 PMA (Phorbol 12myristiol 13-acetate) is a polycyclic alcohol derived from croton oil, and is persistent in
physiological conditions as it is not readily degraded. PMA is a known activator of
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PKC when applied in a short-term manner, and mediates the response to a number of
hormones and growth factors, which stimulate phospholipid hydrolysis (via
phospholipase C, D, and A2).4'ss The activation includes the translocation of PKC to
cellular membranes as a result of increased levels of n-1,2-diacyIglycerol (DAG) of
fatty acids.4,56 12 PKC isoforms are described: conventional PKC (cPKC) a , pi, pH
and y; novel PKC (nPKQ as 8, e, o, p., T |, and 0; and atypical PKC (aPKC) £, X,

l

4,57

The different types o f PKC show different activation patterns: cPKC isoforms are
activated by calcium and DAG fatty acids in presence of phosphatidyl serine. nPKC
isoforms are activated by PMA and DAG, but are insensitive to Ca. aPKC £ and
members of nPKC class can be activated by the phospholipid phosphatidylinositol3,4,5-trisphosphate, produced in response to growth factors and G protein linked
receptors. The unique activation of PKC 8 and PKC ^ link the PKC system to actions
of growth factors which stimulate tyrosine kinase activity. Long term incubation (>12
h) depleted PKC, probably through proteolytic degradation of the activated enzyme 4,58
A number o f PKC inhibitors have been described. A novel PKC inhibitor
GF109203X is a bisindolylmaleimide (Bis). Bis is highly specific as it inhibits only
PKC as a competetive inhibitor of ATP.4,59 In contrast to other PKC inhibitors, Bis is
very specific for PKC without interaction with protein kinase A. Several studies were
performed incorporating the administration o f PMA, PKC inhibitor and peptide to
determine whether peptide activity is dependent on cellular membrane activation and
subsequent increased PKC activity.

Observations clearly indicate that cellular

membrane pathways are involved in the increased susceptibility of infected
macrophages towards cell lysis by selective peptides.
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To test the hypothesis that these peptides selectively destroy infected
macrophages over non-infected macrophages, in vitro studies were performed using a
strain of Ba containing a green fluorescent protein (GFP). Ba is too small to be seen at
the magnification levels used to visualize the macrophages; therefore, the strain
expressing the GFP allows the infected macrophages to be identified. Post-infection,
the infected macrophages are plated out together with the non-infected macrophages
and the infected cells can clearly be visualized by fluorescence photography (See Figure
4.2)

Figure 4.2. Visible photomicrograph o f untreated macrophages infected with Ba- GFP
(top). Fluorescence photomicrograph of untreated macrophages infected with BaGFP (bottom).
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4.2.

RESULTS AND DISCUSSION
It is not known why synthetic peptide of this family selectively destroy

macrophages infected with intracellular pathogens, since macrophages, like most
mammalian cells are known to be relatively resistant to amphipathic peptides o f this

length. Linear a-helical antimicrobial peptides containing high levels of hydrophobic
residues with lengths over 20 residues are known to retain high levels of
cytotoxicity.4-51,52

Lowering the length to 10 amino acid residues reduces direct

bacterial and mammalian cytotoxicity; however, the peptides still retain high levels of
bioactivity against macrophages infected with intracellular pathogens. There are two
plausible explanations for the phenomenon: 1) Infection of the macrophage causes a
cellular membrane alteration, making the peptide more "attracted” towards its
membrane, or, 2) peptide distribution is equal in infected and healthy macrophages and
the infected cells display an increased sensitivity towards membrane disruption.
In order to establish direct antibacterial activity, minimum inhibitory
concentration (MIC) studies were performed to determine relative cytolytic activity
against representative Gram-positive (S. aureus) and Gram-negative (£. coli) bacteria.
The MIC data o f naturally occurring antimicrobial peptides mellitin, cercropin B amide
and magainin 2 amide are included as reference. Table 4.3 summarizes the results. The
synthesized peptides showed moderate to high levels of activity for both representative
bacterial groups. Oddly, Pi-10 and Ipi-10 showed little to no effect on S. aureus. Direct
cytolytic activity against Ba was also tested to verify that no significant cytotoxity was
observed under conditions similar to those o f the studies of selective macrophage
destruction. 20 pL of a 1.4 x 109 suspension o f Brucella abortus 2308/gfp was added to
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Table 4 3 . Peptide antimicrobial activity as determined by minimum

Peptide

MIC (pM) vs. E. coU

MIC (pM) vs. S. aureus

Pi-10

8

123

Ipi-10

4

Not active

Ach-lOa

8

4

Ach-10

4

4

Cyh-10

6

6

Ich-10

13

3

Melittin

3

3

Cecropin B amide

1

12

Magainin 2 amide

10

19

200 |iL of media in individual wells. Each well contained media with 200 pM of one of
the peptides in Table 4.2. At 30 minutes post addition of bacterial cells, the wells were
serially diluted and plated on blood agar. They were left to incubate for 72 hours and
counted. The inoculation suspension was also serially diluted and plated to ascertain the
precise number of bacteria added. A standard two-sample T-test and confidence interval
was run to compare the final counts with the inoculation suspension count, and no
significant differences were noted. There was no significant killing with any of the
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peptides as was apparent by comparing post-treatment colony forming units as
compared with the inoculation dose.

This was not surprising since it has been

thoroughly documented that Ba is considerably more resistant to bactericidal cationic
peptides than most gram-negative bacteria (See Table 4.4).460’62

Table 4.4. Direct toxicity of peptides against Brucella abortus 2308/gfp.
Peptide Treatm ent (200 uM)

CFU/ml

Significance

Ipi-10

1.2X10*

None

Ach-10

1.3 X 109

None

Pi-10

1.5 X 109

None

Ach-lOa

1.4 XIO9

None

Ich-10

1.4 X109

None

Cyh-10

1.3 X 109

None

Control (no peptide)

1.4 XIO9

Table 4.5 summarizes the direct cytotoxic effect o f the presented peptides
against non-infected murine peritoneal macrophages. Peptides were dilutes in warm
0.9% Saline + Fetal Calf Serum (10%) and added to cells. Cells were allowed to
incubate 1.5 hours and then stained for viability with Trypan Blue. As expected, the
more hydrophobic Cyh-10 and Ich-10, incorporating four AC6C residues, had the highest
direct cytolytic activity against non-infected macrophages. ACh-lOa andACh-10
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Table 4.5. Normal macrophage survival versus peptide concentration.
% Macrophage Survival

Peptide

Pi-10

200 uM
>95 %

lOOuM
75%

50uM
100%

10uM
100%

8iiM
100%

6iiM
100%

3uM
100%

luM
100%

Ipi-10

>95 %

>95 %

100%

100%

100%

100%

100%

100%

Ach-lOa

20%

30%

100%

100%

100%

100%

100%

100%

Ach-10

<5%

70%

90%

100%

100%

100%

100%

100%

Cyh-10

0%

0%

<5%

<5%

25%

50%

90%

100%

Ich-10

0%

0%

<5%

85%

>95 % >95 %

100%

100%

show slightly higher cytotoxic character due to the incorporation of two residues of
A ^c; Pi-10 and Ipi-10 had the lowest cytotoxicity levels and are the least hydrophobic
of this family of peptides. Cyh-10 and Ich-10 are highly active, but may be too toxic to
pursue as selective agents for the destruction o f infected macrophages. In contrast, the
high activity and relatively low cytotoxicity of ACh-lOa and ACh-10 make them
promising candidates.
In vitro studies confirming the selective killing of infected vs. non-infected
macrophages by the designed peptides were performed using a strain of Ba containing a
green fluorescent protein (GFP). Ba is too small to be seen at the magnification levels
used to visualize the macrophages; therefore, the strain expressing the GFP allows the
infected macrophages to be identified. Trypan blue occlusion was used to visualize
dead macrophages.

The results of the peptide selectivity studies are illustrated in

Figures 43-4.5. Cyh-10 was, by far, the most bioactive peptide, showing an optimum
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Figure 4 3 . Selective bioactivity of Pi-10 (top) and Ipi-10 (bottom) towards healthy
macrophages and macrophages infected with Brucella abortus-GF?,
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Figure 4.4. Selective bioactivity o f Ach-lOa (top) and Ach-10 (bottom) towards
healthy macrophages and macrophages infected with Brucella abortusGFP.
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Figure 4.5. Selective bioactivity of Cyh-10 (top) and Ich-10 (bottom) towards healthy
macrophages and macrophages infected with Brucella abortus-GFP.
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concentration dose at 3 (iM. Although the in vitro bioactivity and selectivity of this
peptide is very high, in vivo toxicity studies may reveal this peptide to be too cytotoxic
to be used effectively in therapeutic studies. Ich-10 also showed high activity at low
dosage concentrations. However, cytolytic activity was much lower, as was selectivity
at all concentrations. In general, all peptides designed with the 3io-helix permutations
showed significantly lower bioactivity and selectivity than their a-helical counterparts
Table 4.6). The optimum concentration for each peptide was established as the dosage
at which maximum differentiation between infected macrophage killing and noninfected macrophage killing was observed.

Table 4.6. Activity summary of designed peptides. a Optimum concentrations for each
peptide were established at the dose which gave highest selectivity between infected
macrophage killing and non-infected macrophage killing. b Activity = (% Infected
killed - % Non-infected killed) at optimum concentration. 0 Efficacy = Activity /
optimum concentration.
Optimum Concentration QiM)'

Activity"

Efficacy0

Pi-10

100

90

0.9

Ipi-10

>200

25

0.13

Ach-lOa

100

75

0.75

Ach-10

100

60

0.60

Cyh-10

3

95

31.67

Ich-10

20

40

2.0

Peptide

I ll
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Optimum concentrations decreased as the peptides increased in hydrophobia ty,
with the a-helical permutation isomer retaining higher activity than the 3io-helical
isomer. This may suggest that the a-helical conformation is a more active membranedisruption agent than a 3io-helical peptide of the same hydrophobicity. As expected, Pi10 and Ipi-10 showed the lowest direct activity, as a result of their lower
hydrophobicity. Ipi-10 showed significantly lower activity than Pi-10. Overall efficacy
of the tested peptides was established by peptide activity (% difference in infected vs.
non-infected killing at the optimum concentration) divided by the optimum
concentration dosage. As can be seen in Table 4.6., Cyh-10 and Ich-10 showed the
highest efficacy. However, as previously stated, these peptides may be too cytotoxic to
be utilized effectively in in vivo studies. Ach-lOa and Pi-10 are the most interesting
candidates for further study, as they retain high activity and relatively low cytotoxicity.
It is not known what mechanism is responsible for peptide selectivity towards
infected macrophages. However, it is hypothesized that cellular membrane activation is
responsible for increased sensitivity towards the administered peptides. Studies were
performed incorporating the administration of PMA, PKC inhibitor and peptide to
determine whether peptide activity is dependent on cellular membrane activation and
subsequent increased PKC production.

Infected and non-infected macrophages in

DMEM with 5% Fetal bovine serum (FBS) were treated with either 1.0 pM, 100 nM, or
SO nM concentrations of Phorbol-12-myristalate-13-acetate (PMA) at 1 hour prior to
treatment with S pM Bisindoly maleimide 1 (PKC inhibitor). Separate groups of both
infected and non-infected macrophages were treated with 5 pM PKC inhibitor 1 hour
prior to treatment with the various concentrations o f PMA. Following each treatment,

112

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

the macrophages were incubated for 1 hour at 37 °C with 5.0 % CO2 . 100 uM Pi-10
was added to PMA, PMA/PKC inhibitor, or PKC inhibitor/PMA treated infected and
non-infected macrophages and allowed to incubate at 37 °C with 5.0 m% C 02. Infected
and uninfected macrophages, which had not been exposed to PMA or PKC inhibitor,
were also treated with 100 pM Pi-10 for comparison. Macrophages were then washed 3
times with warm Phosphate buffered saline (PBS) with 5% FBS (PBS/FBS) after which
warm PBS/FCS was added back and cells were examined microscopically. Trypan
Blue exclusion was used to determine viability of cells (Table. 4.7).

Table 4.7. PMA / PKC inhibitor studies showing differential bioactivity of Pi-10
towards PMA infected macrophages. “ PMA concentration: H=1.00pM, M=100nM,
L=50nM. b PKC inhibitor concentration: H = l.OOpM , L = 50.0nM. c Peptide
treatment: Pi-10 concentrations = 100pM. * Denotes significant killing o f macrophages
due to PMA activation.
Experiment #
PMA*
Peptide6
PKc Inhibitor1*
% Survival
1

-

-

-

94.4

2

H, M, L

-

-

93.6

3

-

H, L

-

95.8

4

-

-

1 hr

97.1

5

H, M, L

H, L

-

96.7

6

H, M, L

-

1 hr

40.8 (p<0.005)*

7

L

H

1 hr

96.8

8

M

L

1 hr

95.3

9

H

L

1 hr

49.8 (p<0.005)*
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Observations clearly indicate that cellular membrane pathways are involved in
the increased susceptibility of infected macrophages towards cell lysis by selective
peptides.

Control populations of macrophages only (experiment 1), PMA and

macrophages (experiment 2), PKC inhibitor and macrophages (experiment 3), Pi-10 and
macrophages (experiment 4) and PMA with PKC inhibitor (experiment S) all showed
insignificant variation in viable macrophage populations. Macrophage activation with
PMA at varying concentrations combined with Pi-10 treatment showed significant
killing of infected macrophage populations (experiment 6 ). Incubation times for PMA
activation over 2-24 hours showed no significant difference in activation levels of
macrophages. PKC inhibitor was successful in inhibiting low to medium levels of PMA
activation in the presence of peptide to show no significant levels of infected
macrophage killing (experiment 7,8). However, high levels of PMA with low levels of
PKC inhibitor still showed significant cytolytic activity of Pi-10. This suggests that
there is a quenching of the PKC inhibitor by excess PMA and PKC production is not
successfully repressed. Thus, cell membrane activation is still significant enough to
induce cell lysis.
43.

EXPERIMENTAL

43.1. Peptide Synthesis
Peptides were synthesized using standard Fmoc-amino acid fluoride coupling
conditions. The first 3 or 4 residues were manually coupled onto PAL-PEG-PS solid
support by gently stirring

8

equivalents of the Fmoc-acid fluoride, 3 equivalents o f

D1EA and resin in methylene chloride, until an acceptable yield was determined by
quantitative Fmoc test.

Sometimes gentle reflux was required to obtain successful
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coupling. After the first residues were coupled to the resin, the remainder of the peptide
was synthesized using a Milligen 9050 peptide synthesizer on the PAL-PEG-PS solid
support using

8

equivalents of preformed Fmoc-amino acid fluorides, 3 equivalents o f

DIEA and a 1.5 h recycling time. Residues were double coupled when they are third in
a series o f Ca,Ca-disubstituted amino acids and the coupling times were extended to 2.5
hrs. A solution of 20% piperidine / 2% l,8-diazabicyclo[4.5.0]undec-7-ene (DBU) in
DMF was used for Fmoc removal. The peptides were simultaneously cleaved from the
resin and side-chain deprotected using reagent B (8 . 8 : 0.2 : 0.5 : 0.5, trifluoroacetic
acid (TFA) : triisopropylsilane : water : phenol). The resulting solution was diluted
with cold 30% acetic acid, washed with diethyl ether (4 x 50 mL), and lyophilized.
4.3.2. Peptide Purification
The crude peptides were purified by preparative reverse-phase HPLC on a
Waters 15 pM Deltapak C4 column using a water (0.05% TFA) and acetonitrile (0.05%
TFA) gradient system.

The gradient was run from 10% to 50% organic and the

absorption monitored at 222 nm.

P u rity

of the peptides was then checked on a Vydac 5

pM Cig column using the same conditions.
4 3 3 . Peptide Analysis (MALDI-MS, AAA, CD)
Matrix assisted laser desorption ionization (MALDI) mass spectrometry was
used to verify the peptide masses. Pi-10, 1037.1 (M+H)+; Ipi-10, 1037.1 (M+H)+; ACh10a, 1157.6 (M+H)+; ACh-10,1157.6 (M+H)+; Cyh-10,1277.8 (M+H)+; Ich-10,1277.8
(M+H)+.
Amino acid analyses were performed according to reference 2.21 using a
Beckman 6300 Amino Acid Analyzer. In short, the peptides were hydrolyzed in 6N

115

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

HC1 and 0.01% phenol for 24 h at 110°C. The samples were analyzed on a cation
exchange column at 65°C with post-column ninhydrin derivitization at 130°C.
Circular dichroism measurements were taken on a (+)-camphor sulfonic acid
calibrated Aviv 60DS spectrophotometer at S°C. See chapter 3 for experimental details.
43.4. MIC Experiments
E.

coli American type culture collection (ATCC) 25922 and S. aureus ATCC

25922 were used as representative Gram-positive and Gram-negative bacteria in
minimum inhibitory concentration assays. The bacterial cultures were grown in nutrient
broth to midlog phase and standardized using McFarland standard before dilution. A
512 pg/mL peptide stock solution was prepared and 1:2 serial dilutions were prepared
and added to the culture media to give final peptide concentrations o f256 pg/mL.
50 pL of cells (5 X 104) and 50 pL of the peptide solution were added to a
sterile well and the MIC was determined by the lowest concentration that inhibited cell
growth. The inhibition of cell growth was indicated by the absence of turbidity after
four hours.

Turbidity in the wells was monitored visually.

The MIC values are

reported as the median value for at least three experiments.
4 3 3 . Peptide Cytotoxicity Assays Against Brucella abortus
A suspension of 20 pL o f a 1.4xl09 of Brucella abortus 2308/GFP (green
fluorescent protein) was added to 200 pi of media in individual wells. Each well
contained media with 200 pM of a particular peptide. At 30 minutes post addition of
bacterial cells, the wells were serially diluted and plated on blood agar. They were left
to incubate for 72 hours and counted. The inoculation suspension was also serially
diluted and plated to ascertain the precise number of bacteria added. A standard two-
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sample T-test and confidence interval was nm to compare the final counts with the
inoculation suspension count, and no significant differences were noted
4.3.6. Direct Peptide Toxicity Against M urine Peritoneal Macrophages
Briefly, harvested peritoneal macrophages were harvested from Balb/C mice,
and 2xl07 cells were laid down in wells o f a 96 well plate. Cells were allowed to
adhere for 2 1/2 hours at 37 °C, 5.0% CO2 . Peptides were dilutes in warm 0.9 % Saline
+ Fetal Calf Serum (10 %) and added to the cells. Cells were allowed to incubate 1.5
hours and then stained for viability with Trypan Blue. The cells were then examined
microscopically after viable staining with Trypan Blue for morphological changes and
viability. Reported macrophage viability is determined by the total %-ratio of dead vs.
healthy cells in three separate fields of three experimentally identical wells. The results
are reported in the Table 4.5.
43.7. GFP-Ua Studies
Following euthanasia, cells were harvested by lavage from the peritoneal cavity
of ten-week old BALB/c mice using 8 mL of DMEM (Dulbecco’s Modified Eagle
Medium) + 5% fetal calf serum (FCS). The cells were cultured in 96 well plates at a
concentration of 1.5xl05 per well in 200 pL of DMEM + 5% FCS at 37°C in 5% CO2 .
Cell cultures were enriched for macrophages by washing away non-adherent cells after
overnight incubation with PBS + 5% FCS and 200 pL of fresh media was added to the
cultures. Normal macrophage cultures were treated with 0 to 200 pM of the test
peptide. The peptides were incubated with the cells for 1 hour at 37°C in 5% CO2 . The
cells were washed 3 times with PBS + 5% FCS to remove any residual peptide. Peptide
treated cells were stained with 0.04% trypan blue in DMEM + 5% FCS. One to two
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hundred cells per well were counted using an inverted microscope and the number of
stained cells was recorded.

Three wells were examined per peptide concentration.

Percent survival was calculated by subtracting the number o f blue (dead) cells from the
total cells and normalized. B. abortus-GFP opsonized with a sub-agglutinating dilution
(1:2000) of hyperimmune BALB/c mouse sera in DMEM + 5% FCS was added to the
macrophages at a ratio of approximately 100 bacteria per macrophage. Phagocytosis
proceeded for 2 h at 37°C. Extracellular organisms were removed by washing 3 times
with PBS + 5% FCS and fresh DMEM. Peptides were added to infected and noninfected cell cultures for 1 hour at 37°C, 5% C 02. The cells were washed 3 times with
PBS + 5% FCS to remove any residual peptide. Percent viability was determined as
described above.
43.8. PMA Activation / PKC Inhibition of Macrophages.
Infected and non-infected macrophages in DMEM with 5% Fetal bovine serum
(FBS) were treated with either 1.0 pM, 100 nM, or 50 nM concentrations of Phorbal 12myristalate 13-acetate (PMA) at 1 hour prior to treatment with 5 uM Bisindoly
maleimide 1 (PKC inhibitor).

Separate groups o f both infected and non-infected

macrophages were treated with 5 pM PKC inhibitor 1 hour prior to treatment with the
various concentrations of PMA. Following each treatment, the macrophages were
incubated for 1 hour at 37 °C with 5.0 % CO2 . 100 uM Pi-10 was added to PMA,
PMA/PKC inhibitor, or PKC inhibitor/PMA treated infected and non-infected
macrophages and allowed to incubate at 37 °C with 5.0m% C 02. Infected and
uninfected macrophages that had not been exposed to PMA or PKC inhibitor were also
treated with 100 pM Pi-10 for comparison. Macrophages were then washed 3 times
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with warm Phosphate buffered saline (PBS) with 5% FBS (PBS/FBS) after which warm
PBS/FCS was added back and cells were examined microscopically. Trypan Blue
exclusion was used to determine viability of cells (Table 4.7).
4.3.9. Pi-10 Peptide Treatment of PMA Activated Macrophages
100 uM Pi-10 was added to PMA, PMA/PKC inhibitor, or PKC inhibitor/PMA
treated infected and non-infected macrophages and allowed to incubate at 37 °C with
S.0m% COj. Infected and uninfected macrophages which had not been exposed to PMA
or PKC inhibitor were also treated with 100 pM Pi-10 for comparison. Macrophages
were then washed 3 times with warm Phosphate buffered saline (PBS) with 5% FBS
(PBS/FBS) after which warm PBS/FCS was added back and cells were examined
microscopically. Trypan Blue exclusion was used to determine viability of cells.
43.10. Biological Containment and Animal Use
All procedures involving live Brucellae and Mycobacteria were performed in a
Biological Level 3 (BL-3) containment facility at the LSU-SVM following Centers for
Disease Control/National Institutes of Health guidelines.4'63 In conducting research
using animals, the investigators adhered to the “Guide for the Care and Use of
Laboratory Animals” prepared by the Committee on Care and Use of Laboratory
Animals of the Institute of Laboratory Animal Resources, National Research
Council.4'64
4.4.

CONCLUSIONS
A series o f novel linear amphipathic peptides with high levels o f Ca,Ca-

disubstituted amino acids to promote helical conformations have been prepared. The
biological activity of these peptides has been determined.

Although no direct
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bioactivity was observed towards Brucella abortus, MIC studies against representative
Gram-positive and Gram-negative bacteria support the theory that increased
hydrophobicity

in

peptide . composition

increases

cytolytic

activity.

This

hydrophobicity-dependent cytolytic character is also observed in mammalian noninfected peritoneal macrophages from BALB/c mice.
Studies of selective bioactivity in vitro against peritoneal macrophages infected
with an intracellular pathogen, Brucella abortus-GFP, clearly show that the peptides
show a selective cytolytic activity towards infected macrophages at concentrations that
are non-lethal to healthy macrophages. In vitro activation of harvested macrophages
with PMA induces peptide-promoted cell killing in a similar fashion to Ba infected
macrophages.

In contrast, PKC inhibition of PMA-induced cellular activation

suppresses peptide activity completely. This suggests a cellular membrane-mediated
response by infected macrophages towards the presence of a pathogen. This response
may increase susceptibility of the infected cells towards peptide activity or promote
peptide aggregation at the cellular membrane.

Further studies to promote the

understanding of cellular response towards intracellular pathogenic infections are
required to fully understand the mechanism by which these peptides function.

In

addition, peptide activity at the cellular membrane and peptide affinity for infected
versus non-infected macrophages must be determined.
4.5.
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CHAPTERS
ANHYDROUS SYNTHESIS AND SPECTROSCOPIC
CHARACTERISTICS OF o-NITROBENZENE SULFONYLCa,C°-DISUBSTITUTED AMINO ACID ADDUCTS
5.1

INTRODUCTION
Since the first pioneering publication by Merrifield in 1953,51 solid-phase

peptide synthesis (SPPS) has become the primary route by which to obtain many
synthetic peptides,5'2 and peptidomimetics.5'3'7 The technique has since been adapted to
a number of other biomolecules, such as nucleic acids5*8,9 and oligosaccharides.5'10
More recently, the use of solid-phase synthesis has been at the center o f a chemical
revolution with the development of combinatorial methods5'11 and high throughput
synthesis and screening, causing an enormous impact on several aspects of chemistry
and molecular biology, especially drug-discovery. In the wake of the first solid-phase
applications, several new techniques have been developed which further this exciting
new aspect of synthetic chemistry. This chapter introduces new insights with which to
enhance productivity and efficacy o f a recently introduced coupling-protection scheme
o f solid phase peptide synthesis (SPPS). This scheme is intended to overcome problems
associated with difficult couplings in synthetic peptides incorporating high levels of
Ca,C°-disubstituted amino acids. The material covers the synthesis of oNBS-C“,Cadisubstituted amino acid adducts and the UV spectroscopic characterization of the
oNBS-cleavage product
The process o f solid phase synthesis of any compound or peptide is
characterized by the covalent anchoring o f a starting material, or first residue o f an
oligomeric material, to an insoluble polymer resin, or solid support Common resins
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include divinylbenzene cross-linked polystyrene (PS),5'12 polyamides,5*13 polyethylene
glycol grafted covalently onto divinylbenzene cross linked polystyrene (PEG-PS),5*14
and in some cases, natural polymers such as cellulose.5'15 An efficient polymeric
support for solid-phase synthesis must have the following characteristics:5*16

1)

Physical stability and of the right dimensions to allow for manipulation and filtration
from liquids.

2) Chemical inertness to all reagents involved in the synthesis and

manipulation. 3) An ability to swell to an appreciative extent while under reaction
conditions to allow permeation of solvents and reagents to the reactive sites within the
resin. 4) Derivatization with functional groups to allow for the covalent attachment of
an appropriate linker or first monomeric unit. In most cases, this linker unit must be
cleavable under conditions which allows for the isolation of the desired product after
synthesis is complete.
Solid supports for SPPS are functionalized with chemically active linkers, which
are stable to the reaction conditions o f the coupling process, but are labile under
conditions which allow for isolation of the final product

Common linker-

functionalized resins include chloromethyl polystyrene (Merrifield resin)5*12, p~
(carbamoylmethyl)

benzyl

ester

(PAM

resin)5*17,

4-(2',4'-dimethoxyphenyl-

aminomethyl)-phenoxymethyl) (Rink amide resin), tris(alkoxy)-benzylamide (PAL
resin), 4-alkoxybenzyl alcohol (Wang resin) and 2-chlorotrityl resin.5*15

Excess

reagents and solvent can be removed by filtration from the insoluble support and
subsequent reagents or residues are added in an iterative fashion. After the desired
monomer units have been attached to the linker the product is chemically cleaved from
the resin and isolated by filtration. Cleavage conditions are dictated by which linker is
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used. The advantage of solid phase synthesis lies in the ease o f separation of the
product from access reagents, which minimizes loss of material during intermediate
product purification.
The key to successful solid phase synthesis lies in the protection scheme that is
used to assure reaction only at the desired position(s). Any monomeric unit (X) that is
utilized in solid-phase synthesis can be expressed with the empirical formula n-X-e,
where n is the nucleophilic portion of the residue and e is the electrophilic portion. The
first monomeric unit is coupled to the resin at either the nucleophilic or the electrophilic
site. However, the portion of the molecule that is not covalently bound to the resin must
be protected to avoid subsequent polymerization of excess monomers in solution. Thus,
if the electrophilic portion of the first residue is coupled to the resin, the nucleophilic
portion must be protected, and vice versa. The protecting group must be stable to the
reaction conditions under which the couplings are executed. After coupling is
performed, the protecting group is removed to expose a new reactive site and synthesis
continues.
If several nucleophilic and/or electrophilic groups are present in a monomeric
unit, they must be orthogonally protected with groups that vary in reactivity. This
allows for deprotection of the portion of the molecule to which further reaction is
desired to take place in subsequent couplings, while preventing reaction at side-chain
functional groups. SPPS is almost exclusively performed in the C—>N direction, with
the amino group being the nucleophilic portion and the C-terminus the electrophilic
portion (Figure 5.1). Common protecting groups and the conditions under which they
are cleaved are listed in Table 5.1.
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Table 5.1. Common linkers used in SPPS.
Protecting Gronp
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- I
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5.22

Catalytic
Hydrogenation
Acidolysis

5.18

Acidolysis (TFA)

5.2425

Acidolysis (Weak
Acid)

526

Acidolysis
(TFA/DCM)

5.127

0

Side-Chain
Protecting Groups
Benzyloxycarbonyl
(Z)
/-Butyl

Dimethoxytrityl
(Dmt)
/-Butyloxycarbonyl
(Boc)

C

p

A

CH3
H3 C—j—I
CH3

___

__
0083

ch3

0

129

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

One of the difficulties associated with solid-phase peptide chemistry is
prevention o f reaction on fimctionalized side chains o f amino acids such as lysine,
glutamic acid and cysteine. In order to prevent these reactions from taking place, sidechain protecting groups must be applied. These groups must be stable to the coupling
conditions, stable under conditions that cleave the active terminus for continued growth,
but labile under conditions which cleave the product from the resin, allowing for
isolation of the fully deprotected product.

Thus, the ^-terminal and side-chain

protecting groups must be orthogonal to each other in a solid-phase coupling scheme.
Several coupling schemes have been developed which match linker, ^/-terminal
protection and side-chain protection in an orthogonal manner.

Some of the most

commonly used include the Boc-benzyl strategy51,28 (Figure 5.2), the Fmoc-Boc
strategy519,29 (Figure 5.3).
One aspect of solid phase synthesis that has seen tremendous development is in
the field o f coupling reagents.

Traditionally, peptide coupling under solid phase

conditions can be realized in two ways: 1) A reactive electrophilic derivative of the
amino acid , such as an acid halide5-30"36 or an N-carboxyanhydride (NCA)5-37 can be
synthesized, isolated and then allowed to react with the nucleophilic portion of the
resin-bound residue. These active species are easy to synthesize and relatively stable,
allowing for characterization. In addition, the simplicity o f by-products released from
such couplings, such as a carbon dioxide, chloride or fluoride ion, allow for simple
purification after coupling has occurred. Alternately, a coupling reagent may be added
to the reaction mixture, to generate a reactive electrophilic derivative in situ. These
coupling reagents include carbodiimides5-38'40 such as DCC, DEC, and DIPCDI, triazole
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Table 5.2. Common coupling reagents used in SPPS.
Coupling Reagent

DCC
WJV-Dicyclohexylcarbodiimide
DEC
W -D iethylcarbodiimide
DIPCDI
Af^iV-Diisopropylcarbodiimide
HOBt
1-Hydroxybenzotriazole

HOAt
7-Aza-1-hydroxybenzo
triazole
HBTU
N- [(1 -tf-Benzotriazol-1-y1)(dimethylamino)rnethylene]Ar-methylmethanaminium
hexafluorophosphate Noxide
HATU
N-[( 1-//-7-Azabenzotriazol1-yl)-(dimethylamino)methylene]-Afmethylmethanaminium
hexafluorophosphate

Structure

N=C=N—

Reference
5.38-40

H3CH2C -N =C =N -C H 2CH3

5.38-40

h3c .
ch 3
/ — N=C=N—<
h3c
ch 3

5.38-40

5.41

o >

OH

5.42-44

0 3
OH
(H3C)2N ® .N (C H 3)2

5.45

a >
°©
(H3C)2N ® .N (C H 3)2

5.43,46

0 3
°©
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derivatives, such as HOBt5'41 and HOAt542-44 and tertiary ammonium salts of triazole Noxides, such as HBTU545 and HATU5-43,46 (Table 5.2), in addition to several others.5-39
The advantage o f these types of coupling is the relative ease of handling of non
activated species which are introduced into the reaction along with the coupling reagent.
In addition, in situ activation allows for the preparation of highly activated species that
are often not isolable.
Ca,Ca-Disubstituted amino acids, such as Aib (2-aminoisobutyric acid), Ac6c (1amino-l-cyclohexylcarboxylic acid), and Api (4-aminopiperidine-4-carboxylic acid)
(Figure 5.4), are becoming recognized tools for the selective control of peptide
secondary structure54731 and for accentuating physiological properties of resulting
peptides (refer to chapters 2,3 and 4). Recently, these derivatives have been shown to
generate highly helical segments with peptides as short as 10 residues in length.152 In
particular, close proximity of these residues cause dramatic increases in the helical
propensity of resulting peptides, and stabilization of the peptides towards enzymatic
degradation under physiological conditions.543 C^C^-Disubstituted amino acids
(aotAAs) are of current interest in the development of novel amphipathic peptides with
high levels of helicity for study as in vivo selective weapons against macrophages
infected with intracellular pathogens (See Chapter 4).553
As with iV-alkylated amino acids, Ca,Ca-disubstituted amino acids offer a
significant challenge in their ability to couple under solid phase peptide synthesis
conditions.

Their inherent difficulty in coupling stems primarily from the steric

repulsion that arises between the residue which is being coupled and the residue which
is already on the resin.
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H2[nT x o 2h
Aib

H2ivr x o 2h
A c 6c

H2tvr x o 2h
Api

Figure 5.4. Examples of C^C^disubstituted amino adds: 2-aminoisobutyric add
(Aib), 1-amino-l-cyclohexanecarboxylic add (Ac6c), and 4-amino-4-piperidinecarboxylic add (Api).

A number of methods for the solid phase coupling of Ca,Ca-disubstituted amino
adds have been presented over the years, the most effident and cost effective being the
Fmoc-protected amino add fluorides, developed during the early 1990s by Carpino and
coworkers.3JiJU4 For the purposes of proteinogenic amino adds and some less hindered
Ca,Ca-disubstituted amino adds, this technique provides a fast, cheap and effident
method towards peptide synthesis. However, we have found that on-resin couplings
involving multiple Ca,Ca-disubstituted amino adds, in high proximity, result in low
yields and require reaction times on the order of several days. These difficulties are
particularly accentuated with the continuous coupling of several residues of very bulky
amino adds, such as Ac6c and Api. These couplings require large molar excesses of
amino add and high temperature conditions to achieve acceptable coupling yields.
Thus, difficult couplings of this nature become very time-consuming and expensive,
consuming large quantities of excess reagent and solvents.
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Iii an attempt to develop a new, faster method for couplings of these difficult
amino acids, our attention has turned to the higher reactivity of amino acid chlorides,
which have been shown to have very high reaction rates in solution phase
couplings.**'32'11 In addition to being of higher reactivity, amino acid chlorides are
considerably less expensive to synthesize in comparison to their corresponding acid
fluorides and can be prepared by a number of simple reagents such as thionyl chloride,
oxalyl chloride and phosphorous trichloride. Recently, Falb and coworkers described
the effective in situ generation of proteinogenic Fmoc amino acid chlorides using
bis(trichloromethyl)-carbonate.5J0 However, pre-formed C^.C^-disubstituted amino acid
chlorides generally do not perform as well in solid phase peptide synthesis. Oxazalone
formation, by intramolecular cyclization of the acid chloride functionality with Nurethanyl-type moieties like the Fmoc protecting group (Figure 5.5), compete with
coupling.*12

Figure 5.5. Base promoted oxazalone formation of N^fluorenylmethoxycarbonylated
C^C^-disubstituted amino acid halides.
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CaCa-Disubstituted amino acid fluorides have been found to react faster than
corresponding amino acid chlorides under solid phase conditions due to their lower rate
of oxazalone formation.*3* To take advantage of the increased reactivity of the amino
acid chlorides, we face the task of incorporating a different protecting group incapable
of intramolecular cyclization. The protecting group must have chemical properties that
allow it to be orthogonal to the Boc side-chain protection scheme used in Api and lysine
residues. In addition, it must have a quantifiable cleavage chromophore, which allows
for the monitoring of coupling rates and yields by resin tests. The fluorenyl-piperidine
adduct produced as a result of base promoted Fmoc deprotection has a characteristic
UV absorbance at 300 nm and a molar absorbtivity (e^) of 7800 M lcm ‘, which allows
for quantitative monitoring of the couplings by sample resin testing. Other SPPS
monitoring procedures include on-resin ninhydrin testing,5*4 and on-resin infra-red
spectroscopy.***** Because of the difficult, and highly varied, coupling conditions
associated with Ca,Ca-disubstituted amino acids, couplings can take anywhere from a
few minutes to several days. It is thus imperative that a coupling strategy includes
facile, quantitative monitoring of coupling efficiency.
Arylsulfonyl-groups were introduced as protecting groups for solution phase
peptide synthesis as early as the 1950s.**9 Specific use of the o- and pnitrobenzenesulfonyl (oNBS) derivatives was first described by Fukuyama in 1994 for
the purposes of N-alkylation.**0'61 The p-nitrobenzenesulfonyl group has also been
described by Sabirov and coworkers as a suitable side chain protecting group for the
indole moiety of tryptophan.** However, Miller first incorporated this group into solid
phase synthesis context, albeit for use in site specific N-alkylation.*63*

Recently,

Reichwein and Liskamp reported successful tf-alkylation of amino acid esters or resin
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bound amino acids, in which the Fmoc protecting group had been removed and replaced
by the oNBS group while on resin.165 In addition to being orthogonal to both acid and
base labile groups, oNBS-groups introduce high levels of crystallinity to the amino acid
residues. This has allowed for easy isolation and purification of synthesized adducts, as
well as crystallographic description.566 Other arylsulfonyl protecting groups include the
benzothiazole-2-sulfonyl group (Bts) and the 5-methyl-l,3,4-thiadiazole-2-sulfonyl
group (Ths).5ja
The sulfonyl oxygens of the oNBS group are less nucleophilic than the carbonyl
group of a urethanyl type protecting group, such as Fmoc, Alloc or Boc. Thus,
intramolecular cyclization is not of concern in the preparation and application of oNBSamino add chlorides or other activated ester functional groups, such as those of HATU
and/or DIC. This phenomenon may in turn result in lower racemization of oNBS
protected proteinogenic amino adds, since oxazalone formation is the key intermediate
in facilitating this side reaction.

The protecting group differs from the recently

introduced and very popular 2-(4-nitrophenylsulfonyl)ethoxycarbonyl (Nsc) in that
cleavage is performed by an i/uo-nucleophilic aromatic substitution. The Nsc group is
cleaved by base-catalyzed elimination.567 This, and the fact that the Na-Nsc connection
is achieved through a urethanyl bond, capable of oxazalone formation, make the Nsc
group chemically related to the Fmoc group. Other arylsulfonyl protecting groups, such
as Bts and Ths are generally removed by Zn-acetic add hydrolysis. Thus, they are
generally considered to be chemically unrelated to the oNBS group. The oNBS group
is stable to addic and basic conditions (when N-alkylated). Thus, a feasible solid-phase
protection scheme, with oNBS orthogonal to Boc and Z groups, can be visualized
(Figure 5.6).
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Figure 5.6. Solid-phase protection scheme for oNBS-protected Ca,C“-disubstituted and proteinogenic
amino acids on PAL-PEG-PS resin.

8

This chapter discusses the development of a spectroscopic standard by which the
oNBS group can be monitored during solid-phase synthesis. Anhydrous synthesis
conditions of oNBS-amino acid adducts are described, as well as the UV activity of the
oNBS-cleavage adduce This information will help develop the use of the oNBS group
as a successful N“-protecting group for difficult couplings under solid-phase peptide
conditions.
5.2

RESULTS AND DISCUSSION
Standard conditions to generate oNBS adducts of proteinogenic amino acids

under aqueous conditions were reported by Milne and Peng in 1957.5"59 This process
involves dissolving the free amino acids in aqueous base, such as sodium hydroxide,
followed by treatment with the corresponding arylsulfonyl chlorides. However, this
method is ineffective in generating oNBS-Ca,C“-disubstituted amino acid adducts due
to the low solubility o f these compounds under aqueous conditions. This is especially
true in the case of the very hydrophobic residue AC6C. A similar difficulty is faced
when attempting to introduce the Fmoc-group to Ca,Ca-disubstituted amino acids via an
aqueous approach using Fmoc-succinimide. This problem is overcome by the use of a
non-aqueous procedure using Fmoc-Cl.

This procedure seemed logical to extend

towards the generation of oNBS-adducts as well. Thus, we present an effective way to
generate oNBS adducts of C“,Ca-disubstituted amino acids under anhydrous conditions
based on the procedure set forth by Bolin.5'58 This technique has also been extended to
proteinogenic amino acids, such as lysine(Z). Theoretically, it could be extended to a
variety of amino acids. In the procedure, chlorotrimethylsilane is used to facilitate
solubilization o f the diisopropyl-ethylammonium salts of the Ca,Ca-disubstituted amino
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acids in DCM.

This is followed by the slow addition of 2-nitrobenzenesulfonyl

chloride. The silylated amino acids react very quickly and efficiently. Using this
procedure, the amino acids are successfully protected in high yield and without need for
further purification after crystallization (Figure 5.7). The high crystallinity of the oNBS
adducts allows for easy purification and analysis.
u p p u ____________________________ ___

3x JX o h

h2n

i >D|g » '™ s g '
2) oNBS-CI

-

rt H3C CH3

r y ^ »_ HN> Y0 0H

O

N02
5.1
QH

1) DIEA, TMS-CI

✓=\
/= \

2) oNBS-CI

\~ \

1) DIEA, TMS-CI
2) oNBS-CI

/= \_ f
o

0

o«
O H
N02

Boc
1
,N
U
OH
H2N X
O

H

NHZ

NHZ

OH

2) oNBS-CI

Q

O

f

r

Y

N02
5.4

Figure 5.7. Synthesis of oNBS adducts of Aib, Acsc, Api(Boc) and Lys(Z) to yield
oNBS-amino acid adducts 5.1,5.2, 5 3 and 5.4.
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Several reagents have been proposed as suitable cleavage agents for the removal
of the oNBS-group, such as mercaptoethanol / potassium ferr-butyloxide, thiophenol /
potassium carbonate and n-propylamine in DCM. Cleavage of the oNBS group by all
of these methods is reported as an ipso-attack of the mercaptoacetic acid sulfide
followed by sulfur dioxide elimination and subsequent deprotection through a
nucleophilic aromatic substitution mechanism (Figure 5.8).560-61

Cleavage with

mercaptoacetic add offers the advantage of using a relatively non-noxious reagent, and
the cleavage adduct which is generated (8) by this reagent has spectroscopic advantages
which allow for in situ monitoring of the progress of the reaction. The cleavage
product, 2-nitrophenylcarboxymethylthioether (5.5), can be readily synthesized by
nucleophilic aromatic substitution using the DBU salt of mercaptoacetic add with ochloronitrobenzene (Figure 5.9).

HSCH2C 02H
DBU, CH3CN
^C 02
5.5

Figure 5.8. On-resin nucleophilic displacement of the oNBS-group by the
mercaptoacetic add anion yielding the 2-(2-nitrothiophenyl)acetate anion (5.5) as a
cleavage product
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NO2

mercaptoacetic add

0

DBU— H

5.5
Figure 5.9. Nucleophilic aromatic substitution of o-nitrochlorobenzene by the
mercaptoacetic add anion to yield the cleavage adduct 5.5.

One of the key advantages of traditional Fmoc procedures in solid phase peptide
synthesis is the ability to actively monitor coupling rates and efficiency by
spectrometric analysis.

The piperidine-fulvene adduct which result from the

deprotection of Fmoc groups can be analyzed by removing a small portion of resin from
the reaction and cleaving the Fmoc-groups which are covalently linked to the solid
support This cleavage adduct has a molar absorptivity of 7800 M‘,cm'1 at 300 nm in
DMF/MeOH which can be quantitated on a very small scale (4-8mg resin; ~20pM) by
UV-spectroscopy. By comparing the level of Fmoc-protected termini on the resin with
the established substitution level of the resin used, one can determine the degree of
coupling. Applying oNBS-amino add chlorides as successful activated reagents in
SPPS requires the adaptation of such a procedure for the quantitative analysis of
coupling effidency.
Repetitive scans from 700-200 nm of the deprotection adduct 5.5 at various
concentrations shows a consistent absorption maximum at 390 nm (Figure 5.10). Thus,
the cleavage product of oNBS-protected amino acids allows the couplings to be easily
quantitated by spectrometric determination.

To determine the exact spectroscopic

nature of 5.5, a series of dilution studies under reaction conditions were performed to
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oNBS Cleavage Product Dilution Studies
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Figure 5.10. Scanning UV-Vis Spectrometry of 5.5 under reaction
conditions showing consistent X ^ at 390 nm at various concentrations.

show a linear correlation between concentration and

at 390nm in acetonitrile (Table

53). For absorbances under 2.0, Beer’s Law correlation results in a molar absorptivity
(e) o f 2950 M'Icm't. At high concentrations, deviations from Beer’s Law are discarded.
In-solution cleavage of the oNBS-amino acid adducts with 0.4M mercaptoacetic acid
and 0.8M DBU in acetonitrile for 20 minutes yields quantitative detection of the
cleavage product, with a maximum absorbance at 390nm. According to Beer's Law, the
molar absorptivity of 8 can be determined by plotting the data in Table 5 3 and
extrapolating the slope for absorbance values under 2.0 as shown in Figure 5.11.

Table 5 3 . Summary of dilution studies done on cleavage adduct 5 3 . ‘Absorptivities
above 2.0 are discarded in averaging
due to Beer’s Law deviations at high
concentrations.
Concentration (fiM)

K .

A ^ (corrected)

By*

10.0

391

0.030

3021

25.0

390

0.074

2942

50.0

390

0.149

2978

100.0

390

0391

2949

250.0

391

0.729

2947

500.0

390

1.457

2934

1000.0

390

2.427

2425*

Average

390

-

2950

145

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

A b s o rb a n c e v s. C o n c e n tra tio n @ 390nm (AcCN) (Aviv)

2.5

at

&

w
3
•
o 1.5
c
<0
€
o
M
JQ

<
0.5
0
0.2

0.4

0.6

0.8

Concentration (mM)
Figure 5.11. Graph showing the linear correlation of absorption versus concentration
of the oNBS cleavage product 5.5 in 5:1 acetonitrile/water. (Slope=
=2950).
Deviation from Beer's Law linear correlation is clearly visible above A=2.0.

1.2

Thus, the progress of a potential coupling of oNBS-amino acid adducts on the solid
phase can be monitored by a process similar to that of the Fmoc-piperidine assay. The
sampled resin (5-10 mg) would be treated with l.OmL deprotection solution for 30
minutes, washed with 6 x 1.0 mL acetonitrile and the washes combined. The cleavage
sample would be analyzed for absorbance at 390 nm and percent substitution would be
determined by:

%Substitution=[(AMOxl0sx0.007)/(EMoxW)J/L

, where A*, is the corrected absorbance at 390 nm, e*, is the molar absorbtivity at 390
nm for the cleavage adduct (2950M'*cm I), W is the mg of resin tested and L is the
substitution level of the resin used (mmol/g).
To test the ability of the deprotection reagent to effectively cleave the oNBS
group in a consistent and quantitative way, cleavage studies were performed with four
oNBS-amino acid adducts: oNBS-Aib-OH 5.1, oNBS-Acsc-OH 5.2, oNBS-Api(Boc)OH S 3 and oNBS-Lys(Z)-OH 5.4. The pure adducts are weighed out in various
amounts and treated with 1.00 mL deprotection solution for 30 minutes. The resulting
solutions are then diluted with 5 x 1.00 mL acetonitrile and the resulting solution tested
by UV-spectroscopy at 390 nm for observed absorbance. In all cases, deprotection is
efficient, quantitative, and correlates well with the theoretical predictions based on the
derived molar absorbtivity of the cleavage product (Table 5.4).
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Table 5.4. In-solution cleavage study o f four oNBS-amino acid adducts.
Substrate

MW

mg

M

oNBS-Aib-OH

288.23

1.20

5.95e-4

oNBS-Api(Boc)-OH

429.42

1.71

oNBS-Ac6c-OH

32832

oNBS-Lys(Z)-OH

455.45

A^».

A/A.(% )

1.75

1.75

100%

535e-4

1.56

130

95%

1.40

6.09e-4

1.79

1.76

973%

1.40

439e-4

1.29

1.32

102%

Coupling of the synthesized oNBS-amino acids onto PAL-PEG-PS was initially
performed by the use of PyAOP/HOAt in DMF over several hours without success.
The acid fluorides of the oNBS-adducts were then generated and allowed to couple in
DCM / 2,4,6-collidine for 24 hours. The use of excess base in the coupling reactions of
oNBS-protected amino acids was found to be detrimental to the reaction due to
decomposition of oNBS protected primary amines, which was evident by (he
development of S02 gas from the resin under these conditions. This occurs by catalytic
deprotonation of the sulfonamide and an intramolecular rearrangement to eliminate S02
via decomposition of the intermediate Mesenheimer Complex (Figure 5.12). The
decomposition takes place even in the presence of excess weak, hindered bases such as
2,4,6-collidine. Although the decomposition should not directly compete with the
mechanism of coupling, the resulting o-nitrophenylated amine, 5.6, can not be
deprotected and thus caps the peptide from further growth, in addition to preventing
spectrometric analysis of coupling yield to be determined. Due to this composition, it is
impossible to determine exact coupling yield. In addition, one cannot be sure as to (he
efficiency of the deprotection step versus the coupling efficiency.
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Figure 5.12. Base catalyzed rearrangement of the oNBS-protected N-terminus of an
amino acid by sulfonamide proton extraction and subsequent intramolecular sulfur
dioxide elimination, to yield N-arylated amino acid 5.6.560,61

A number of methods were investigated for the chlorination of the oNBSprotected amino acids. For the chlorination of 5.1 it was found that oxalyl chloride is
superior to all other chlorinating agents studied (phosgene, thionyl chloride, Bis(trichloromethyl) carbonate (BTC)). The reaction of the free acid of oNBS-protected
amino acids with BTC results in almost quantitative yield of the corresponding Ncarboxyanhydride (NCA) derivative, 5.7, by intramolecular cyclization. Cyclization
results from one of two routes involving either cyclization of the initial mixed
anhydride of BTC (Scheme 1; Figure 5.13), or induced nucleophilic attack of the
sulfonamide on BTC followed by secondary cyclization by the free carboxylate
(Scheme 2; Figure 5.13). The resulting NCA derivative, 5.7, was verified by NMR and
X-ray crystallography. Crystals were isolated in 75% yield from the corresponding
oNBS-protected amino acid. (Figure 5.14) NCAs have been used extensively as
coupling agents and have the advantages of being highly crystalline and very stable in
dry conditions for extended periods of time. In addition, the coupling side product is
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Figure 5.14. ORTEP of dimethyl-N-o-nitrobenzenesulfonyl N-carboxyanhydride.
carbon dioxide, causing minimal contamination during purification.

Preliminary

investigations of the coupling ability of 5.7 showed poor activity under solid phase
synthesis conditions.

However, it has not been exhaustively studied.

Different

coupling conditions and applications of this derivative are under current investigation
and may yield desired results as a successful activated derivative of <?NBS-Aib-OH.
Further attempts to generate oNBS-amino acid chlorides with oxalyl chloride, S0C1,,
PCI, and PCI, have met with mixed results.

Most problems associated with the

synthesis of this derivative are due to the presence of excess base in the reaction which
acts as a proton sponge to keep the oc-amino group deprotonated.

However,

sulfonamide deprotonation may be causing severe side reactions. These synthetic
problems are currently being addressed.
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S3.

EXPERIMENTAL

5.3.1

oNBS-C^C^-Disubstituted Amino A dd Derivatives

5.3.1.1. Na-(2-nitrophenyIsulfoiiyI)-2-aininoisobutyric add (5.1)

1) DIEA. TMS-CI
2) oNBS-CI

O

N 02

5.1
2-aminoisobutyric add (10.0 g, 95.8 mmol) was added to a 500 mL Schlienk
flask and dissolved in DCM (200 mL). Diisopropylethylamine (27.55 g; 213.0 mmol)
was added and the reaction stirred for ten minutes while being flushed with argon.
Chlorotrimethylsilane (21.05 g; 210.0 mmol) was added via syringe slowly and the
reaction refluxed for 3 hours until all solid was in solution. After allowing the reaction
to cool to room temperature, o-nitrobenzenesufonyl chloride (21.47 g; 194.0 mmol),
dissolved in 100 mL DCM, was added dropwise from an addition funnel to the reaction
mixture and the reaction stirred for 15 hours at room temperature. The DCM was
removed by rotary evaporation and the resulting residue was distributed between 2.5%
sodium carbonate solution (100 mL) and 100 mL diethyl ether. The aqueous layer was
separated and washed with portions o f diethyl ether (2 x 100 m L ). The aqueous layer
was placed on a rotary evaporator to remove residual organic solvent for 10 minutes.
The reaction was cooled in an ice bath and acidified to pH 2.0 with 1.0 N hydrochloric
arid, then allowed to sit in a refrigerator for 1 hour. The resulting precipitate was
extracted with ethyl acetate (3 x 200 mL), which was dried over Na2 S0 4 and
concentrated in vacuo to yield 24.7 g (89%) o f the crude oNBS-amino arid adduct The
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product was recrystallized from dichloroethane to yield 20.7 g (75%) analytically pure
5.1. lH NMR (250 MHz, tfc-DMSO) 8 12.83 (s, 1H), 8.34 (s, 1H), 8.09-7.81 (m, 4H),
1.31 (s, 5H). l3C NMR (60MHz, de-DMSO) 174.95, 147.10, 135.47, 133.58, 132.39,
129.34, 124.18, 58.57, 25.55.

FAB-MS (glycerol) m/z 2892 (M+H)+. (For

crystallographic data see Appendix I).
5.3.1.2. Na-(2-nitrophenyIsulfonyI)-l-amino-l-cyclohexanecarboxylic add (5.2)

1) DIEA, TMS-CI
2) oNBS-CI
O

NOz
5.2

1-Aminocyclohexane-l-carboxylic add (3.0 g; 20.95 mmol) was weighed out
into a 250 mL 3-necked round bottom flask. The flask was filled with anhydrous DCM
(100 mL) while flushing with argon. Diisopropylethylamine (5.95 g; 45.09 mmol) was
added in one portion and the reaction allowed to stir at room temperature for 10 minutes
under argon.

Chlorotrimethylsilane (5.3 mL; 4.55 g; 41.90 mmol) was added via

syringe and the reaction was stirred for 4 hours under argon. 2-Nitrobenzenesulfonyl
chloride (4.41 g; 20.0 mmol) dissolved in 30 mL anhydrous DCM, was added dropwise
from an addition funnel to the reaction while stirring in an ice bath, while flushing
under a slow stream of argon. The reaction was allowed to rise to room temperature
and stirred for 3 hours. The DCM was removed in vacuo and the crude distributed
between 2.5% sodium carbonate solution (100 mL) and diethyl ether (100 mL). The
aqueous layer was washed with portions of diethyl ether (2 x 100 mL), separated and
residual diethyl ether removed on a rotary evaporator. The water layer was cooled in an
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ice bath and acidified to pH 2.0 with 1.0 N hydrochloric acid and then allowed to sit in a
refrigerator for 1 hour. The resulting precipitate was extracted with ethyl acetate (3 x
100 mL), dried over Na2 SC>4 and the solvent removed in vacuo to yield the crude
product in 85% yield (5.5 g). The crude product was recrystallized from hot 100%
ethanol to yield the analytically pure product as pale yellow crystals (4.9 g; 74%). lH
NMR (250 MHz, dfi-DMSO) 8 12.55 (s, 1H), 8.21 (s, 1H), 8.08-7.81 (m, 4H), 1.91-1.05
(m, 10H). l3C NMR (60MHz, dfi-DMSO) 175.08, 147.13, 135.04, 133.73, 132.30,
129.65, 124.18, 51.54, 32.47, 24.54, 20.88; FAB-MS (glycerol) m/z 329.2 (M+H)+.
(For crystallographic data see Appendix I).
5 3 .1 3 . Na-(2-nitrophenylsulfonyl)-4-amino-l-(tert-butyloxycarbonyl)piperidine4-carboxyIic add (53)
Boc
Boc
1) DIEA, TMS-CI
2) oNBS-CI

O

N02

53
Api(Boc)-OH (4.12g;17.0mmol) was weighed out into a 250 mL 3-necked
round bottom flask. The flask was filled with anhydrous DCM (100 mL) while flushing
with argon. Diisopropylethylamine (5.05 g; 39.1 mmol) was added in one portion and
the reaction allowed to stir at room temperature for 10 minutes under argon.
Chlorotrimethylsilane (4.0 mL; 3.42 g; 31.6 mmol) was added via syringe and the
reaction was stirred for 4 hours under argon. 2-Nitrobenzenesulfonyl chloride (3.39 g,
16.3mmol), dissolved in 30 mL anhydrous DCM, was added dropwise from an addition
funnel to the reaction while stirring in an ice bath, while flushing under a slow stream of
argon. The reaction was allowed to rise to room temperature and stirred for 3 hours.
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The DCM was removed in vacuo and the crude distributed between 2.5% sodium
carbonate solution (100 mL) and diethyl ether (100 mL). The aqueous layer was
washed with portions of diethyl ether (2 x 100 mL), separated and residual diethyl ether
removed on a rotary evaporator.

The water layer was cooled in an ice bath and

acidified to pH 2.0 with 1.0 N hydrochloric acid and then allowed to sit in a refrigerator
for 1 hour. The resulting precipitate was extracted with ethyl acetate (3 x 100 mL),
dried over Na2 S0 4 and the solvent removed in vacuo to yield the crude product in 95%
yield (6.3 g). The crude product was recrystallized from hot 100% ethanol to yield the
analytically pine 5J as pale yellow crystals (5.2 g; 79%).
*H NMR (250 MHz, dfi-DMSO) 8 12.91 (s, 1H), 8.53 (s, 1H), 8.09-7.84 (m, 4H), 3.45
(m, 4H), 1.93 (m, 2H), 1.75 (m, 2H), 1.35 (s, 9H). ,3C NMR (60MHz, de-DMSO)
174.08,153.55,147.07,134.53,134.04,132.49,129.55,124.35,78.87,59.95,31.70,
27.99. FAB-MS (glycerol) m/z 430.2 (M+H)+. (For crystallographic data see Appendix
I).
5.3.I.4. N°-(2-nitrophenylsulfonyl)-N*-(benzyIoxycarbonyl)-L-lysine (5.4)

OH

1) DIEA. TMS-CI
2) oNBS-CI

S— N

OH

O
5.4
NE-(benzyloxycarbonyl)-L-lysine (3.0g; 10.7mmol) was dried for 1 hour under
vacuum and suspended in 100 mL anhydrous DCM in a 250 mL three-necked round-
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bottom flask fitted with an argon inlet valve, a septum and reflux condenser.
Diisopropylethylamine (3.04g; 23.5mmol) was added and the reaction mixture was
allowed to stir for 10 minutes at room temperature. While flushing with argon, the
solution was cooled to 0 °C in an ice bath and chlorotrimethylsilane (2.33 g; 21.40
mmol) was added via syringe slowly. Extensive HC1 gas production was observed.
The reaction was refluxed under argon for 2 hours until the solution was homogenous.
The solution was then re-cooled to 0 °C and 2-nitrobenzenesulfonyl chloride (2.26 g;
10.17 mmol), dissolved in SO mL anhydrous DCM, was added dropwise from an
addition funnel. The reaction was allowed to rise to room temperature and stirred for 2
hours. The DCM was removed in vacuo by rotary evaporation and the crude residue
distributed between 2.5% sodium carbonate (100 mL) and diethyl ether (100 mL). The
aqueous layer was washed with diethyl ether (2 x 100 mL) and placed on a rotary
evaporator to remove residual organic solvent. The resulting clear aqueous solution
was cooled to 0 °C and acidified to pH 2.0 with 1.0 N HC1. The solution was allowed to
sit in a refrigerator for 2 hours and the resulting lightly colored precipitate was extracted
with ethyl acetate (3 x 100 mL). The organic solution was dried over Na2 S0 4 and
concentrated in vacuo, yielding the crude product in 62% yield (5.1 g). The crude was
recrystallized from chloroform to yield 7 as analytically pure crystals (4.5 g; 47%). lH
NMR (250 MHz, cfe-DMSO) 6 12.35 (s, 1H), 8.48 (d, 1H), 8.05-7.81 (m, 4H), 7.35 (m,
5H), 721 (t, 1H), 5.01 (s, 2H), 3.81 (m, 1H), 2.90 (m, 2H), 1.54 (m, 2H), 1.23 (m, 4H).
l3C NMR (60MHz, (fc-DMSO) 172.58, 155.071, 147.27, 137.30, 133.95, 133.34,
132.42, 129.84, 128.37, 127.75, 124.09, 55.13, 55.74, 31.40, 28.59, 22.38; FAB-MS
(glycerol) m/z 455.2 (M+H)+. (For crystallographic data see Appendix I).
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5 J.2 . 2-(2-nitrothiobenzene)-acetic ad d (5.5)

N02

H S^.
DBU, CH3CN

s^

Y 0H
o

2-ChIoronitrobenzene (1.0 g; 5.35mmol) was dissolved in 40 mL acetonitrile
and mercaptoacetic acid (0.92 g; 9.50 mmol) was added. The reaction was cooled to 0
°C and DBU (2.85 g; 19.05 mmol) was added slowly, dropwise while stirring. The
reaction was allowed to rise to room temperature over 1 hour and monitored by thin
layer chromatography (1:1 DCM; Hexane) on silica.

After 15 minutes, no 2-

chloronitrobenzene was visible in the reaction the acetonitrile was removed in vacuo by
rotary evaporation. The resulting crude oil was dissolved in 50 mL ethyl acetate and the
organic solution was washed with 1.0 N hydrochloric acid (3 x 50 mL). The organic
layer was dried over anhydrous Na2 S0 4 and the solvent removed by rotary evaporation
to yield the crude product as bright yellow clumps, which has some impurity by TLC
(99:1 ethyl acetate; acetic acid). Recrystallization from hot ethanol, followed by slow
cooling and refrigeration yielded the analytically pure adduct 5.5 as small bright yellow
crystals in good yield and with excellent purity (1.12 g; 83%). lH NMR (250 MHz, ckDMSO) 8 13.04 (s, 1H), 8.24 (d, 1H), 7.73 (dd, 1H), 7.59 (d, 1H), 7.42 (dd, 1H), 4.03
(s, 2H). l3C NMR (60MHz, (fe-DMSO) 8 170.04, 145.39, 135.90, 134.32, 127.30,
125.95,125.53,34.39. FAB-MS (glycerol) m/z 213.0 (M-H)‘. (For crystaUographic data
see Appendix I).
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5 3 3 . A-(2-nitrobenzenesulfonyl)-2-aininoisobutyric acid-A'-carboxyanhydride
(5.7)

1) 2,4,6-Collidine
2) BTC. DCM

5.7

2.57g Bis-(trichloromethyl)carbonate was dissolved in anhydrous DCM (20 mL)
and stirred at 0 °C. A solution o f e>NBS-Aib-OH (5.0 g, 17.35 mmol) and 2,4,6collidine (4.2 g; 34.59 mmol), in 50 mL DCM, was slowly added and the reaction was
allowed to go to room temperature. After stirring for 2 hours, 1.0 N hydrochloric acid
(100 mL) was added and the reaction stirred for an additional five minutes. The organic
layer was separated, washed with an additional 1.0 N hydrochloric acid (100 mL) and
dried over Na2 SC>4 . The solvent was removed by rotary evaporation and the crude
product (5.03 g; 98%) was recrystallized from hot chloroform overnight to yield the
NCA adduct as large white crystals (3.57 g; 73%). lH NMR (250 MHz, d2 -DCM)

8

8.41 (d, 1H), 7.93-7.81 (m, 3H), 1.92 (s, 5H). I3C NMR (60MHz, d2 -DCM) 159.24,
148.54, 14737, 135.99, 134.54, 132.54, 129.82, 124.97, 59.15, 24.38.

FAB-MS

(glycerol) m/z 3153 (M+H)+. (For crystallographic data see Appendix I).
53.4. Deprotection Solution
The deprotection solution (0.4 M mercaptoacetic acid; 0.8 M DBU; in
acetonitrile) was prepared by diluting mercaptoacetic acid (3.58 g, 40 mmol) to 50 mL
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in acetonitrile and DBU (12.18 g, 80 mmol) to SO mL with acetonitrile. Both solutions
were sealed and cooled to 5 °C. The solutions can be stored this way for several
months. The DBU solution is slowly added to the thiol solution dropwise while stirring
and maintaining a low temperature. After addition, the solution is stirred to ensure
complete mixing, and stored in the refrigerator. Kept at 5 °C, the deprotection solution
can be stored for several weeks before discoloration appears, which may cause
interference in spectrometric analysis. At room-temperature, the deprotection solution
becomes discolored after 2-3 days.
5.3.5. UV-Absorbance vs. Concentration Studies
Serial dilutions were made to produce the desired concentrations of 2nitrophenyl-mercaptoacetid acid under experimental conditions (CH3CN / Deprotection
solution, 6:1). The cleavage adduct was dissolved and diluted in a 1:6 mixture of
deprotection solution (0.4 M mercaptoacetic acid; 0.8 M DBU in acetonitrile) and
acetonitrile. Serial dilutions were made to 1.0 mM, 500 pM, 250 pM, 125 pM, 100
pM, 50 pM, 25 pM and 10 pM. The samples were scanned on an AVIV Instruments
14DS UV-Vis-IR Scanning Spectrometer in quartz cells (path length=l cm) from 500250 nm. The background spectra ( 1 : 6 deprotection solution : CH3CN), were subtracted
from the sample spectra.

Derivation of molar absorptivity is determined by

extrapolation from Beer’s Law so 8 3 9 0 = A3 9 0 /be (where E3 9 0 is the molar absorptivity of
the cleavage product at 390nm, A3 9 0 is the absorbance, b is the path length (lem ) and c
is the molar concentration o f the dissolved cleavage adduct) for all concentrations. The
observed molar absorptivities are plotted according to A vs. c, and the graph slope
extrapolated to yield the average molar absorbtivity o f2950 M'Lcm_1.
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53.6. Solution Phase Cleavage Studies
In-solution deprotection studies were performed on four oNBS-protected amino
acids: oNBS-Aib-OH, 0 NBS-AC6 C-OH, oNBS-Api(Boc)-OH and oNBS-Lys(Z)-OH.
All of the amino acids were weighed out and treated with 1.0 mL deprotection reagent
(0.4 M mercaptoacetic acid; 0.8 M DBU in acetonitrile). The solution rapidly becomes
bright yellow. The solution was agitated for 30 minutes at room temperature and then
diluted with 6.0 mL acetonitrile to simulate resin cleavage conditions. The solutions are
scanned from 500-300 nm using an AVTV Instruments

14DS UV-Vis-IR

Spectrophotometer in a quartz cuvette with 1.0 cm path length and background
corrected from a solution of 1.0 mL deprotection reagent in 6.0 mL acetonitrile in a
matched quartz cuvette. The corrected absorbance at 390 nm is recorded and correlated
to calculated theoretical absorbances for the corresponding concentrations.
53.7. Solid-Phase Cleavage Studies
Solid-phase coupling was performed with 4 equivalents of oNBS-Aib-OH and 4
equivalents of HATU in the presence of 2,4,6-collidine or preformed amino add
fluorides. The activated ester was preformed in CHjCN for thirty minutes, then added
to a pre-swollen suspension of PAL-PEG-PS in CH3 CN. The coupling was allowed to
proceed for 24 hours with coupling tests performed every two hours. Coupling tests
were performed by removing 5-10 mg o f the resin, successive washing with CH3 CN
and MeOH and drying the resin under high vacuum for 1 h. An exact amount of the
resin was weighed out and treated with I mL of the deprotection solution for 30
minutes. The supernatant was then removed and the resin washed with CH3 CN

(6

x

1.00 mL) to give a total volume o f 7.00 mL. A 1.0 mL sample of the combined washes
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was studied by scanning UV-spectroscopy from 500-300 nm and the background
corrected absorbance value at 390 nm was noted. This value was entered into the
substitution equation %Substitution=[(A3Mxl0‘x0.007)/(eJWxW)]/L.

Couplings of

several attempts never reached higher values than 32%. This may be due to poor
coupling or poor compatibility of the highly polar deprotection solution with the
relatively hydrophobic interior of the PEG-PS resin. Increased coupling efficiency may
be reached with the use of more polar resins.
5.4.

CONCLUSIONS
We have shown that the ort/jo-nitrobenzenesulfonyl group (oNBS) is a viable

potential alternative to many common protecting groups, including the Fmoc-group.
The oNBS group should allow for the use of highly activated C-terminus activating
groups, such as acid chlorides and HATU adducts. The lowered nucleophilicity of the
sulfonamide oxygen of oNBS-amino acid adducts are not prone to oxazalone formation
and should greatly increase coupling yields and lower reaction times. In addition, the
oNBS group is considerably less bulky than the Fmoc-group and should interfere less
with solid-phase couplings of hindered amino acids. The deprotection of the oNBS
group by mercaptoacetic acid in basic media is fast, effective and quantitative. In
addition, the cleavage reaction yields a stable chromophore that can be detected by UVspectroscopy for in situ reaction monitoring in real time. Solid-phase coupling attempts
using preformed amino acid fluorides and activated esters (HATU) o f the oNBSadducts were inconclusive. Poor observed coupling yields may be due to poor activity
of the activated amino acid derivative, or incompatibility of the deprotection solution
with the PEG-PS resin. The use of different resins and varying solvents may aid in
coupling efficiency. The application of this new coupling scheme could lead to the
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ability to generate longer, more difficult sequences in high yields, with lower costs and
decreased reaction times.
5.5.
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CHAPTER 6
SUMMARY, FUTURE STUDIES AND INSIGHTS
6.1.

DISCUSSION
There is still much to be learned about the synthesis, structure, and bioactivity of

linear, helical, amphipathic peptides. This dissertation addresses some of the hurdles
that must be overcome if the development of this field is to continue. The design and
synthesis o f short, amphipathic helical peptides incorporating high levels of Ca,Cadisubstituted amino acids is a difficult task. Development of new methods with which
to synthesize these difficult targets with greater efficiency and purity is crucial for the
successful continued study of the bioactivity of these compounds. New amino acids
need to be synthesized and their helix promoting ability and their ability as structure
stabilizing elements need to be assessed.

Foremost, the mechanism by which

antimicrobial peptides function must be further studied. Insights into these and other
areas of peptide synthesis, characterization and biological screening will allow linear,
helical peptides to be at the forefront of biomedical studies in the next few years. As
bacterial resistance becomes a growing problem, newer and "smarter" drugs are
required to battle increasing pathogenic activity. Antimicrobial peptides are one of the
best candidates to take on this task.
Chapter 2 of this dissertation presents the synthesis of orthogonally protected
polyfunctional

Ca,Ca-disubstituted

amino

acids

(Fmoc-Api(Boc)-OH,

Fmoc-

Bglu(/Bu)2 -OH, Fmoc-Basp(/Bu)2 -OH and Fmoc-Bap(Boc)2 -OH). Ca,Ca-Disubstituted
amino adds have provided peptide chemists with powerful tools for secondary structure

promotion. 6 1 ' 5

Api has found a niche as the preferred source of cationic Ca,C°-

disubstituted amino adds for the synthesis of peptides of this family. 6 ' 6 ' 8 It allows high
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levels of ionizable residues to be incorporated into short peptides containing up to 80%
Ca,Ca-disubstituted amino acids, yet still retain a preferred helical sense, allowing
secondary structure studies to be performed. 6 ,9 Api complements the family of alicyclic
Ca,Ca-disubstituted amino acids, all of which have been found to be strongly helix
promoting. 6 1 0 ' 1 3 The synthesis o f Api is characterized by the selective hydrolysis of a
di-Boced hydantoin, which can be easily purified under aqueous/organic alkaline
conditions to yield the ^-protected amino acid in good yield. N“-Fmoc-protection is
then realized to give the orthogonally protected amino add . 6 ,1 4
Ethyl nitroacetate (ENA) is a common precursor to a number of organic
targets. 6 ,1 5

It has provided us with an exciting starting material for the synthesis of

orthogonally protected, polyfunctional Ca,Ca-disubstituted amino adds.

The mild

conditions under which ENA can be alkylated, allows for tremendous versatility in the
choice o f electrophilic alkylating agents. Mild base-catalyzed alkylation of ENA allows
for the preparation of a number of tetrafunctional precursors, suitable for conversion
towards orthogonally protected polyfunctionalized Ca,C°-disubstituted amino adds . 6 1 6
The

synthesis

of

Fmoc-Bglu(rBu)2 -OH,

an

orthogonally

protected

tetrafunctional Ca,Ca-disubstituted amino acid analog o f glutamic add, and FmocBap(Boc)2 -OH, an orthogonally protected tetrafunctional Ca,Ca-disubstituted amino
add analog of lysine, are based on base catalyzed nucleophilic alkylation of the ethyl
nitroacetate (ENA) anion. This electrophilic addition has been highly accelerated by
utilizing a tetraalkyl ammonium halide to function as a highly dissodated counter-ion

during alkylation. 6 ' 1 6 The nucleophilic addition o f the ethyl nitroacetate anion has been
extended to several alkyl halide acceptors and Michael acceptors. As a result o f the
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base-catalyzed cyclization of ethyl-2,2-bis(/-butylcarboxyethyI) glycine during the aamino ester hydrolysis, the synthesis was refocused on the corresponding Bis-aspartic
acid derivative Fmoc-Basp(/Bu)2 -OH.

The shorter side-chain length allows for

hydrolysis without competition from cyclization reactions. Subsequent ^-protection
of this amino acid is currently underway.
Regioselective reduction o f ethyl 2,2-bis(3-cyanoethyl)-2-nitro acetate towards
the synthesis of Bap(Boc)2 -OH has proven very difficult Thus, several alternative
synthetic pathways have been envisioned for the successful synthesis of Bap-like
analogs. These schemes are illustrated in Figure 6.1 and Figure 6.2. The synthetic
scheme in Figure 6.1 takes advantage of the already optimized dialkylation of ethyl
nitroacetate with /-butyl acrylate. Acid catalyzed /-butyl ester cleavage may allow for
the preparation o f a Boc-protected diamino derivative through a modified Curtius
rearrangement. Subsequent nitro reduction and ethyl ester hydrolysis should allow for
the preparation of Fmoc-Bae(Boc)2 -OH (Bae=Bis(amino ethyl)).
o
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'
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Figure 6.1. Curtius rearrangement approach towards the synthesis of Fmoc-Bae(BochOH.
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The second synthetic scheme (Figure 6.2) is based on the ring opening ability of
N-alkylated aziridines. The high nucleophilicity o f the ethyl nitroacetate anion may
allow for a one-step conversion to the side-chain protected a-nitro ester. Subsequent
nitro reduction, hydrolysis and N“-protection may provide a very rapid and efficient
route to Fmoc-Bae(Boc)2 -OH. The development of these exciting new amino acids
towards functional SPPS monomers will allow for the preparation of new peptides with
which to further study amino acid induced secondary structure promotion.

DIEA, TEAE
4

.

AcCN
Boc

HN

A

NH

HN
Boc

Boc

Boc

NH
i
Boc

0

Fmoc—N

OH

tTM 8-a, DIEA
Fmoc-CI

HN"
i
Boc

NH
t
Boc

EtOH

Figure 6.2. Aziridine ring-opening approach towards the synthesis of FmocBae(Boc)2-OH.

Several key secondary structure questions can be addressed utilizing these new
amino acids.

It has recently been shown that helical secondary structures can be

induced and stabilized by amphipathic control.6*9 Studies have also determined that
higher bis(n-alkyl) Ca,Ca-disubstituted amino

acids strongly favor extended

conformations.6'3’4 Incorporation of bifunctional amino acids, such as Bap or Bae into a
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short peptide increases the amphipathic character of the peptide by introducing higher
levels of cationic functional groups.

According to amphipathic stabilization of

secondary structures, this should increase the peptides ability to form helical
conformations under micellar-type environments.

However, these amino acids

structurally resemble the bis(n-alkyl) Ca,Ca-disubstituted amino acids which are known
to preferentially adopt an extended conformation. Table 6.1 shows proposed variations
of peptides that could be synthesized to determine the secondary structure promoting
ability o f these amino acids.

Table 6.1. Suggested helical peptides incorporating Bap.
Peptide

Sequence

Helix
Design

Pi-10*

H-Aib-Aib-Bap-Z.ys-Aib-Aib-Bap-Z,ys-Aib-Aib-NH2

a

Ipi-10*

H-Bap-Aib-Aib-Lys-Aib-Aib-Iys-Aib-Aib-Bap-N^

3io

Ach-lOa®

H-Ac6 C-Aib-Iys-Bap-Aib-Ac6 C-Bap-£ys-Ac6 C-Aib-NH2

a

Ach-10®

H-Bap-Aib-Ac6 C-£ys-Ac6 C-Aib-Iy$-Aib-Ac6 C-Bap-NH2

3io

Bap-6

H-Ac6c-Ac6c-Bap-Lys-Ac6c-Ac6c-NH2

a

Bap-8

H-Ac6c-Ac6c-Iys-Ac6c-Ac6c-Bap-Ac6c-Ac6c-NH2

3io

Salt-bridge stabilization of secondary structure is also well documented. The
presence of tetrafunctional amino acids, such as Bglu and Bap should provide several
interesting opportunity to study highly salt-bride stabilized secondary structures as is
illustrated in Figure 6.3. These peptides complement the family o f peptides presented
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in Chapter 3 of this dissertation and would greatly increase our understanding of the
factors that promote and stabilize secondary structures in peptides.

In addition to

determining structures by electronic circular dichroism spectroscopy, vibrational
circular dichroism spectroscopy (VCD) (10) and NMR will be utilized to gain better
understanding o f helical conformations.618'20

^

0 2C^ ^ C 0 2 HaN ^ ^ N HaOzQ ^ ^ C Oz Ha N ^ ^ N Ha

C°2

/W lflA#'
Figure 6 3. Highly stabilized salt-bridge peptide incorporating Bap and Bglu.

Chapter 4 of this dissertation addresses the bioactivity of the presented peptides
as selective cytolytic agents towards macrophages infected with intracellular pathogens.
Due to exponential growth in the use of classical antibiotic therapy, bacterial resistance
towards antibiotics is becoming an ever-growing problem. This problem is exacerbated
in the case of intracellular pathogens since they reside within the cellular environment
of the very immune system which is used to target it, and infection is not associated
with a significant extracellular component of the pathogen. Because of this resistance
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problem, several new approaches towards antimicrobial defense have been explored
within the past twenty years. One of the most promising routes toward developing a
new weapon to battle bacterial agents have been the growing interest in linear
amphipathic peptides as antimicrobial agents.

Amphipathic peptides are highly

ubiquitous in nature and make up an important part of the natural defenses of several
species in the animal kingdom. The peptides are characterized by the presence of a
definable cationic amphipathic helical structure and are usually relatively short (<40
residues), thus suggesting that considerable biological activity can be exhibited by
relatively short sequences.6,21 These peptides have been found to be active against a
wide array of pathogens, including gram-positive and gram-negative bacteria, protozoa,
and fungi.6,22 Although currently not prevalent as therapeutic agents, some peptides are
currently under review for use as drugs.
Although no direct bioactivity was observed towards Brucella abortus, MIC
studies against representative Gram-positive and Gram-negative bacteria support the
theory that increased hydrophobicity in peptide composition increases cytolytic activity.
This hydrophobicity-dependent cytolytic character is also observed in mammalian non
infected peritoneal macrophages from BALB/c mice. Thus, Pi-10 and Ipi-10, which
contain Aib as their hydrophobic residues, show the lowest cytolytic activity.

In

contrast, Cyh-10 and Ich-10, in which the Aib residues have been substituted with much
more hydrophobic AC6C, show the highest levels of cytotoxicity. ACh-10 and ACh10a, which contain a mixture of Aib and Acgc residues, show cytolytic activities
roughly in between those o f Pi-10 and Cyh-10. These peptides may be the best suited
for further study as in vivo therapeutics.
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Studies of the selective bioactivity in vitro against peritoneal macrophages
infected with an intracellular pathogen, Brucella abortus-GFP, clearly show that the
peptides show a selective cytolytic activity towards infected macrophages at
concentrations that are nan-lethal to healthy macrophages. An additional interesting
feature to note is the higher selectivity of a-helical peptides versus 3io-helical peptides.
This suggests a strongly structure-dependent mechanism o f cell lysis and activity. In
vitro activation o f harvested macrophages with PMA induces peptide-promoted cell
killing in a similar fashion to Ba infected macrophages. In contrast, PKC inhibition of
PMA-induced cellular activation suppresses peptide activity completely. This suggests
a cellular membrane-mediated response by infected macrophages towards the presence
o f a pathogen. This response may increase susceptibility of the infected cells towards
peptide activity or promote peptide aggregation at the cellular membrane.

Further

studies to promote the understanding of cellular response towards intracellular
pathogenic infections are required to fully understand the mechanism by which these
peptides function.

These studies include fluorescently labeling peptides to observe

peptide distribution in infected versus non-infected macrophages, and PKC inhibitor
treatment of Sa-infected macrophages. In addition, peptide activity at the cellular
membrane and peptide affinity for infected versus non-infected macrophages must be
determined. We plan to further test the presented peptides through in vivo studies to
determine cytotoxicity and efficacy in combination with classical antibiotic therapy.
These studies are planned to be extended towards the search for potent therapeutic
approaches to treat bacterial infections of greater current interest, such as
Mycobacterium tuberculosis.
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Chapter 5 of this dissertation addresses the role of C^C^-disubstituted amino
acids, such as Aib (2-aminoisobutyric acid), Ac6c (1-amino-1-cyclohexy Icarboxy lie
acid), and Api (4-aminopiperidine-4-carboxylic acid), in solid phase peptide synthesis.
C^C^-Disubstituted amino acids have become recognized tools for the selective control
of peptide secondary structure*10,13 and for accentuating physiological properties of
resulting peptides (see chapters 2,3 and 4). Recently, these derivatives have been
shown to generate highly helical segments with peptides as short as 10 residues in
length.*9 In particular, close proximity of these residues causes dramatic increases in
the helical propensity of resulting peptides, as well as stabilizes these peptides towards
enzymatic degradation under physiological conditions.*6 These amino acids are of
current interest in the development of novel amphipathic peptides with high helicity for
study as in vivo selective weapons against macrophages infected with intracellular
pathogens (See Chapter 4).

As with //-alkylated amino acids, Ca,Ca-disubstituted

amino acids offer a significant challenge in their ability to couple under solid phase
peptide synthesis conditions. Couplings generally require large excesses of reagent and
extended coupling-times. This, in turn, makes peptides rich in C^.C^disubstituted
amino adds very expensive to synthesize. The inherent difficulty in coupling of several
residues of C“,C°-disubstituted amino adds in a row stems primarily from the steric
repulsion that arises between the residue that is being coupled and the residue that is
already on the resin.
In an attempt to develop a new, faster method for couplings of these difficult
amino adds, our attention has turned to the higher reactivity of amino add chlorides,
which have been shown to have very high reaction rates in solution phase couplings.*33,26
In addition to being o f higher reactivity, amino add chlorides are considerably less

174

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

expensive to synthesize in comparison to their corresponding acid fluorides and can be
prepared by a number of simple reagents such as thionyl chloride, oxalyl chloride and
phosphorous trichloride. However, pre-formed amino acid chlorides generally do not
perform as well in solid phase peptide synthesis due to competing oxazolone
formation.” 4
The sulfonyl oxygens of the o-nitrobenzenesulfonyl (oNBS) group are
considerably less nucleophilic than the corresponding carbonyl group of a urethanyl
type protecting group.

Thus, the problem of intramolecular cyclization is not of

concern in the preparation and application of oNBS-amino acid chlorides or other
activated ester functional groups.

This phenomenon may in turn result in lower

racemization of oNBS protected proteinogenic amino acids, since oxazalone formation
is the key intermediate in facilitating this process.
Chapter 5 of this dissertation introduces a new scheme for solid-phase peptide
synthesis based on the oNBS group as the ^-protecting group. The group has been
shown to be easily introduced into a number of C^C^-disubstituted amino a c i d s , i s
stable as an amino acid adduct and is readily cleaved to form a UV-active chromophore
which is quantitatively characterizable during the coupling reaction is in progress.
The oNBS group should allow for the use of highly activated C-terminus
activating groups, such as acid chlorides and HATU adducts.

The lowered

nucleophilicity of the sulfonamide oxygen of oNBS-amino acid adducts are not prone to
oxazalone formation and should greatly increase coupling yields and lower reaction
times. The deprotection o f the oNBS group by mercaptoacetic acid is fast, effective and
quantitative.

This coupling scheme should lead to the ability to generate longer,

difficult sequences in high yields, with lower costs and decreased reaction times.
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APPENDIX. CRYSTAL STRUCTURE ANALYSIS OF o NITROBENZENESULFONYL AMINO ACID DERIVATIVES
A .l.

oNBS-Aib-OH

Coordinates
Atom

X

Y

Z

S

0.72056(4)

0.74709(4)

0.66517(4)

01

0.7351(1)

0.6310(1)

0.7369(1)

02

0.6911(1)

0.8615(1)

0.7143(1)

03

0.9857(1)

0.8572(1)

0.9103(1)

04

0.9402(1)

1.0585(1)

0.8421(1)

05

0.7824(1)

0.5380(1)

0.5226(1)

06

0.6262(1)

0.4020(1)

0.4448(1)

N1

0.8494(1)

0.7755(1)

0.6512(2)

N2

0.6668(1)

0.5099(1)

0.4677(2)

Cl

0.9453(2)

0.9467(2)

0.8181(2)

C2

0.9124(2)

0.8995(2)

0.6751(2)
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Coordinates (continued)
C3

0.5912(2)

0.7231(2)

0.4981(2)

C4

0.4957(2)

0.8161(2)

0.4452(2)

H4

0.505

0.891

0.496

C5

0.3871(2)

0.8002(2)

0.3197(2)

H5

0324

0.865

0384

C6

0.3702(2)

0.6904(2)

0.2465(2)

H6

0.296

0.680

0.161

C7

0.4617(2)

0.5946(2)

0.2986(2)

H7

0.449

0.518

0.250

C8

0.5715(2)

0.6127(2)

0.4224(2)

C9

1.0419(2)

0.8788(2)

0.6737(2)

H9A

1.093

0.816

0.742

H9B

1.090

0.958

0.694

H9C

1.026

0.849

0.584

CIO

0.8295(2)

0.9953(2)

0.5664(2)

H10A

0.811

0.963

0.477

H10B

0.876

1.075

0.584

H10C

0.748

1.008

0.570

H30

1.010(3)

0.894(3)

0.991(3)

H1N

0.887(2)

0.716(2)

0.648(3)
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Bond Distances and Bond Angles
Bond_____________Distance__________________ Bond Angle
S-O l

1.434(1) A

01-S-02

120.1(1)°

S -02

1.438(1)A

0 1 -S-N l

109.9(1)°

S-Nl

1.610(1)A

01 - S - C3

106.3(1)°

S-C3

1.783(2)A

0 2 -S-N l

106.2(1)°

02-S-C 3

106.3(1)°

N1-S-C3

107.5(1)°

C l - 03 - H30

107.3(20)°

01 -S

1.434(1) A

0 2 -S

1.438(1) A

0 3 -C l

1.314(2) A

03-H 30

0.896(30) A

0 4 -Cl

1.224(2) A

05-N2

1.229(1) A

06-N2

1.220(2) A

N l-S

1.610(1) A

S - N l -C2

124.1(1)°

N1-C2

1.470(2) A

S-N1-H1N

115.0(10)°

N1 -H1N

0.780(18)A

C2-N1-H 1N

119.3(11)°

N2-05

1229(1) A

05 - N2 - 0 6

124.1(1)°

N2-06

1220(2) A

05-N2-C8

118.0(1)°

N2-C8

1.469(2) A

06-N2-C8

117.8(1)°

C l -03

1.314(2) A

0 3 - C l -04

124.6(1)°

C l -04

1224(2) A

03-C 1-C 2

113.4(1)°
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Bond Distances and Bond Angles (continued)
C1-C 2

1.535(2) A

04-C1-C2

121.9(1)°

C2-N1

1.470(2) A

N1 - C2 - Cl

110.0( 1)°

C2-C1

1.535(2) A

N1-C2-C9

106.4(1)°

C2-C 9

1.533(1) A

N 1 -C 2 -C 1 0

111.9(1)°

C2-C10

1.530(2) A

C1-C2-C9

106.6(1)°

Cl - C 2 -C10

111.2(1)°

C 9-C 2-C 1 0

110.5(1)°

C3-S

1.783(2)A

5-C 3-C 4

117.3(1)°

C 3-C4

1.396(2) A

S-C3-C8

124.6(1)°

C3-C8

1.398(2) A

C4-C3-C8

117.7(1)°

C4-C3

1.396(2) A

C3-C4-H4

119.6°

C4-H4

0.949 A

C3 - C4 - C5

120.8(2)°

C4-C5

1.390(2) A

H4-C4-C5

119.6°

C5-C4

1.390(2) A

C4-C5-H5

119.8°

C5-H5

0.950 A

C4-C5-C6

120.5(2)°

C5-C6

1.382(3) A

H5-C5-C6

119.8°

C6 -C5

1.382(3) A

C5 - C6 - H6

120. 0°

C 6-H6

0.950 A

C5-C6-C7

120.0(2)°

C6-C7

1.390(2) A

H6-C6-C7

120.0°

C7-C6

1.390(2) A

C6 - C7 - H7

120.4°

C7-H7

0.950 A

C6-C7-C8

119.1(2)°

C7-C8

1.389(2) A

H7-C7-C8

120.5°
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Bond Distances and Bond Angles (continued)
C8-N2

1.469(2) A

N2-C8-C3

122.1(1)°

C8-C3

1398(2) A

N2-C8-C7

116.0(1)°

C8-C7

1389(2) A

C3-C8-C7

121.9(1)°

C9-C2

1.533(1) A

C 2 - C 9 - H9A

109.4°

C9-H9A

0.980 A

C 2 - C 9 - H9B

109.5°

C9 - H9B

0.980 A

C2-C 9-H 9C

109.5°

C9-H9C

0.980 A

H9A-C9-H9B

109.5°

C10-C2

1.530(2) A

C2 - CIO - H10A

109.5°

C10-H10A

0.980 A

C2 - CIO - H10B

109.5°

C10-H10B

0.980 A

C2-C10-H10C

109.5°

C10-H10C

0.980 A

H10A-C10-H10B

109.5°

Experimental
Crystal Data
CioH12N20 6S

a - 11.665 (3) A

D*=1.572 Mgm'J

M r- 28828

b = 10.614 (2) A

Mo Ka radiation

Monoclinic

c = 11.121 (4) A

A = 0.71073 A

Space Group; P2\!c

0=117.80(2)°

T= 100 K

Data collection
3536 independent reflections
6 U = 30.0°
R(F) = 0.042 (183 parameters)

182
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A.2.

0 NBS-Ac*c-OH

C3B
C2B

H2B

O lA

04B

C11A
C10A

05B

C4B

C12A

C8A
C9A

06B

02B
SlA

C6A
C7A

03A

,C5A
H2A

U1B

03B

02A

C9B

C6B

SIB

C8B

04A

H1A

06A

C1B
C7B

CIA
C4A

05A

C10B

OIB

CU B
C13B

C2A

CI2B

C3A

Coordinates
Atom

X

Y

Z

SI

0.09596(3)

0.97588(3)

0.32063(4)

01

0.07698(10)

0.95375(10)

02103(1)

02

0.06725(10)

0.91675(10)

0.3854(1)

03

0.2461(1)

0.81592(10)

0.4065(1)

H30

0.241(2)

0.760(2)

0.413(2)

04

0.24094(10)

0.81240(9)

0.5707(1)

05

0.14870(10)

1.1214(1)

0.1952(1)

06

0.0177(1)

1.1534(2)

0.0649(1)

N1

02041(1)

0.9921(1)

03861(1)

H1N

0230(2)

1.003(2)

0.345(2)

N2

0.0665(1)

1.1387(1)

0.1599(1)

Cl

02458(1)

0.8540(1)

0.4949(2)
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Coordinates (continued)
C2

02565(1)

0.9556(1)

0.4958(2)

C3

0.0400(1)

1.0790(1)

0.3179(2)

C4

0.0017(1)

1.0927(2)

0.3932(2)

H4

0.011

1.050

0.449

C5

-0.0502(1)

1.1680(2)

0.3893(2)

H5

-0.075

1.177

0.443

C6

-0.0664(1)

1.2302(1)

0.3079(2)

H6

-0.103

1.281

0.304

C7

-0.0290(1)

1.2184(1)

0.2318(2)

H7

-0.040

1.261

0.176

C8

0.0245(1)

1.1443(1)

02386(2)

C9

0.3585(1)

0.9748(1)

0.5226(2)

H9A

0.397

0.945

0.592

H9B

0.375

0.950

0.465

CIO

0.2294(1)

0.9995(1)

0.5820(2)

H10A

0.164

0.989

0.563

H10B

0264

0.971

0.654

C ll

0.3792(1)

1.0750(1)

0.5333(2)

H11A

0.446

1.084

0.556

H11B

0.348

1.104

0.462

C12

0.3490(2)

1.1189(2)

0.6155(2)

H12A

0.358

1.184

0.615
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Coordinates (continued)
H12B

0.387

1.096

0.689

C13

0.2488(2)

1.0999(1)

0.5899(2)

H13A

0210

1.129

0.520

H13B

0.233

1.126

0.647

sr

0.39312(3)

0.48665(3)

0.68607(4)

01'

0.3976(1)

0.49706(10)

0.7938(1)

02’

0.42115(10)

0.55820(10)

0.6352(1)

03’

0.2330(1)

0.63264(10)

0.5829(1)

H30'

0.231(2)

0.691(2)

0.573(2)

04’

023567(10)

0.64204(9)

0.4180(1)

05*

0.34019(10)

0.3166(1)

0.7739(1)

06’

0.4629(1)

0.2774(1)

0.9117(1)

NV

0.2909(1)

0.4609(1)

0.6055(1)

H1N'

0.260(2)

0.433(2)

0.632(2)

N2'

0.4230(1)

0.3043(1)

0.8187(1)

C l'

0.2384(1)

0.5980(1)

0.4959(2)

C2'

0.2447(1)

0.4959(1)

0.4948(2)

C3’

0.4653(1)

0.3952(1)

0.6891(2)

C4'

0.5174(1)

0.4014(2)

0.6278(2)

H4’

0.512

0.453

0.584

C5'

0.5775(2)

0.3341(2)

0.6293(2)

H5'

0.611

0339

0.585
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Coordinates (continued)
C6'

0.5890(1)

0.2599(2)

0.6956(2)

H6'

0.630

0214

0.697

CT

0.5399(1)

02535(1)

0.7599(2)

H7'

0.549

0204

0.807

C8'

0.4778(1)

0.3197(1)

0.7547(2)

C9'

0.1459(1)

0.4597(1)

0.4502(2)

H9'l

0.118

0.474

0.502

H9*2

0.110

0.490

0.380

CIO’

02909(1)

0.4666(1)

0.4192(2)

H10C

0.260

0.496

0.348

H10D

0.355

0.486

0.450

cir

0.1424(1)

0.3588(1)

0.4324(2)

H11C

0.172

0.329

0.504

H11D

0.078

0.339

0.400

C12'

0.1897(2)

0.3313(2)

0.3586(2)

H12C

0.190

0265

0.353

HI 2D

0.156

0.356

0285

C13'

0.2877(1)

0.3656(1)

0.4029(2)

H13C

0.316

0.350

0.352

H13D

0.323

0.336

0.473
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Bond Distances and Bond Angles
Bond

Distance

SI -O l

1.429(2) A

0 1 - S I -02

119.9(1)°

S I-02

1.440(1) A

01-S1-N 1

109.7(1)°

SI -N1

1.613(1) A

01-S1-C3

106.5(1)°

S1-C3

1.778(2)A

02-S1-N1

107.1(1)°

0 2 - SI - C3

105.5(1)°

N l-Sl-C 3

107.5(1)°

H30 - 0 3 - C 1

107.5(16)°

Bond Angle

0 1 -S I

1.429(2) A

0 2 -SI

1.440(1) A

03 - H30

0.850(30)A

0 3 -Cl

1.319(2) A

0 4 -Cl

1.224(2) A

0S-N2

1.232(2) A

06-N2

1.221(2) A

N l-S l

1.613(1) A

S1 -N 1 -H 1 N

112.3(16)°

N1-H1N

0.829(21)A

S1-N1-C2

123.0(1)°

N1-C 2

1.478(3) A

H1N -N 1 -C 2

119.9(16)°

N2-05

1.232(2) A

0 5 - N2 - 06

125.3(2)°

N2-06

1.221(2) A

05-N2-C8

117.3(2)°

N2-C8

1.465(2) A

06-N2-C8

117.3(1)°

C l -03

1.319(2) A

0 3 - C l -04

123.6(2)°

C l -04

1224(2) A

0 3 - Cl - C2

113.4(2)°

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Bond Distances and Bond Angles (continued)
C 1-C 2

1331(3) A

0 4 -C l - C2

123.0(2)°

C2-N1

1.478(3) A

N 1 -C 2 -C 1

110.1(2)°

C2-C1

1.531(3) A

N 1 -C 2 -C 9

106.7(1)°

C 2-C 9

1.548(2) A

N1 -C 2-C 10

112.0( 1)°

C2-C10

1.538(3) A

Cl - C2 - C9

106.9(1)°

Cl -C 2-C 10

111.5(1)°

C 9-C 2-C 10

109.4(1)°

C3-S1

1.778(2) A

S 1 -C 3 -C 4

118.5(2)°

C 3-C 4

1.391(2) A

S 1 -C 3 -C 8

124.1(1)°

C 3-C 8

1.394(3) A

C 4 -C 3 -C 8

117.2(2)°

C4-C3

1.391(2) A

C 3 -C 4 -H 4

119.3°

C 4-H 4

0.950 A

C 3 -C 4 -C 5

121.5(2)°

C 4-C 5

1.389(3) A

H 4-C 4-C 5

119.2°

C 5-C 4

1.389(3) A

C4 - C5 - H5

120. 1°

C 5-H 5

0.950 A

C 4 -C 5 -C 6

119.9(2)°

C 5-C 6

1.381(3)A

H 5-C 5-C 6

120.0°

C6-C 5

1.381(3) A

C 5 -C 6 -H 6

120. 1°

C 6-H 6

0.951 A

C 5 -C 6 -C 7

119.9(2)°

C 6-C 7

1.386(2) A

H 6 -C 6 -C 7

120. 1°

C 7-C 6

1.386(2) A

C 6 -C 7 -H 7

120.3°

C 7-H 7

0.950 A

C 6 -C 7 -C 8

119.4(2)°

C 7-C 8

1.382(2) A

H 7 -C 7 -C 8

120.3°

188
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Bond Distances and Bond Angles (continued)
C 8-N 2

1.465(2) A

N 2-C 8-C 3

1213(1)°

C 8-C3

1.394(3) A

N 2 -C 8 -C 7

116.7(2)°

C 8-C 7

1.382(2) A

C 3 -C 8 -C 7

122.1(1)°

C 9-C 2

1.548(2) A

C 2-C 9-H 9A

109.3°

C9 - H9A

0.990 A

C 2-C 9-H 9B

1092°

C9 - H9B

0.989 A

C 2-C 9-C 11

111.8(1)°

C9-C11

1.532(3) A

H9A -C9-H9B

108.0°

H9A-C9-C11

109.2°

H 9B-C9-C11

109.3°

C10-C2

1.538(3) A

C2-C10-H 10A

109.4°

C10-H10A

0.989 A

C 2-C10-H 10B

109.5°

C10-H10B

0.990 A

C 2-C 10-C 13

111.2(1)°

C10-C13

1.531(3) A

H10A-C10-H10B

108.0°

H10A-C10-C13

109.4°

H10B-C10-C13

109.4°

C11-C9

1.532(3) A

C9-C11 -H11A

109.2°

C ll -H11A

0.989 A

C9-C11 -H11B

109.2°

C11-H11B

0.990 A

C 9-C 11-C 12

111.9(2)°

C11-C12

1.521(3) A

H11A-C11 -H11B

107.9°

H11A-C11 -C12

1092°

H 11B -C ll -C12

109.3°

C ll -C12-H12A

109.4°

C12-C11

1.521(3) A
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Bond Distances and Bond Angles (continued)
C12-H12A

0.990 A

C ll -C 12- H12B

109.4°

C12 - H12B

0.990 A

C ll -C12-C13

111.4(2)°

C12-C13

1.524(2) A

H12A-C12 - H12B 108.0°
H12A-C12-C13

109.4°

H12B-C12-C13

109.3°

C10-C13 -C12

111.4(2)°

C13-C12

1.524(2) A

C10-C13 -H13A

109.4°

C13-H13A

0.990 A

CIO -C13 - H13B

109.4°

C13-H13B

0.990 A

C12-C13-H13A

109.3°

C12-C13 -H13B

109.3°

H13A-C13-H13B

108.0°

sr-or

1.429(2) A

0 1 '- S I '- 0 2 ’

120.1(1)°

a>

1.436(1)A

O l '- S l '- N l '

109.6(1)°

S l’ - N l ’

1.604(1) A

0 1 '-S 1 ’-C3'

106.9(1)°

S l’ -C 3’

1.781(2) A

02’ - S l ’-N l'

106.6(1)°

02’- S l ’-C3’

105.3(1)°

N 1'-S 1'-C 3’

107.8(1)°

H 3 0 '-0 3 ’-C l'

105.6(16)°

I

1.531(3) A

8

C13-C10

or-sr

1.429(2) A

’- s r

1.436(1)A

03' - H30'

0.883(30)A

0 3 '- C l'

1.314(2) A

0 2

f—4

U
1

8

05' - N2'

1223(2) A
1.228(2) A
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Bond Distances and Bond Angies (continued)
06' - N2'

1222(2) A

N r-sr

1.604(1) A

S I'-N l'-H IN '

117.0(16)°

N l'-H IN '

0.828(22) A

S1'-N 1'-C 2'

1243(1)°

N l' - C2*

1.468(2) A

H1N '-N 1'-C2'

118.0(16)°

N2* - 05’

1.228(2) A

05' - N2' - 06'

124.7(1)°

N2' - 06'

1.222(2) A

05’ -N 2 '-C 8 ’

117.9(2)°

N2’ -C8’

1.471(2) A

06’-N 2'-C 8'

117.4(1)°

C1‘ - 0 3 ’

1.314(2) A

03’- C l’-0 4 '

123.7(2)°

C l '- 0 4 '

1.223(2) A

0 3 '-C l'- C 2 '

115.5(2)°

C l' - C2'

1.532(3) A

04’- C l’-C2’

120.7(2)°

C 2'-N 1'

1.468(2) A

N l'- C 2 '- C l’

110.8(2)°

C 2 '- c r

1.532(3) A

N l’-C 2 '-C 9 ’

106.9(1)°

C2’ -C9'

1.546(2) A

N l'-C 2 '-C 1 0 '

112.7(1)°

C2' - CIO'

1.540(2) A

C l'-C 2 '-C 9 '

107.1(1)°

C l’-C 2'-C 10'

110.0(1)°

C 9'-C 2'-C 10'

1092(1)°

C3* - SI'

1.781(2) A

S l'-C 3 '-C 4 ’

118.1(2)°

C3’ -C4’

1.389(2) A

S l'-C 3 '-C 8 '

124.5(1)°

C 3'-C 8’

1.398(3) A

C4’ -C3’ -C8'

117.3(2)°

C 4'-C3'

1.389(2) A

C3'-C4’ -H4’

119.4°

C4' - H4'

0.951 A

C3* - C4' - C5'

1212(2)°

C4'-C5'

1387(3) A

H4'-C4’-C5'

119.4°

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

C 5'-C 4’

1.387(3) A

C4’ -C 5'-H 5'

119.9°

C5' - H5'

0.949 A

C4’ -C5’-C6’

120.3(2)°

C5’-C 6’

1.390(3) A

H5’ -C5’ -C6’

119.9°

C 6'-C5'

1.390(3) A

C5’-C 6’-H6’

120.2°

C6' - H6'

0.950 A

C5’ -C6’ -C7’

119.6(2)°

C 6'-C7'

1.384(2) A

H6' - C6’ - C7'

120.2°

C T -C &

1.384(2) A

C 6'-C 7'-H 7'

120.3°

C 7'-H 7’

0.949 A

C 6'-C 7'-C 8'

119.4(2)°

C 7 -C 8 ’

1.384(2) A

H7' - C7' - C8'

120.3°

C 8'-N 2’

1.471(2) A

N2’-C 8’-C3*

121.7(1)°

0
00
1
O
OJ

Bond Distances and Bond Angles (continued)

1.398(3) A

N2’-C 8’-C7’

116.1(2)°

C8' - C7'

1.384(2) A

C3' - C8' - C7'

122.1(1)°

C9'-C2'

1.546(2) A

C2' - C9' - H9'l

109.2°

C9' - H9'l

0.990 A

C2' - C9' - H9'2

109.2°

C9' - H9'2

0.990 A

C 2 '-C 9 '-C ll'

112.0(1)°

C 9 '- C ir

1.528(3) A

H9'l -C9’-H9’2

107.9°

H9'l -C9’-C11’

109.2°

H O S -C y -C ll'

1092°

C10’ -C2'

1.540(2) A

C2' - CIO' - H10C

1092°

CIO' - H10C

0.990 A

C2'-C10'-H10D

109.1°

CIO’-HIOD

0.990 A

C2' - CIO' - C13'

112.4(1)°

CIO' - C13’

1.527(3) A

HIOC-CIO'-HIOD 107.8°
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Bond Distances and Bond Angles (continued)
H io c -c io '-c n *

109.1°

HIOD-CIO'-CB*

109.1°

c ii'-c y

1.528(3) A

C9'- C ll' -H I 1C

1092°

C ll’ -H I 1C

0.991 A

C 9 '-C ll’ -H I ID

1092°

C l l ’ -H llD

0.990 A

C9’ -C11’ -C12’

111.9(2)°

c ir -c ir

1.525(3) A

H l l C - C l l ’ - H llD

107.9°

H llC -C ir -C B ’

1092°

H 1 1 D -C ir -C 1 2 ’

109.3°

c iz -c ir

1.525(3) A

C ll'-C 12'-H 12C

109.5°

C12' - H12C

0.990 A

C ir -C 1 2 ’ -H12D

109.5°

C12’ -H12D

0.990 A

C l l'- C U '- C B ’

110.7(2)°

c ir -c u ’

1.524(2)A

H12C-C12'-H12D 108.1°

H12C - C12' - C13'

109.5°

H12D-C12'-C13*

109.5°

C B '-C IO 1

1.527(3) A

CIO’ - C B ’ -CB*

111.1(1)°

C13’ -C12’

1.524(2) A

C10'-C13’ -H13C

109.4°

C13' - H13C

0.990 A

C10'-C13'-H13D

109.4°

C13'-H13D

0.990 A

C12'-C13'-H13C

109.4°

C12’-C 13'- H13D

109.4°

H13C-C13'-H13D 108.1°
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Experimental
Crystal data
CijHisNzOfiS

a = 15.9780 (12) A

Dx= 1.479 Mg m'J

Mr = 328.34

b = 14.9840 (11) A

Mo Ka radiation

Monoclinic

c = 13.4360 (10) A

A = 0.71073 A

Space Group: F ljc

j8 = 113.568 (6) °

T - 100 fC

Data Collection
7815 independent reflections
R[F*>2o(F2)] = 0.043
6 U = 29.0°

194
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A J.

oNBS-Api(Boc)-OH

06

C9

N2

CIO
05
C17

C8

C ll
C16

C3

C7

07

N3

Cl 4

C12
C2

02

Cl 5

Cl 3

N1

C4

08

Cl
01

C5
C6
04
03

Coordinates
Atom

X

Y

Z

S

0.40527(8)

0.15956(2)

0.93612(5)

01

0.5100(2)

0.13887(5)

1.04800(10)

02

0.2038(2)

0.17126(5)

0.9391(2)

03

0.6663(2)

0.02447(5)

0.9209(2)

04

0.3601(2)

0.04815(5)

0.9285(2)

05

0.2524(3)

0.20772(6)

0.6689(2)

06

0.1454(3)

0.26927(7)

0.7482(3)

07

0.8907(2)

0.08623(6)

0.41070(10)

08

1.1248(2)

0.11205(5)

0.5641(2)
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Coordinates (continued)
N1

0.4260(2)

0.12758(5)

0.8108(2)

N2

02692(3)

0.23997(6)

0.7425(2)

N3

0.8018(2)

0.12037(6)

0.5896(2)

Cl

0.5716(3)

0.09143(6)

0.8013(2)

C2

0.5404(3)

0.07291(7)

0.6596(2)

C3

0.5994(3)

0.10653(8)

0.5574(2)

C4

0.8353(3)

0.14132(7)

0.7190(2)

C5

0.7825(3)

0.10889(7)

0.8263(2)

C6

0.5367(3)

0.05204(7)

0.8925(2)

C7

0.5302(3)

0.21103(7)

0.9088(2)

C8

0.4530(3)

0.24542(7)

0.8264(2)

C9

0.5494(4)

0.28608(8)

0.8136(3)

CIO

0.7278(4)

0.29226(9)

0.8827(3)

C ll

0.8077(4)

0.25951(9)

0.9655(3)

C12

0.7087(4)

0.21879(8)

0.9802(2)

C13

0.9540(3)

0.10617(7)

0.5241(2)

C14

1.0210(3)

0.07312(8)

03102(2)

CIS

1.1620(5)

0.03750(10)

03628(3)

C16

0.8829(5)

0.05520(10)

0.2018(3)

C17

1.1285(6)

0.11400(10)

02665(3)

H1N

0.340(3)

0.1287(6)

0.756(2)

H40

0.358(4)

0.0218(9)

0.980(3)
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Coordinates (continued)
H2a

0.4060

0.0658

0.6409

H2b

0.6162

0.0462

0.6537

H3a

0.5869

0.0928

0.4725

H3b

0.5169

0.1323

0.5572

H4a

0.7571

0.1678

0.7215

H4b

0.9693

0.1493

0.7342

H5a

0.8693

0.0838

0.8288

H5b

0.7959

0.1241

0.9089

H9

0.4930

0.3093

0.7580

H10

0.7969

0.3197

0.8729

H ll

0.9310

02644

1.0133

H12

0.7636

0.1963

1.0391

H15a

1.2450

0.0295

02965

H15b

1.2384

0.0490

0.4379

H15c

1.0919

0.0116

0.3874

H16a

0.9539

0.0456

0.1305

H16b

0.8133

0.0303

0.2335

H16c

0.7934

0.0783

0.1721

H17a

1.2126

0.1053

02015

H17b

1.0372

0.1357

02302

H17c

12035

0.1267

0.3403
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Bond Distances and Bond Angles
Bond_____________Distance__________________ Bond Angle
S -O l

1.429(1) A

01 - S - 02

120.6(1)°

S -0 2

1.430(1) A

O l-S -N l

107.8(1)°

S -N l

1.602(2) A

01 - S - C7

105.8(1)°

S -C 7

1.781(2) A

0 2 - S -N 1

108.2(1)°

0 2 -S -C 7

106.1(1)°

N 1 -S -C 7

107.7(1)°

C 6 -0 4 -H 4 0

106.8(15)°

C 1 3 -0 7 -C 1 4

123.0(1)°

-s

1.429(1) A

0 2 -S

1.430(1) A

0 3 -C6

1.223(2) A

0 4 -C 6

1.303(2) A

0 4 -H 4 0

0.939(28) A

0 5 -N 2

1211(3) A

0 6 -N 2

1.219(3) A

0 7 - C13

1.333(2) A

0 7 - C14

1.467(2) A

0 8 - C13

1221(2) A

N l-S

1.602(2)A

S - N l - Cl

126.0(1)°

N l-C l

1.473(2)A

S -N 1-H 1N

115.5(14)°

N1-H 1N

0.777(20) A

C 1-N 1-H 1N

117.6(14)°

N 2 -0 5

1211(3) A

05 - N2 - 06

124.0(2)°

N 2 -0 6

1219(3) A

0 5 -N 2 -C 8

118.4(2)°

0 1
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Bond Distances and Bond Angles (continued)
N 2-C 8

1.470(3) A

0 6 -N 2 -C 8

117.6(2)°

N 3-C 3

1.460(2) A

C 3 -N 3 -C 4

113.3(2)°

N 3-C 4

1.453(3)A

C 3-N 3-C 13

124.4(2)°

N3-C13

1.354(2) A

C 4-N 3-C 13

120.5(1)°

C l-N l

1.473(2) A

N l - C l - C2

106.2(2)°

C 1-C 2

1.537(3) A

N 1 -C 1 -C 5

112.4(1)°

C 1-C 5

1.539(3) A

N 1 -C l-C 6

111.9(2)°

Cl -C6

1.520(3) A

C 2 -C 1 -C 5

109.1(2)°

C2 - Cl - C6

106.3(2)°

C5 - Cl - C6

110.6(2)°

C2-C1

1.537(3) A

C l-C 2 -C 3

112.5(2)°

C2-C 3

1.517(3) A

Cl -C 2 -H 2 a

108.7°

C2-H 2a

0.950 A

Cl - C2 - H2b

108.8°

C2 - H2b

0.951 A

C3 - C2 - H2a

108.7°

C3 - C2 - H2b

108.7°

H2a - C2 - H2b

109.4°

C 3-N 3

1.460(2) A

N 3 -C 3 -C 2

109.6(2)°

C 3-C 2

1.517(3) A

N3 - C3 - H3a

109.4°

C3 -H3a

0.950 A

N3 - C3 - H3b

109.4°

C3-H 3b

0.950 A

C2 - C3 - H3a

109.4°

C2 - C3 - H3b

109.4°

H3a - C3 - H3b

109.5°
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Bond Distances and Bond Angies (continued)
C 4-N 3

1.453(3) A

N 3 -C 4 -C 5

110.5(2)°

C 4-C5

1.519(3) A

N 3 -C 4-H 4a

109.2°

C4-H 4a

0.951 A

N3 - C4 - H4b

1092°

C4 - H4b

0.950 A

C5 - C4 - H4a

109.3°

C 5-C 4-H 4b

1092°

H4a - C4 - H4b

109.5°

C5-C1

1.539(3) A

C 1 -C 5 -C 4

111.9(2)°

C 5-C 4

1.519(3) A

Cl - C5 - H5a

108.8°

C5 - H5a

0.951 A

Cl - C5 - H5b

108.8°

C5 - H5b

0.949 A

C 4-C 5-H 5a

108.9°

C4 - C5 - H5b

108.9°

H5a - C5 - H5b

109.5°

C 6 -0 3

1.223(2) A

03 - C6 - 04

123.5(2)°

C 6 -0 4

1.303(2) A

0 3 -C 6 -C 1

120.3(2)°

C6-C1

1.520(3) A

0 4 -C 6 -C 1

116.0(2)°

C 7 -S

1.781(2) A

S -C 7 -C 8

123.6(1)°

C 7-C 8

1.392(3) A

S -C 7 -C 1 2

118.4(2)°

C7-C12

1.389(3) A

C 8-C 7-C 12

117.8(2)°

C 8-N 2

1.470(3) A

N 2 -C 8 -C 7

122.1(2)°

C 8-C 7

1.392(3) A

N 2 -C 8 -C 9

115.8(2)°

C 8-C 9

1.384(3) A

C 7 -C 8 -C 9

122.0(2)°

C 9-C 8

1.384(3) A

C 8-C 9-C 10

118.8(2)°
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Bond Distances and Bond Angles (continued)
C9-C10

1.371(4) A

C 8-C 9-H 9

120.6°

C 9-H 9

0.950 A

C 10-C 9-H 9

120.6°

C10-C9

1371(4) A

C 9 -C IO -C ll

121.0(2)°

C IO -C ll

1.366(4) A

C 9-C 10-H 10

119.6°

C10-H10

0.950 A

C ll -C10-H10

119.5°

C ll-C IO

1.366(4) A

C IO -C ll -C12

1203(2)°

C11-C12

1.397(4) A

C10-C11 - H ll

120.0°

C ll-H ll

0.951 A

C12-C11 -H ll

119.8°

C12-C7

1.389(3) A

C7-C12-C11

120.2(2)°

C12-C11

1.397(4) A

C 7-C 12-H 12

119.9°

C12-H12

0.950 A

C ll -C12-H 12

120.0°

C 1 3 -0 7

1.333(2) A

07-C 13 -0 8

125.7(2)°

C I3 -0 8

1.221(2) A

0 7 -C 1 3 -N 3

110.7(2)°

C13-N3

1.354(2) A

0 8 -C 1 3 -N 3

123.6(2)°

C 1 4 -0 7

1.467(2) A

07-C 14-C 15

110.7(2)°

C14-C15

1.498(4) A

07 -C14-C16

102.7(2)°

C14-C16

1.488(4) A

07 -C14-C17

109.8(2)°

C14-C17

1.503(4) A

C15 -C14-C16

111.4(2)°

C15 -C14-C17

110.6(2)°

C16-C14-C17

111.5(2)°

C15-C14

1.498(4) A

C14-C15 -H15a

109.4°

C15 -H15a

0.949 A

C14-C15 -H15b

109.3°
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Bond Distances and Bond Angles (continued)
C15 -H15b

0.951 A

C14-C15 -H15c

109.5°

C15-H15c

0.950 A

H15a-C15 - H15b

109.5°

H15a-C15 - Hl5c

109.6°

C16-C14

1.488(4) A

C 14-C16-H 16a

109.5°

C16 -H16a

0.951 A

C14-C16-H 16b

109.5°

C16-H16b

0.949 A

C14-C16 - H16c

109.5°

C16-H16c

0.951 A

H16a-C16 - H16b

109.5°

H16a-C16 - H16c

109.5°

C17-C14

1.503(4) A

C14 - C17 - HI7a

109.4°

C17 - H17a

0.950 A

C14-C17-H 17b

109.4°

C17 - H17b

0.949 A

C14-C17 - H17c

109.4°

C17 - H17c

0.950 A

H17a-C17 - H17b

109.6°

H17a-C17-H17c

109.5°

Crystal data
C 17H 23N 3O 8S

a = 6.8729 (2) A

Dx= 1.386 Mgm"

Mr = 429.45

b = 29.564 (2) A

Cu-Ka radiation

Monoclinic

c = 10.1549 (7) A

A =1.54184 A

Space Group: P2\lc

0 = 94.946(4)°

r=294K

Data Collection
4239 independent reflections
A = 0.044

6 U = 75.0°
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A.4.

oNBS-Lys(Z)-OH

Coordinates
Atom

X

Y

Z

S

0.44587(7)

0.67712(2)

0.46520(10)

01

0.4531(2)

0.68197(6)

0.7285(4)

02

0.5378(2)

0.68989(6)

0.3148(4)

03

0.2694(2)

0.58453(7)

0.2571(5)

04

0.3539(2)

0.57244(6)

-0.1043(5)

05

0.8200(2)

0.47620(6)

0.8214(5)

06

0.9475(2)

0.45421(6)

0.5450(4)

07

0.1068(2)

0.68812(9)

0.8071(6)

08

02359(2)

0.64832(7)

0.7029(5)

N1

0.4293(2)

0.63241(6)

0.4098(4)

N2

0.8168(2)

0.49479(7)

0.4197(5)

N3

0.1852(2)

0.67845(8)

0.6774(6)

Cl

0.4419(3)

0.61719(8)

0.1570(5)

C2

0.3451(3)

0.58965(8)

0.1150(7)

C3

0.5575(3)

0.59816(8)

0.1208(6)
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Coordinates (continued)
C4

0.5763(3)

0.56441(9)

0.2916(7)

C5

0.6926(3)

0.54563(9)

0.2592(6)

C6

0.7085(3)

0.51490(9)

0.4496(8)

Cl

0.8582(2)

0.47533(8)

0.6128(7)

C8

0.3251(3)

0.70409(8)

0.3652(6)

C9

0.2178(3)

0.70464(9)

0.4745(7)

CIO

0.1358(3)

0.72990(10)

0.3948(9)

C ll

0.1598(4)

0.75480(10)

0.2063(9)

C12

0.2634(4)

0.75470(10)

0.0963(8)

C13

0.3464(3)

0.72966(9)

0.1770(7)

C14

0.9931(3)

0.42960(10)

0.7356(7)

C15

1.0614(3)

0.39888(8)

0.6157(6)

C16

1.1617(3)

0.38783(9)

0.7161(7)

C17

1.2246(3)

0.35840(10)

0.6177(7)

C18

1.1872(3)

0.33990(10)

0.4125(8)

C19

1.0859(3)

0.35010(10)

0.3057(7)

C20

1.0236(3)

0.37970(10)

0.4082(7)

H40H

0.300(3)

0.5537(9)

-0.097(6)

H1N

0.378(3)

0.6235(8)

0.472(6)

H2N

0.850(3)

0.496(1)

0.273(5)

HI

0.4392

0.6373

0.0384

H3a

0.6148

0.6167

0.1511
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Coordinates (continued)
H3b

0.5629

0.5894

-0.0454

H4a

0.5197

0.5457

0.2594

H4b

0.5697

0.5731

0.4577

H5a

0.7500

0.5645

03781

H5b

0.6975

0.5346

0.0987

H6a

0.7063

0.5263

0.6093

H6b

0.6487

0.4968

0.4347

H10

0.0632

0.7301

0.4703

H ll

0.1035

0.7723

0.1513

H12

02m

0.7718

-0.0361

H13

0.4190

0.7301

0.1014

HI 4a

0.9329

0.4185

0.8274

H14b

1.0398

0.4442

0.8435

HI6

1.1892

0.4009

0.8584

H17

1.2939

0.3510

0.6931

H18

1.2313

0.3199

0.3421

H19

1.0590

0.3369

0.1634

H20

0.9537

03870

0.3345
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Bond Distances and Bond Angles
Bond_____________Distance

Bond Angle

S -O l

1.435(2) A

01 - S - 02

118.8(1)°

S -0 2

1.427(2) A

O l-S -N l

107.9(1)°

S -N l

1.598(2) A

0 1 -S -C 8

106.5(1)°

S -C 8

1.791(3) A

0 2 -S -N l

106.9(1)°

0 2 -S -C 8

105.7(1)°

N 1 -S -C 8

110.9(1)°

C 2 -0 4 -H 4 0 H

103.2(21)°

C 7 -0 6 -C 1 4

1152(3)°

0 1 -S

1.435(2)A

0 2 -S

1.427(2) A

0 3 -C2

1.192(4) A

0 4 -C2

1.332(4) A

0 4 -H 4 0 H

0.913(33)A

0 5 -C7

1.214(4) A

0 6 -Cl

1.337(3) A

0 6 -C 1 4

1.444(4) A

0 7 -N 3

1209(4) A

0 8 -N 3

1216(4) A

N l-S

1.598(2) A

S -N 1 -C 1

120.8(2)°

N l-C l

1.473(3)A

S -N 1 -H 1 N

114.4(22)°

N1-H 1N

0.759(34) A

C 1-N 1-H 1N

110.1(24)°

N 2-C 6

1.467(4) A

C 6 -N 2 -C 7

118.4(3)°

N 2-C 7

1.337(4) A

C 6-N 2-H 2N

117.5(22)°
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Bond Distances and Bond Angles (continued)
N 2-H 2N

0.885(29) A

C 7-N 2-H 2N

124.1(22)'

N 3 -0 7

1209(4) A

07 - N3 - 08

123.5(3)°

N 3 -0 8

1.216(4) A

0 7 -N 3 -C 9

1172(3)°

N 3-C 9

1.477(5) A

0 8 -N 3 -C 9

119.3(3)°

C l-N l

1.473(3) A

N 1 -C 1 -C 2

107.0(3)°

C 1-C 2

1.509(5) A

N 1-C 1-C 3

111.4(2)°

C 1-C 3

1.530(5) A

N1 - Cl - HI

110.9°

C l- H I

0.950 A

C2-C1 -C3

112.4(2)°

C 2-C 1-H 1

110.0°

C3 - Cl - HI

105.3°

C 2 -0 3

1.192(4) A

03 - C2 - 04

124.4(3)°

C 2 -0 4

1.332(4) A

03 -C 2-C 1

124.5(3)°

C2-C1

1.509(5) A

0 4 -C 2 -C 1

111.1(3)°

C3-C1

1.530(5) A

Cl - C3 - C4

113.0(3)°

C 3-C 4

1.511(5) A

Cl - C3 - H3a

108.6°

C3 - H3a

0.950 A

Cl - C3 - H3b

108.6°

C3 - H3b

0.951 A

C4 - C3 - H3a

108.6°

C4 - C3 - H3b

108.5°

H3a - C3 - H3b

109.5°

C4-C 3

1.511(5) A

C 3 -C 4 -C 5

1132(3)°

C 4-C 5

1.531(5) A

C3 - C4 - H4a

108.6°

C 4-H 4a

0.950 A

C3 - C4 - H4b

108.5°
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Bond Distances and Bond Angles (continued)
C 4-H 4b

0.950 A

C 5 -C 4 -H 4 a

108.5°

C5 - C4 - H4b

108.5°

H4a - C4 - H4b

109.5°

C 5-C 4

1.531(5) A

C 4 -C 5 -C 6

109.8(3)°

C 5-C 6

1.496(5) A

C4 - C5 - H5a

109.4°

C5 - H5a

0.950 A

C4 - C5 - H5b

109.4°

C5 - H5b

0.950 A

C6 - C5 - H5a

109.4°

C6 - C5 - H5b

109.3°

H5a - C5 - H5b

109.5°

C 6-N 2

1.467(4) A

N 2 -C 6 -C 5

112.0(3)°

C 6-C 5

1.496(5) A

N2 - C6 - H6a

108.9°

C6 - H6a

0.950 A

N2 - C6 - H6b

108.8°

C6 - H6b

0.950 A

C 5 - C 6 - H6a

108.8°

C 5-C 6-H 6b

108.9°

H6a - C6 - H6b

109.5°

C 7 -0 5

1.214(4) A

0 5 -C 7 -0 6

124.1(3)°

C 7 -0 6

1.337(3) A

0 5 -C 7 -N 2

1253(3)°

C 7-N 2

1.337(4) A

0 6 -C 7 -N 2

110.7(3)°

C 8 -S

1.791(3) A

S -C 8 -C 9

127.0(2)°

C 8-C 9

1.398(5) A

S -C 8 -C 1 3

114.7(3)°

C8-C13

1375(5) A

C 9-C 8-C 13

118.0(3)°

C 9-N 3

1.477(5) A

N 3 -C 9 -C 8

122.8(3)°
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Bond Distances and Bond Angles (continued)
C 9-C 8

1.398(5) A

N 3-C 9-C 10

116.3(3)°

C9 - CIO

1.377(5) A

C 8-C 9-C 10

120.9(3)°

CIO - C9

1.377(5) A

C9-C10-C11

119.5(4)°

C IO -C l 1

1.367(6) A

C 9-C 10-H 10

120.3°

C10-H10

0.949 A

C 11-C 10-H 10

120.2°

C11-C10

1.367(6) A

C10-C11-C12

120.7(4)°

C11-C12

1.360(7) A

C10-C11 - H ll

119.7°

C ll-H ll

0.950 A

C12-C11 - H ll

119.6°

C12-C11

1.360(7) A

C ll -C12-C13

120.1(4)°

C12-C13

1.383(5) A

C ll -C 12-H 12

120.0°

C12-H12

0.948 A

C13 -C 12-H 12

119.9°

C13 - C8

1.375(5) A

C 8-C 13-C 12

120.8(3)°

C13-C12

1.383(5) A

C8-C 13-H 13

119.6°

C13-H13

0.950 A

C12-C13 -H13

119.6°

C 1 4 -0 6

1.444(4) A

0 6 -C 1 4 -C 1 5

108.6(3)°

C14-C15

1.488(5) A

06 - C14 - H14a

109.6°

C14-H14a

0.949 A

0 6 - C14 - H14b

109.7°

$
SB
1
Tf
rH
u

0.950 A

C15 -C 1 4 - H14a

109.9°

C15-C14

1.488(5) A

C 14-C 15-C 16

1202(3)°

C15-C20

1.379(5) A

C 16-C 15-C 20

118.0(3)°

C16-C15

1.358(5) A

C15 -C 16-C 17

121.9(3)°
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Bond Distances and Bond Angles (continued)
C16-C17

1.373(5) A

C15 -C 16-H 16

119.0°

C16-H16

0.951 A

C17 -C 16-H 16

119.1°

C17-C16

1.373(5) A

C16-C17-C18

119.7(3)°

C17-C18

1.356(5) A

C 16-C17-H 17

1 2 0 2

°

C17-H17

0.950 A

C 18-C17-H 17

1 2 0 2

°

C18-C17

1.356(5) A

C 17-C 18-C 19

120.2(3)°

C18-C19

1.375(5) A

C17-C18-H 18

119.8°

C18-H18

0.949 A

C19-C18-H 18

119.9°

C19-C18

1.375(5) A

C 18-C 19-C 20

1192(3)°

C19-C20

1.382(5) A

C 18-C19-H 19

120.4°

C19-H19

0.951 A

C 20-C 19-H 19

120.5°

C20-C19

1.382(5) A

C 15-C 20-H 20

119.5°

C20-H20

0.951 A

C 19-C 20-H 20

119.6°

Crystal data
C2 0 H2 3 N3 O8 S

a = 11.8092 (13) A

Dx = 1.391 Mg m 3

M r- 465.49

b = 34.832 (4) A

Cu-Aa radiation

Orthorhombic

c = 5.4033 (6 ) A

A= 1.54184 A

Space Group: P2{2\2

V-

2 2 2 2 .6

(7) A

T - 296 K

Data Collection
2680 independent reflections
R = 0.039

flU* = 75.0°
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A3.

oNBS-Aib-NCA

04
C4

03
N2

C5

C8
C7
C9
C6

C10

02

C2

C3

05

C11
07

Coordinates
Atom

X

Y

Z

S

0.38287(3)

1.00000

022477(3)

01

026310(10)

1.0866(2)

0.14078(9)

02

0.55330(10)

1.0747(2)

0.25570(10)

03

0.0169(2)

0.7683(3)

0.1517(2)

04

0.0698(2)

0.7896(3)

-0.02220(10)

05

0.2661(2)

0.9594(2)

0.52552(9)

06

0.0771(2)

1.1794(3)

0.55930(10)

07

0.4541(2)

0.7813(2)

0.44240(10)

N1

027750(10)

0.9938(2)

0.34001(9)
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06

Coordinates (continued)
N2

0.1103(2)

0.7518(3)

0.07750(10)

Cl

0.1524(2)

1.1395(2)

036710(10)

C2

0.1565(2)

1.1025(3)

0.49300(10)

C3

0.3461(2)

0.9003(3)

0.43430(10)

C4

-0.0350(2)

1.1062(3)

0.3096(2)

C5

0.2160(2)

1.3324(3)

0.3487(2)

C6

0.4124(2)

0.7722(2)

0.18340(10)

C7

0.2888(2)

0.6795(2)

0.10970(10)

C8

0.3284(2)

0.5143(3)

0.06310(10)

C9

0.4936(3)

0.4408(3)

0.0912(2)

CIO

0.6181(2)

0.5306(3)

0.1647(2)

C ll

0.5782(2)

0.6967(3)

0.2101(2)

H4a

-0.0689

0.9843

0.3234

H4b

-0.1137

1.1884

0.3393

H4c

-0.0386

1.1251

03304

H5a

0.3324

13467

0.3857

H5b

0.2152

1.3540

02699

H5c

0.1401

1.4172

0.3788

H8

0.2429

0.4522

0.0124

H9

0.5222

0.3272

0.0596

H10

0.7313

0.4781

0.1841

H ll

0.6648

0.7594

02597
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Bond Distances and Bond Angles
Bond_____________Distance

Bond Angle

S-O l

1.421(1) A

01 - S - 02

1203(1)°

S -0 2

1.420(1) A

O l-S -N l

104.8(0)°

S-N l

1.674(1) A

01-S-C 6

108.7(1)°

S-C6

1.763(1)A

02-S-N 1

108.4(1)°

02-S-C 6

107.0(1)°

N1 - S - C6

107.1(1)°

C2-05-C3

109.4(1)°

0 1 -S

1.421(1) A

0 2 -S

1.420(1) A

03-N2

1.208(2) A

04-N2

1.222(2) A

0 5 -C2

1369(2) A

0 5 -C3

1.379(2) A

0 6 -C2

1.194(2) A

0 7 -C3

1.197(2) A

N l-S

1.674(1) A

S -N l -Cl

122.8(1)°

N l-C l

1.495(2) A

S-N1-C3

120.8(1)°

N1-C3

1.365(2) A

C1-N1-C3

111.9(1)°

N 2-03

1.208(2) A

03 - N2 - 0 4

125.8(2)°

N 2-04

1322(2) A

03-N2-C7

1173(1)°

N 2- C7

1.471(2) A

04-N2-C7

116.9(1)°

C l-N l

1.495(2)A

N1-C1-C2

98.5(1)°
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Bond Distances and Bond Angies (continued)
C 1-C 2

1.520(2) A

N l - C l - C4

1122(1)°

C1 -C 4

1.531(2) A

N1-C1-C5

1142(1)°

C1-C5

1.520(3) A

C2-C1-C4

108.6(1)°

C2-C1-C5

109.8(1)°

C4-C1-C5

112.5(1)°

C2-05

1.369(2) A

05 - C2 - 06

121.2(1)°

C2-06

1.194(2) A

05-C2-C1

110.8(1)°

C2-C1

1.520(2) A

06-C2-C1

128.1(2)°

C3-05

1.379(2) A

05-C 3-07

122.2(1)°

C3-07

1.197(2) A

05 - C3 - N1

109.1(1)°

C3-N1

1.365(2) A

0 7 - C3 - N1

128.7(1)°

C4-C1

1.531(2) A

Cl -C 4 -H 4 a

109.4°

C4 - H4a

0.950 A

Cl -C4-H 4b

109.5°

C4 - H4b

0.950 A

Cl - C4 - H4c

109.5°

C4-H4c

0.950 A

H4a - C4 - H4b

109.5°

H4a - C4 - H4c

109.5°

H4b - C4 - H4c

109.5°

C5-C1

1.520(3) A

Cl - C5 - H5a

109.5°

C5 - H5a

0.950 A

Cl -C5-H 5b

109.5°

C5 -H5b

0.951 A

Cl - C5 - H5c

109.5°

C5-H5c

0.950 A

H5a - C5 - H5b

109.4°

H5a - C5 - H5c

109.5°
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Bond Distances and Bond Angles (continued)
H5b - C5 - H5c

109.4°

C6-S

1.763(1) A

S-C6-C7

122.7(1)°

C6-C7

1.387(2) A

S -C 6-C 11

117.3(1)°

C6-C11

1.385(2) A

C7-C6-C11

119.0(1)°

C7-N2

1.471(2) A

N2-C7-C6

121.9(1)°

C7-C6

1.387(2) A

N2-C7-C8

116.9(1)°

C7-C8

1.381(2) A

C6 - C7 - C8

121.2(1)°

C8-C7

1.381(2) A

C7-C8-C9

119.0(2)°

C8-C9

1.377(3) A

C7-C8-H8

120.5°

C8-H8

0.950 A

C9-C8-H8

120.5°

C9-C8

1.377(3) A

C8 -C9-C 10

120.6(2)°

C9-C10

1.380(3) A

C8-C9-H9

119.7°

C9-H9

0.950 A

C1 0-C 9-H 9

119.7°

C10-C9

1.380(3) A

C9-C10-C11

120.0(2)°

C IO -C ll

1.381(3) A

C9-C10 -H10

120.0°

C10-H10

0.950 A

C ll -C10-H10

120.0°

C11-C6

1.385(2) A

C6-C11 - CIO

120.1(2)°

Cll-CIO

1.381(3) A

C6-C11-H11

119.9°

C ll-H ll

0.951 A

C10-C11 - H l l

119.9°
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Crystal data
CuHwNaOrS

a = 7.6466 (5) A

Dx= 1.58Mgm*J

Mr = 31428

b = 7.3302 (3) A

Cu-A'a radiation

Monoclinic

c — 11.9056 (5) A

X-

Space Group: P2\

j8 = 96.966 (4) °

r=298K

1.54184 A

Data Collection
2703 independent reflections
R = 0.028

6 U = 75.0°
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